Developing of Germyldesulonylation and Thiodesulfonylation Reactions for the Synthesis of Novel Nucleoside Analogues. Efficient Synthesis of Novel (α-Fluoro)vinyl Sulfides by Sacasa, Pablo R, Jr
Florida International University
FIU Digital Commons
FIU Electronic Theses and Dissertations University Graduate School
7-19-2010
Developing of Germyldesulonylation and
Thiodesulfonylation Reactions for the Synthesis of
Novel Nucleoside Analogues. Efficient Synthesis of
Novel (α-Fluoro)vinyl Sulfides
Pablo R. Sacasa Jr
Florida International University, psaca001@fiu.edu
Follow this and additional works at: http://digitalcommons.fiu.edu/etd
Part of the Medicinal-Pharmaceutical Chemistry Commons, and the Organic Chemistry
Commons
This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in
FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.
Recommended Citation
Sacasa, Pablo R. Jr, "Developing of Germyldesulonylation and Thiodesulfonylation Reactions for the Synthesis of Novel Nucleoside
Analogues. Efficient Synthesis of Novel (α-Fluoro)vinyl Sulfides" (2010). FIU Electronic Theses and Dissertations. Paper 265.
http://digitalcommons.fiu.edu/etd/265
FLORIDA INTERNATIONAL UNIVERSITY 
 
Miami, Florida 
 
 
 
 
 
DEVELOPING OF GERMYLDESULFONYLA ION AND 
THIODESULFONYLATION REACTIONS FOR THE SYNTHESIS OF NOVEL 
NUCLEOSIDE ANALOGUES. EFFICIENT SYNTHESIS OF NOVEL 
T
(α-FLUORO)VINYL SULFIDES. 
 
 
 
 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of 
DOCTOR OF PHILOSOPHY 
in 
CHEMISTRY 
by 
Pablo R. Sacasa 
 
2010 
 
 
ii 
 
To:  Dean Kenneth Furton    choose the name of dean of your college/school   
 College of Arts and Sciences    choose the name of your college/school  
 
This dissertation, written by Pablo R. Sacasa, and entitled Developing of 
Germyldesulonylation and Thiodesulfonylation Reactions for the Synthesis of Novel 
Nucleoside Analogues. Efficient Synthesis of Novel (α-Fluoro)vinyl Sulfides, having 
been approved in respect to style and intellectual content, is referred to you for judgment. 
 
We have read this dissertation and recommend that it be approved. 
 
 
_______________________________________ 
Kevin O'Shea 
 
_______________________________________ 
Martin J. Quirke 
 
_______________________________________ 
Piero Gardinali 
 
_______________________________________ 
Rene Herrera 
 
_______________________________________ 
Stanislaw F. Wnuk, Major Professor 
 
 
Date of Defense: July 19, 2010 
 
The dissertation of Pablo R. Sacasa is approved. 
 
 
_______________________________________ 
choose the name of dean of your college/school   Dean Kenneth Furton 
choose the name of your college/school   College of Arts and Sciences 
 
 
_______________________________________ 
Interim Dean Kevin O’Shea 
University Graduate School 
 
 
 
Florida International University, 2010 
 
 
 
 
 
 
 
 
 
 
 
 
DEDICATION 
I dedicate this dissertation to my family: 
Pablo, Ruth, Juan Pablo and Ruth Paola Sacasa for all of their love and support. 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
 
 
 
 
 
ACKNOWLEDGMENTS 
I am extremely grateful to my major Professor, Dr. Stanislaw F. Wnuk for all of his 
guidance, support, understanding, patience, friendship and most important of all for 
believing in me. I would also like to thank Dr. J. Martin Quirke for all of his friendship, 
help, suggestions, and for being there for me. I also want to thank Dr. Kevin O'shea and 
Dr. Piero Gardinali for their guidance and friendship throughout the years. I also want to 
thank Dr. Rene Herrera for all the helpful insights and support. Finally, I would like to 
also thank all of my coworkers in the lab for providing a family atmosphere in the work 
place. 
 
 
 
 
 
 
 
 
 
iv 
 
 
 
ABSTRACT OF THE DISSERTATION 
DEVELOPING OF GERMYLDESULFONYLATION AND 
THIODESULFONYLATION REACTIONS FOR THE SYNTHESIS OF NOVEL 
NUCLEOSIDE ANALOGUES. EFFICIENT SYNTHESIS OF NOVEL                           
(α-FLUORO)VINYL SULFIDES. 
by 
Pablo R. Sacasa 
Florida International University, 2010 
Miami, Florida 
Professor Stanislaw F. Wnuk, Major Professor 
S-adenosyl-L-homocysteine (AdoHcy) hydrolase effects hydrolytic cleavage of 
AdoHcy to produce both adenosine and L-homocysteine and is a feedback inhibitor of S-
adenosyl-L-methionine (SAM). Nucleoside analogues bearing an alkenyl or fluoroalkenyl 
chain between sulfur and C5′ utilizing Negishi coupling reactions were synthesized. 
Palladium-catalyzed cross-coupling between the 5′-deoxy-5′-(iodomethylene) 
nucleosides and alkylzinc bromides gives analogues with the alkenyl unit. Palladium-
catalyzed selective monoalkylation of 5′-(bromofluoromethylene)-5′-deoxy-adenosine 
with alkylzinc bromide afford adenosylhomocysteine analogues with a 6′-(fluoro)vinyl 
motif. The vinylic adenine nucleosides produced time-dependent inactivation of the S-
adenosyl-L-homocysteine hydrolases. 
Stannydesulfonylation reaction is a critical step in the synthesis of E-fluorovinyl 
cytidine (Tezacitabine) a ribonucleoside reductase inhibitor with a potent anticancer 
activity. The synthesis involves the removal of the sulfonyl group by a radical-mediated 
v 
 
 
 
stannyldesulfonylation reaction using tributyltin hydride. In order to eliminate the 
toxicity of tin, I developed a radical-mediated germyldesulonylation utilizing less toxic 
germane hydrides. Treatment of the protected (E)-5'-deoxy-5'-[(p-toluenesulfonyl)-
methylene]uridine and adenosine derivatives with tributyl- or triphenylgermane hydride 
effected radical-mediated germyldesulfonylations to give 5'-(tributyl- or 
triphenylgermyl)methylene-5'-deoxynucleoside derivatives as single (E)-isomers. 
Analogous treatment of 2'-deoxy-2'-[(phenylsulfonyl)methylene]uridine with Ph3GeH 
afforded the corresponding vinyl triphenylgermane product. Stereoselective 
halodegermylation of the (E)-5'-(tributylgermyl)-methylene-5'-deoxy nucleosides with 
NIS or NBS provided the Wittig-type (E)-5'-deoxy-5'-(halomethylene) nucleosides 
quantitatively. 
Radical-mediated thiodesulfonylation of the readily available vinyl and (α-fluoro) 
vinyl sulfones with aryl thiols in organic or aqueous medium to provide a bench and 
environmentally friendly protocol to access (α-fluoro)vinyl sulfides were developed. 
Methylation of the vinyl or (α-fluoro)vinyl phenyl sulfide gave access to the 
corresponding vinyl or (α-fluoro)vinyl sulfonium salts. These sulfonium ions were tested 
as possible methyl group donors during reactions with thiols, phenols or amino groups 
which are commonly present in natural amino acids. 
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1. INTRODUCTION 
Nucleoside analogues have been synthesized as potential anticancer and antiviral 
chemotherapeutic agents to mimic those created by microorganisms (1-8, figure 1).1 
There are enzymes which apply nucleosides and/or nucleotides as cofactors or substrates 
that can intervene with targets for antibiotic as well as synthetic antiviral and antitumor 
agents. In nucleic acid replication, deviant nucleosides inhibit elongation of embryonic 
nucleic acid strands or can severely suspend certain normal functions or activities of 
completed nucleic acids. For instance, certain nucleoside antibiotics can interrupt protein 
synthesis. An example of this interruption that takes place in the ribosome causing 
premature chain termination during translation involves puromycin, 4, which is derived 
from the Streptomyces alboniger bacterium, an aminonucleoside antibiotic. Part of 
puromycin resembles the 3' end of the aminoacylated tRNA. Puromycin enters the A site 
and transfers to the growing chain, causing premature chain release. How this action 
takes place is still unknown, but, the 3' position instead of containing the normal ester 
linkage of tRNA contains an amide linkage.  Thus, the amide linkage makes the molecule 
much more resistant to hydrolysis and causes complete blockage of the ribosome.1b 
 Transition state inhibitors bind rigidly to the enzymes active site, owing to their 
resemblance to the transition state that occurs during a normal enzyme reaction. 
Coformycin, 5, and 2'-deoxycoformycin, 6, are transition state inhibitors that are potent 
inhibitors of adenosine deaminase. Both 5 and 6 mimic the transition state structures of 
the adenosine and 2'-deoxyadenosine substrates during their hydrolysis to form inosine 
and 2'-deoxyinosine by adenosine deaminase.2,3  
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Figure 1. Selected Nucleoside Antibiotics. 
 Affinity labeling agents are reactive compounds that have an arrangement 
associated with that of the substrate of the target enzyme.3 After the formation of the 
reversible enzyme-inhibitor complex, acylation or alkylation reaction mechanisms tend to 
occur with the active site nucleophiles forming a stable covalent bond to the enzyme. 
Affinity labeling agents contain many reactive functional groups. As a result, these agents 
not only react with the active site of the enzyme, but also with nucleophiles associated 
with other enzymes and biomolecules. For that reason, these inactivators are potentially 
toxic, and are not useful in drug design as other types of enzyme inhibitors. 
 A mechanism-based enzyme inhibitor is an inactive compound that bears 
structural resemblance either to the substrate or the product of a specific enzyme.  Once 
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this compound binds to the active site of the target enzyme its normal catalytic 
mechanism alters it to a transitional state that is usually very reactive. Prior to escaping 
from the active site, this species can form a covalent bond to the enzyme; however, a 
tight-binding inhibitor-enzyme complex may be sufficient. The deactivator must first be 
transformed by the target enzyme into the actual deactivating species, and the 
deactivation must occur before the release of this species from the active site of the 
enzyme.2-4 Therefore, the activation of the mechanism-based inhibitors depends on the 
catalytic mechanism of the target enzyme. As a result, these inhibitors can be designed by 
coherent organic mechanistic approaches. 
1.1.  An overview of S-Adenosyl-L-Homocysteine Hydrolase.  
1.1.1.  Biological Functions of S-Adenosyl-L-Homocysteine Hydrolase 
 S-adenosyl-L-homocysteine hydrolase (AdoHcy hydrolase) effects hydrolytic 
cleavage of AdoHcy to produce both adenosine (Ado) and L-homocysteine (Hcy) and is a 
feedback inhibitor of S-adenosyl-L-methionine (SAM or AdoMet).5-7 The methyl group 
from AdoMet is transferred to a variety of acceptor macromolecules, for example, nucleic 
acids, phospholipids, proteins and small molecules such as neurotransmitters and 
hormones from specific methyl transferases in AdoMet-dependent transmethylation 
reactions. Biomethylation reactions have an effect on various aspects of metabolism, 
gene regulation and cell function.8-10 
 S-Adenosyl-L-homocysteine (AdoHcy), the product of the AdoMet-dependent 
methyl transferases must be efficiently eliminated because it is an effective competitive 
product inhibitor of methyltransferases. The AdoHcy hydrolase provides the only known 
mechanism for AdoHcy metabolism in eukaryotes by catalyzing its hydrolysis to 
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adenosine (Ado) and L-homocysteine (Hcy).  This catalytic reaction is reversible, with 
the equilibrium favoring the synthetic direction.11 Nevertheless, under physiological 
conditions, the reaction is driven in the hydrolytic direction by successive metabolic 
conversions of adenosine (e.g., to ATP, inosine) and homocysteine (e.g., to methionine, 
cystathionine).5-7 
 A side-reaction catalyzed by AdoHcy hydrolase is the conversion of adenosine to 
adenine,5  This reaction is very important because it is the only source of cellular adenine 
in the body. Another way to express this reaction is by enzymatic synthesis and 
hydrolysis of AdoHcy but it is inefficient in vitro.  The main features of the role of 
AdoHcy hydrolase in the metabolism of purine and sulfur containing compounds are 
summarized in Figure 2.  
 S-adenosyl-L-homocysteine hydrolase plays an important part in controlling 
cellular level of Hcy, which is a cystathionine synthetase-catalyzed precursor to cysteine 
and methionine.  The metabolism of AdoHcy by this enzyme is the only known source of 
Hcy in mammalian cells.12 It has been proven in clinical studies that elevated plasma 
levels of Hcy in humans is linked to coronary heart disease.13 Inhibitors of AdoHcy 
hydrolase have the potential to reduce the risk of developing coronary heart disease by 
lowering the plasma levels of Hcy.  It is known that by taking supplements containing 
folic acid and vitamin B there is a drastic effect in lowering the plasma Hcy levels in 
patients with homocysteinemia with residual activities of cystathionine synthetase.13,14 
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Figure 2. Biosynthesis Pathway and Metabolism of S-Adenosyl-L-Homocysteine and S- 
    Adenosyl-L-Methionine. 
 
 A distribution study was performed on AdoHcy hydrolase in a variety of 
mammalian tissues and it revealed that the enzyme activity was lowest in the heart and 
brain; intermediary in the spleen and testes; and highest in the liver, pancreas and 
kidneys.5 It was found that the liver of the mouse contains about twelve times more 
AdoHcy hydrolase then in the kidneys, which in turn has five times more AdoHcy 
hydrolase then in the brain. A one molar equivalent of copper is bound per subunit of 
mouse liver enzyme.15 In copper-deficient mice there is a 45% decrease in the hepatic 
level of AdoHcy.16 Therefore, binding of copper by enzyme plays a role in copper 
metabolism. 
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 The AdoHcy hydrolase from Dictyostelium discoideum can be reversibly 
inactivated by cAMP by causing dissociation of enzyme bound NAD+. Interestingly, 
cAMP is secreted by the amoebas to attract neighboring cells to a central location. This 
suggests a viable regulation mechanism by cAMP for AdoHcy or AdoMet metabolism. 
Another way to inactivate the AdoHcy hydrolase from the liver of the rat is by means of 
ATP.  The binding site for cAMP of the hydrolase is particularly different from the 
cAMP-binding site of the R1 regulatory subunit of cAMP-dependent protein kinase. 
These observations indicate that AdoHcy hydrolase competes for cAMP or ATP against 
some unknown receptors or kinases.8 
 Recently, AdoHcy hydrolase has attacted attention as a target for drug design,6,17 
because inhibitors of this enzyme exhibit antiviral,17-19 antiparasitic,20 antiarthritic21 and 
immunosuppressive effects.22 Inhibition of cellular AdoHcy hydrolase results in 
intracellular buildup of AdoHcy, as a result, it causes an increase in the intracellular 
AdoHcy/AdoMet ratios and subsequent inhibition of fundamental AdoMet-dependent 
methylation reactions. The established relationships are particularly well recognized for 
the antiviral effect of AdoHcy hydrolase inhibitors. A linear correlation between log IC50 
values (inhibition concentration which inhibits viral replication by 50%) and their log Ki 
values (inhibition potency of AdoHcy hydrolase) for a series of AdoHcy hydrolase 
inhibitors has been observed.1 
1.1.2. Mechanism of Action for S-Adenosyl-L-Homocysteine Hydrolase.  
 Palmer and Abeles23 proposed a mechanism by which AdoHcy hydrolase 
catalyzes the conversion of AdoHcy 9 to Ado 13 and Hcy (Figure 3). The first step 
(oxidative activity) of the mechanism involves the oxidation of the 3'-hydroxyl group of 
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AdoHcy by the enzyme-bound NAD+ (E•NAD+) to form E•NADH and 3'-keto-AdoHcy 
10, which then undergoes a β-elimination to Hcy to form the 3'-keto-4',5'-didehydro-5'-
deoxyAdo (KDDA, 11).  This is then followed by a Michael type addition of water to this 
tightly bound intermediate (hydrolytic activity) to give the 3'-ketoAdo 12, which is then 
reduced by E•NADH to yield Ado 13 and E•NAD+. The 4',5'-didehydro-5'-
deoxyadenosine, (DDA, 14, Figure 3) was found to be an alternative substrate of the 
enzyme.  
O
Ade
OHHO
RS E-NAD+
E-NADH
O
Ade
OHHO
HO E-NAD+
E-NADH
O
Ade
OHO
RS
O
Ade
OHO
HO
+RSH
-RSH O
Ade
OHO
O
Ade
OHHO
E-NAD+
KDDA, 11
DDA, 14
+H2O
-H2O
R = -O2CCH(NH3+)CH2CH2 E-NAD(H)
+ = Enzyme Bound
NAD(H)+
9 10
1213
 
Figure 3. Proposed Mechanism for S-Adenosyl-L-Homocysteine Hydrolase. 
 Porter and Boyd showed that neither the apoenzyme nor the reduced form of S-
adenosyl-L-homocysteine hydrolase (E•NADH) was catalytically active.24 Porter and 
Boyds’ mechanism suggest that breakage of the C5'-S bond (elimination of the Hcy from 
the 3'-keto-AdoHcy) and the formation of C5'-O bond (addition of water to the KDDA, 
11) were dependent on the oxidative activity of the enzyme. Parry and Askonas studied 
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the stereochemistry of this reaction25 and found syn geometry of the addition of Hcy to 
KDDA.  This geometry results because of the reaction, which is catalyzed by AdoHcy 
hydrolase, occurs with retention of the configuration in C5'. The elimination step is 
catalyzed by an enzyme also containing syn geometry. 
 Palmer and Abeles made the assumption that the mechanism;23 is operated in a 
sequential manner in which the oxidation of the hydroxyl functionality at C3' forms the 
3'-ketone. The "oxidative activity" was said to be a prerequisite for the conjugate addition 
of water ("hydrolytic activity") across the double bond of the activated enone.26 Borchardt 
and coworkers later demonstrated that these two catalytic activities of AdoHcy hydrolase 
were independent of one another.27 They first defined type I mechanism-based inhibitors 
of AdoHcy hydrolase as inhibitors that serve as substrates for the "oxidative" activities of 
the enzyme. These inhibitors were oxidized to the corresponding 3'-keto derivatives 
which converted the enzyme from its active form (NAD+) to its inactive form (NADH; 
cofactor depletion mechanism).  Secondly, they defined type II mechanism-based 
inhibitors of AdoHcy hydrolase as compounds that use the "oxidative" and/or 
"hydrolytic" activity of the enzyme to produce electrophiles on the active site of the 
enzyme. The electrophiles react with the enzymes nucleophiles to modify the enzyme 
(covalent inactivation mechanism).6a,14,26 Finally, they defined type III inhibitors as those 
that use neither "oxidative" nor the "hydrolytic" activity, but that they are reversibly 
bound to the enzyme.14 
The x-ray crystal structure of substrate-bound NADH from human AdoHcy 
hydrolase was determined.28 The pure NADH form of the enzyme was inactivated with 9-
(2,3-dihyroxycyclopent-4-en-1-yl)adenine (DHCeA, 15, figure 4) to produce crystals of 
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the 3'-ketoDHCeA/NADH form of human AdoHcy hydrolase which was appropriate for 
X-ray crystallographic analysis. The sequestered water molecules in the active site were 
found to hydrogen bond to His55, Asp131 and His301. Water has a dual role in the 
catalytic mechanism; it is not just used for the catalytic base responsible for the H4' 
abstraction initiating Hcy elimination, but it may also add to the intermediate enone in the 
formation of 3'-ketoAdo.14b,28 A crystal structure obtained from the liver of a rat in a 
substrate free NAD+ showed an open catalytic site in the absence of  substrate.29 The 
experiment helped identify Glu55 as a proton acceptor from the 3'-OH during the 
abstraction of the H3' by NAD+. Also it is indicated that either His54 or Asp130 acts as a 
general acid-base catalyst. The Cys194 was expected to modulate the oxidation state of 
the bound NAD+. Unfortunately, these two crystal structures do not unambiguously 
define the binding site of the homocysteine moiety of AdoHcy at the active sites of the 
enzyme. 
N
N N
N
NH2
OHHO
15  
Figure 4. 9-(2,3-Dihydroxycyclopent-4-en-1-yl)adenosine (DHCeA). A Potential  
    Inhibitor of S-Adenosyl-L-Homocysteine Hydrolase. 
 
1.1.3.  Hydrolytic Activity of S-Adenosyl-L-Homocysteine Hydrolase with Halovinyl 
Adenosine Analogues. 
 McCarthy and coworkers designed and synthesized vinyl fluoride 16 (4',5'-
didehydro-5'-deoxy-5'-fluoroAdo) and vinyl chloride 17 as feasible type II mechanism 
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based inhibitors that also displayed significant biological activity (Figure 5).30 The 
synthesis of 16 was performed by fluorination of a protected 5'-S-aryl-5'-thioadenosine 
analogue, 19, with (diethylamino)sulfur trifluoride (DAST) to produce the α-
fluorothioesters 21. Subsequent oxidation with m-chloroperoxybenzoic acid (m-CPBA) 
gave the α-fluoro sulfoxide diastereomers 22.30b,31 Thermal elimination of sulfenic acid 
(Figure 6) from 22 and deprotection gave the vinyl fluoride 16 as E/Z isomers.30 The most 
important step in this reaction sequence was fluorination of sulfoxide 19, or thioether 20 
using DAST/SbCl3 combinations developed by Wnuk and Robins.32  
O
N
N N
N
NH2
OHHO
O
N
N N
N
NH2
OHHO
OX
16   X = F
17   X = Cl
18
 
Figure 5. Selected Inhibitors of S-Adenosyl-L-Homocysteine Hydrolase. 
Borchardt and coworkers proved27 that vinyl fluoride 16 is not a type II based 
inhibitor. Instead, 16, is a "pro-inhibitor" that was altered by the AdoHcy hydrolase to 
form both adenosine 5'-aldehyde 18 and its 4'-epimers which inactivates the enzyme by a 
type I mechanism. The elimination of the fluorine from 16 was executed by the 
"hydrolytic" activity of the enzyme and was found to be independent of the enzymes 
"oxidative" activity.27,33 The Ado-5'-aldehyde 18 was independently synthesized and 
shown to be a potent inhibitor of AdoHcy hydrolase.34  
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Figure 6. Synthesis of the 5'-Fluoro(vinyl)adenosine. 
 It was found that AdoHcy hydrolase also adds water across the isolated 5',6' 
double bond of the 6'-halo(vinyl)homoAdo derivative.  A combination of a sulfonyl-
stabilized Wittig-type reagent and organotin chemistry was utilized for the synthesis of 
homovinyl halides 27 (scheme 1).35 Thus, Moffatt oxidation of the 2',3'-O-
isopropylideneadenosine and treatment of the crude 5'-aldehyde 23 with [(p-
tolylsulfonyl)methylene]-triphenylphosphorane, Ph3P=CHTs, afforded the 6'-
tosyl(vinyl)-sulfone 24 with the E isomer being the major product.36 Radical 
stannyldesulfonylation35 (Bu3SnH/AIBN/toluene/∆) of 24 produced separable mixtures of 
the vinyl 6'-stannane 25 (E/Z, > 6:1). Quantitative and stereospecific halodestannylation35 
of 25 (E or Z isomers) occurred with I2 or Br2 (or the respective N-halosuccinimides) gave 
the Wittig type 6'-iodo (or bromo) homovinylAdo 26 (E/Z isomers). Deprotection and 
purification afforded 27. Treatment of 25 with XeFe2/silver triflate37 resulted in 
fluorodestannylation, 27 (X = F). Chlorine converted 25 to 6'-chloro derivative 27 (X = 
Cl, E and Z) but with less stereoselectivity.35 
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Scheme 1. Synthesis of 6'-Halo(vinyl)homoadenosine Analogues. 
The 6'-halo(homo)vinylAdo analogues 27 were found to be concentration and 
time-dependent inactivators of AdoHcy hydrolase. The inhibition potencies which were 
linked with anticancer and antiviral activities of 27, were found to be in the following 
order: I > Br > Cl > F (and E > Z).35 Astonishingly, AdoHcy hydrolase exhibits the 
catalytic control to achieve the addition of water to the isolated double bonds of 27.38 
AdoHcy hydrolase effected hydrolysis of the 6'-halogen from 27 by the addition of water 
at C6' (path a). Subsequent halogen elimination produced homoadenosine 6'-aldehyde 28, 
which undergoes a spontaneous decomposition to Ade (figure 7). Addition of water at 
C5' of 27 (X = F) resulted in the formation of 6'-deoxy-6'-fluoro-5'-hydroxyhomo-
adenosine 31 (path b). In the third pathway, the enzymatic oxidation of 27 provided 3'-
ketone 29 which may further react with water at either the C5' of the C6' position (path 
c).38 The hydrolytic (C5'/C6') and oxidative (C3') activities of AdoHcy hydrolase are 
differentiated effectively by the 6'-fluoro analogue 27 (X = F) with the following partition 
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ratio among three pathways: k3': k5': k6' = 1:79:29.38b Lys426 was shown to be a crucial 
residue for the enzymatic hydrolysis of 27 (X = F).26 
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Figure 7. Inactivation of S-Adenosyl-L-Homocysteine Hydrolase by the 6'-Fluoro(vinyl)  
    Homoadenosine. 
 
Interestingly, the 4', 5'-didehydro-5'-deoxy-5'-fluoroaristeromycin (33a, Figure 8) 
is not a substrate for the hydrolytic activities of the enzyme. Incubation of AdoHcy 
hydrolase with 33a did not show the release of the fluoride ion.39 However, both 33a and 
the independently synthesized aristeromycin 5'-aldehyde 33b are potent type I 
inhibitors.39,40 Thus, it is reasonable to assume that enzyme mediated protonation of the 
ribosyl ring oxygen in 16 (as well as in 27) enhances the electrophilicity of the C5', hence 
allowing the 5' position to be more vulnerable to the attack by the enzyme bound water. 
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Figure 8. The 5'-Halo(vinyl)homoaristeromycin and 5'-Aldehyde Analogue. 
 To probe "pure" hydrolytic activity of the AdoHcy hydrolase,26 analogues of vinyl 
halides 16 and 27 without an oxidizable functional group (hydroxyl group) at C3' have 
been targeted for studying.41 The 3'-deoxy modified analogues (34 and 37) lack a 
hydrogen bounding  acceptor-donor hydroxyl group at C3' (Figure 9). In other series, the 
3'-hydroxyl group was replaced with a fluoro 35 or chloro 36 substituent to give a closer 
stereoelectronic analogue to the natural substrates, but still preventing the oxidative 
activity at C3'.  The 3' modified analogues 34-36 were found to be weak inhibitors of 
AdoHcy hydrolase in a sharp contrast to the 3'-hydroxy analogues 16 and 27.41 Thus, it is 
reasonable to conclude that the 3'-hydroxyl group is necessary for the effective 
inhibitor/substrate binding to the AdoHcy hydrolase, and such binding is required for the 
execution of the "hydrolytic" activity of the enzyme. 
O
Ade
OHR
F
34 R = H
35 R = F
36 R = Cl
O
Ade
OH
X
37 X = I, Br, F
 
Figure 9. The 3'-Modified Vinyl Halides Analogues of Adenosine and Homoadenosine. 
The geminal and vicinal dihalo(homo)vinyl analogues 38-40 were also designed 
as potential novel substrates for the "hydrolytic" activity of AdoHcy hydrolase (figure 
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10).42 Thus treatment of the crude Ado-5'-aldehyde 23 with (bromofluoromethylene)-
triphenylphosphorane (generated in situ with CBr3F/Ph3P/Zn) and deprotection produced 
the bromofluorovinyl diastereomers 38 (E/Z, ~3:2).42 The analogous treatment of 23 with 
dibromomethylene-Wittig reagent provided the geminal dibromo derivatives 39. 
Bromination of the 5'-bromo(homo)vinyl derivatives 41 gave the 5',5'',6'-tribromo 
compound and the subsequent amine-mediated dehydrobromination and deprotection 
produced the vicinal 5',6'-dibromo(homo)vinyl derivative 40 as a single diastereomer.42 
O
Ade
OHHO
Br
X
O
Ade
OHHO
O
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OROR
Br
Br
Br
38 X = F
39 X = Br
40 41 R, R = CMe2  
Figure 10. The Dihalo(homo)vinyladenosine Analogues. 
 The [bromo(fluoro)](homo)vinyl analogue 38 covalently modified the human 
placental AdoHcy hydrolase and was also found to be the first type II inhibitor that uses 
only "hydrolytic" activity.43 Thus, the enzyme mediated addition of water to 38 at C6' of 
the 5', 6'-double bond (followed by elimination of bromide ion) generated an electrophilic 
acyl fluoride 42a (figure 11). Nucleophilic attack by a proximal Arg196-NH2 group 
formed a covalent adduct 42b (a lethal event). The enzyme maintained its original 
NAD+/NADH content indicating no oxidation at C3'. In the second non-lethal event 
depurination and hydrolysis of 42a (with elimination of fluoride ion) produced the hexose 
derived 6-carboxylic acid.43      
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Figure 11. Plausible Mechanism for the Inactivation of S-Adenosyl-L-Homocysteine  
      Hydrolase by 6'-Bromo-6'-fluoro(homovinyl)adenosine. 
 
1.2. An Overview of S-Adenosyl-L-Methionine  
1.2.1. Biological Functions of S-Adenosyl-L-Methionine 
Giulio Cantoni discovered S-adenosyl-L-methionine (SAM or AdoMet) in 
1953.44,45 S-adenosyl-L-methionine was formed from the reaction catalyzed by 
methionine adenosyltransferase (MAT or SAM synthetase) with methionine and the 
adenosyl moiety of adenosine triphosphate (ATP). S-adenosyl-L-methionine was used as 
a source of methylation for a wide array of biological reactions, giving AdoMet the title 
of one of the most used enzyme substrates after ATP. S-adenosyl-L-methionine can 
donate to a wide array of chemical groups including ribosyl, aminoalkyl, methylene and 
amino groups, as well as a source of 5'-deoxyadenosyl radicals. More or less 15 
subfamilies have been found containing different structural folds and domains which 
execute all of these chemical reactions.44  
Thus, DNA methyltransferases catalyze the alteration of adenine and cytosine 
methylations, which are critical in many cellular events especially those involving DNA 
replication, defense against phage invasion, gene regulation and mismatch repair.46 
Human homologues DNMT1, DNMT2, DNMT3a and DNMT3b all are known to modify 
DNA at cytosine C5 (Figure 12), which are essential for gene regulation, host defense 
mechanisms and genetic imprinting.47 Owing to their contribution in bacterial virulence 
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and tumorigenesis, both human and bacterial enzyme are targets for antibiotic and 
chemotherapeutic drugs.48 
        CH3
5'.....CG.....3'
3'.....GC.....5'
        CH3
5'.....CG.....3'
3'.....GC.....5'
CH3
Human DNMT1
 
Figure 12. C-5 Methylation of Cytosine by Human DNA Methyltransferase (DNMT1). 
  The SAM-dependent methylation of proteins and nucleic acids plays a 
fundamental role in gene transcription regulations.49,50  Errors in the expression levels, 
and activities of eukaryotic DNA methyltransferases (MTase) DNMT1 was shown to be 
linked to oncogenic potential.51 Therefore, compounds which can undergo DNMT1-
dependent transfer to DNA might prove useful in a novel chemotherapeutic strategy by 
asset of altered transcriptional repression mechanisms which are connected with promoter 
methylation.52  These substances can undergo transfers to nucleic acids in MTase-
dependent fashion serving as biological tools to better comprehend biological 
methylations.  
1.2.2. S-Adenosyl-L-Methionine: A Methyl Group Donor. 
S-adenosyl-L-methionine has been claimed to have played a diverse role in the 
"last universal common ancestor" (LUCA) of bacteria, Archaea and Eukarya.53 Most 
probably, LUCA synthesized SAM de novo (44, Scheme 2) and used to (i) affect 
translation by methylating both RNA and proteins, (ii) decarboxylate SAM (yielding 
decarboxylated SAM, dcSAM) through the synthesis of polyamines, (iii) generate SAM 
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(5'-deoxyadenosyl) radicals. Approximately 95% of SAM is employed for methylation 
and 3-5% is used for the generation of the decarboxylated SAM.54 In humans, it is 
believed that 85% of the methylation reactions and around 50% of methionine 
metabolisms takes place in the liver. 
S-adenosyl-L-methionine is coined "mother nature's methyl iodide" because it is a 
potent nonspecific alkylating agent, which is very specific when it guides MTases 
capable of alkylating DNA, RNA and proteins. SAM is also used as a biosynthetic tool 
for the production of secondary metabolites.55 Understanding the role of biological 
methylation, generally in gene transcription, has been hindered by the lack of tools for the 
identification of MTase substrates.56 Owing to the methyl groups' lack of functionality, 
they are difficult to identify in complex biological environments.  
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Scheme 2. Biosynthesis of S-Adenosyl-L-Methionine. 
The SAM-dependent methyltransferases catalyze the transfer of the activated 
methyl group from the substrate to a carbon, sulfur, nitrogen or oxygen containing 
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acceptor of small entities, phospholipids, proteins, RNA and DNA with a good 
specificity.57 Kimzeys' group noted that the methyl group is transferred into the proteins 
of hemoglobin without any apparent involvement of an enzyme. The methyl group can be 
incorporated into multiple sites into hemoglobin, because both α and β chains are 
methylated.   The methyl transfer to hemoglobin from AdoMet is slow and inefficient 
(kcat/Km ~5 x 10-2), the reaction rate tends toward a plateau with increasing AdoMet 
concentrations signifying that saturable binding of AdoMet to hemoglobin is involved in 
methyl transfer. The rate of hemoglobin methylation is inhibited by S-
adenosylhomocysteine, the known inhibitor of methyltransferases, an additional sign that 
methyl group transfer involves binding and catalysis by a specific site (or sites) in the 
hemoglobin molecule.58  
1.2.3. Regulation of S-Adenosyl-L-Methionine Levels 
S-adenosyl-L-methionine is created from ATP and methionine by methionine 
adenosyltransferase which are present in all cells in virtually all organisms, including 
archaea, eubacteria, and eukaryotes. The reaction involves, primarily, the transfer of the 
adenosyl group of ATP to methionine, with the remnants of the ATP being transformed 
to enzyme-bound tripoly-phosphate (43, Scheme 2). The final compound is hydrolyzed to 
pyrophosphate and phosphate, which are then expelled from the cell. S-adenosyl-L-
methionine, a sulfonium compound, provides a large amount of free energy (20 
~kcal/mol) needed for methyl group transfers. It is possibly the most multitalented 
compound in nature; it is a not just a source of methyl groups but, in assorted reactions in 
various organisms, provides methylene groups, four-carbon moieties, ribosyl groups, 
amino groups, and, after decarboxylation, three-carbon moieties for polyamines and 
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ethylene.59 It may be converted to a 5'-deoxyadenosyl free radical that participates in a 
great variety of “radical SAM” reactions. It also functions as a regulator of many 
metabolic pathways in mammals, plants, and bacteria. 
In mammals, more than 90% of AdoMet is used for methylation reactions, which 
involve at least 50 different methyltransferases. Methylation of both small molecules (e.g. 
phosphatidylethanolamine) and macromolecules (DNA, RNA, proteins) plays vital roles 
in cellular metabolism. For instance, methylations of DNA and histones are major events 
in epigenetics [changes in phenotype (appearance) or gene expression caused by 
mechanisms other than changes in the underlying DNA sequence]. As a result, the level 
of AdoMet must be carefully regulated to maintain cellular homeostasis. Recent evidence 
has established that glycine N-methyltransferase (GNMT) plays a major role in 
maintaining normal AdoMet levels in mammals. 
1.2.3.1. By Glycine N-Methyltransferase 
Enzymatically catalyzed direct transfer of a methyl group from AdoMet to 
glycine (forming sarcosine, e.g. N-methylglycine) was confirmed in 1960. AdoMet was 
shown to have activity in liver extracts from guinea pig, rat, rabbit, and mouse, but 
unfortunately, the enzyme was not purified until 1972 after Heady and Kerr, found that 
glycine was a better acceptor of AdoMet methyl groups than tRNA. They proceeded to 
purify the GNMT activity from rabbit liver.60 It was found that GNMT expression is 
down-regulated or even completely inhibited in liver, prostate tumor tissue61 and in most 
cultured cells. Even though not much is known about the properties of the GNMT gene 
promoters of experimental animals, it has been shown that GNMT activity is induced by 
vitamin A, glucocorticoids, and glucagon.62 Decreased levels of GNMT in prostate tumor 
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tissues might be negatively correlated with that the level of sarcosine in prostate tissue. 
However, sarcosine is found in elevated amounts in metastatic prostate tissue compared 
with normal human prostate and localized prostate cancer. It is found that sarcosine is 
increased in the urine of men with metastatic prostate cancer, which implies that this 
metabolite may be a marker for progression of the cancer.63 
1.2.3.2. By Arginine N-Methyltransferase 
Enzymes which use SAM as methyl donors catalyze all post-translational 
formation of monomethylated Arg residues (MMA, Scheme 3). Protein arginine 
methyltransferases (PRMTs) are responsible for catalyzing the methylation of Arg 
residues, 46, in various proteins which include histones (H2A, H3 and H4) and various 
other proteins involved in cell signaling and RNA splicing.  These Arg residues are then 
further processed to form either asymmetric dimethylated Arg (49, ADMA) or symmetric 
dimethylated Arg (48, SDMA) by utilizing either Type I or II PRMTs. In humans, there 
are at least nine different PRMTs which are known to play a physiological role in a 
number of cellular processes (transcriptional regulation). For instance, PRMT1 and 
PRMT4/CARM1 (coactivator associated arginine methyltransferase 1), act as 
transcriptional coactivators for a variety of transcriptional forces.  The PRMTs are 
interesting because dysregulated PRMT activities appear to be associated with heart 
disease and cancer, making them a potential target for therapeutic design.64 
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Scheme 3. Biosynthesis of Mono and Dimethylated Arginine Residues by S-Adenosyl-L- 
         Methionine. 
 
1.2.3.3. By C5 Methylation of Cytosine. 
Contrary to the well-established methylation of C5 of 2'-deoxyuridine by 
thymidylate synthase, it was reported that SAM can perform C5 methylation of cytidine 
catalyzed by methyltransferases.65 The positioning of the AdoHcy and AdoMet 
methylsulfonium to the C5 of cytosine base provides an ideal trajectory and distance for 
methyltransfer reaction to occur (Scheme 4).65 
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Scheme 4. C5 Methylation of Cytidine by Methyltransferases. 
The DNA (cytosine-5)-methyltransferase (C5 MTases) are recognized for their 
ability to catalyze the transfer of the methyl group from AdoMet to cytosine, 50, C5 atom 
in specific DNA sequences. Thus, the methylation reaction of C5 MTases arises with the 
addition of a cysteine thiol group from the preserved Pro-Cys motif to the C6 position of 
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the target cytosine, 51, in a step which resembles action of thymidylate on 2'-
deoxyuridiine. It is then followed by the methyl transfer from AdoMet to C5 of the target 
base and the release of the methylated substrate, 52. The source of the methyl group 
(Tetrahydrofolate; THF in the case of thymidylate synthase) is the biggest difference 
between these two enzymes. There are some cytosine analogues, 5-fluorocytosine (FC), 
5-azacytosine (AzaC) and 2-pyrimidinone (2P), which have been identified as 
mechanism-based inhibitors of C5 MTases.65,66 When a fluorine atom is introduced to the 
C5 position of the target cytosine, it results in an irreversible covalent attack of a cysteine 
residue and transfer of a methyl group to the C5 position of the target base. 
The Gromovas group65 studies the mechanism of inhibition of EcoRII DNA 
methyl
involves the addition of a cysteine thiol group of the 
enzyme
transferases (M.EcoRII) by DNA containing 2-pyrimidinone, as well as, DNA 
containing 2 pyrimidinone which they used to probe contacts of M.EcoRII with 
functional groups of pyrimidine bases of the recognition sequence. 2-Pyrimidinone is a 
cytosine analogue, in which the exocyclic amino group is replaced by a hydrogen atom. It 
is known that removing the exocyclic amino group from the cytosine results in an 
increase of reactivity at the C6 position in 2-Pyrimidinone and in a reduction of the 
energy barrier for base flipping. 
The reaction mechanism 
 to the C6 position of 2-pyrimidinone, 53, followed by proton transfer to the C5 
position, 54. Owing to the absense of the exocyclic amino group in 55, β-elimination of 
the proton from the C5 position is deinhibited. It is noteworthy, that 1-(β-D-
ribofuranosyl)-2-pyrimidinone, which is also known as Zebularine. It is used in vivo as 
 
 
an antitumor drug. It is known that its antitumor properties are probably attributed to 
inhibition of C5 MTase activity in tumor cells.67 
Gromova proposed that stable covalent adducts 56 between M.EcoRII and 2-
Pyrimidinone residue in DNA were formed, and that the quantity grew with the 
increasing enzyme concentration. For that reason, inhibition of M.EcoRII by 2-
Pyrimidinone containing DNA occurs with methyl group transfer to the C5 position of 2-
Pyrimidinone. All active enzyme molecules become covalently bound to 2-Pyrimidinone 
-containing DNA (Fig. 13B, step 1). It is suggested that a covalent adduct with M.EcoRII 
is formed within the first few minutes of the reaction. In the absence of AdoMet, proton 
transfer to the C5 position of 2-pyrimidinone occurs instead (Fig. 13A). In the presence 
of AdoMet, methyl transfer to the C5 position of 2-pyrimidinone occurs (57, Fig. 13B). 
The formation of stable covalent intermediate between M.EcoRII and 2-Pyrimidinone -
containing DNA in the presence of AdoMet causes the inhibition of the methylation. 
From these results, 2-pyrimidinone is seen as a potent inhibitor that arises from the 
retardation of proton elimination from 58, leading to the formation of 59 from the 
covalent intermediate.67 
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Figure 13. Proposed Mechanism for the Inhibition of M.EcoRII by 2-Pyrimidone  
      Containing DNA Duplexs in the Absence (A) or in the Presence (B) of    
      S-Adenosyl-L-Methionine. 
 
1.3. Overview of the Biological Activity of the Vinyl and α-(Fluoro)vinyl Sulfone,     
             Sulfoxide, Sulfide and Sulfonium Compounds Containing Fluorine. 
Since the synthesis of the fluoro organic compounds have been extensively 
reviewed68,70,71 the next section of my dissertation will mostly deal with the literature 
review of the biological activity of the vinyl and α-(fluoro)vinyl sulfones, sulfoxides, 
sulfides and sulfonium salts. Special attention will be placed on the rational that can be 
used for design of the novel mechanism-based inhibitors. 
1.3.1. General Importance of the Fluorine Containing Drugs. 
Significant alterations in biological activity are often observed in organic 
compounds associated with the replacement of an H-atom in a molecule by an F-atom. 
The replacement not only enhances the biological activity of parent compounds, but it 
also increases their thermal and oxidative stabilities.68 A wide array of monofluoro 
compounds display extraordinary biological activities,68 and medical and biological 
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sciences put forth an increasing demand for fluorinated organic compounds. Compounds 
with a fluorine atom attached to a vinylic group are of great importance, as this moiety is 
present in a number of enzyme inhibitors. Therefore, the synthesis of selectively 
fluorinated building blocks, such as phenyl-substituted fluoro alkenes has become an 
important area for research.  
Fluorinated compounds make up some of the most successful pharmaceutical 
drugs (Figure 14) on the market today ranging from antidepressants, for example, 
Prozac® (60, Eli Lilly), Paxil®, 61 to the most prescribed antibiotic Ciprofloxacin® (62, 
Bayer). The integration of a fluorine atom is considered a simple method for the 
modification that often results in a improved bioactivity as compared to the original 
drug.69 In general, fluorinated compounds require a lower dosage than their non-
fluorinated drugs or compounds counterpart to be effective.69a For example, the 
introduction of a fluorine atom into Ciprofloxacin 62, increases the rate of cell 
penetration by up to 70 times.70 The fluorine atom is strongly electronegative,69,71 
possibly leading to increased interactions between calcitriol and the vitamin D receptor 
(VDR). Fluorine is sterically comparable to hydrogen atom; therefore it creates no 
increased steric hindrance for VDR binding. Furthermore, fluorine is known to form the 
strongest covalent bonds69b-71 with carbon which may encumber the catabolic pathway. 
These encouraging characteristics, in addition to the synthetic simplicity of fluorine 
incorporation, make fluorine an excellent candidate for drug design and synthesis. 
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Figure 14. Selected Fluorinated Drugs. 
The importance of the fluorinated compounds have increased significantly owing 
to the unique influence of the fluorine atom on the chemical, physical, and physiological 
properties.72 For example, fluoroolefins are significant, because of their application in the 
synthesis of biologically active mechanism-based inhibitors including materials like 
peptide isosteres.73 To start a versatile synthetic method of desired fluorinated 
compounds, there must first be fluorine-containing building blocks which are frequently 
lacking.74  
1.3.2. Biological Activity of the Vinyl and α-(Fluoro)vinyl Sulfones. 
Enzymes that degrade polypeptides are known as proteases. Cysteine proteases 
are widely found in fruits including papaya, pineapple, and kiwi. They are prevalent in 
nature and hold a fundamental position in the metabolism of both eukaryotic and 
prokaryotic organisms.75 Numerous inhibitors are studied in drug development programs 
that target human proteases for diseases such as osteoporosis, rheumatoid arthritis, 
metastasis, arterial thrombosis, tumor invasion and Alzheimer’s disease.76 Cysteine 
proteases also play a considerable role in  protozoa such as Plasmodium, Trypanosome 
and Leishmania and inhibitors of falcipain and cruzain, whch are two key parasitic 
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cysteine proteases. These proteases are now under examination as probable treatment for 
Chagas’ disease and malaria.77 
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Scheme 5. Cysteine Protease Mechanism for the Hydrolysis of Amide Bond (Proteins). 
The general catalytic mechanism of the cysteine proteases (Scheme 5) involves a 
nucleophilic attack of one of the cysteine thiol. The initial step is the deprotonation of the 
thiol in the enzyme's active site by an adjacent basic amino acid (I). The pathway 
continues with a nucleophilic attack by the deprotonated cysteine anion (II) on the 
substrate carbonyl carbon via the proposed transition state of type III. The amino acid 
residue in the protease is then returned to its deprotonated form, and a thioester 
intermediate connecting to the new carboxy-terminus of the substrate to the cysteine thiol 
and the fragment of the substrate with an amine terminus are formed (IV). Finally, the 
thioester bond is hydrolyzed to generate the carboxylic acid (V) on the remaining 
substrate fragment, while regenerating the free enzyme (I).  
A great number of these inhibitors were designed from the corresponding peptide 
substrate of the target enzyme which are modified at the P1 position where the amide 
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group is substituted by a “warhead”: an electrophilic group with high affinity for the 
active site thiol group.75 Warheads tend to consist of ketones and nitriles, producing 
reversible tight binding inhibitors, epoxides and Michael acceptors.  These groups are 
then capable of reacting covalently with the thiolate, affording irreversible inhibitors.76 
Peptide vinyl sulfones and their analogues such as vinyl sulfonamides and vinyl sulfonate 
esters are some of the most interesting Michael acceptors to be developed as cysteine 
protease inhibitors.78 Vinyl sulfones selectively inhibit several cysteine proteases in a low 
nM range.75 For example, compounds 63-65 inhibit falcipains and cruzains and are an 
important tool in antiprotozoal drug design and development (Figure 15). 
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63 R1 = CH2CH2Ph; R2 = H
64 R1 = CH2Ph;        R2 = H
65 R1 = CH2Ph;        R2 = F  
Figure 15. Fluorinated and Nonfluorinated Vinyl Sulfones as Potential Cysteine Protease  
      Inhibitors. 
 
Haemers' interest in fluoro-olefins allowed him to evaluate the influence of α-
fluorine in a Michael acceptor type cysteine protease inhibitor.75 The introduction of an 
inductively electron-withdrawing group on the α-carbon, such as, fluorine is assumed to 
increase the electron deficiency at the α-carbon. Alternatively, the lone pairs of electrons 
of the fluorine atom could then contribute and overlap with the existing conjugate π-
system, contributing as a mesomeric donor. The insertion of a fluorine atom at the α-
carbon resulted in an astonishing effect: the positive charge at the α-carbon entails that 
the fluorine atom influences the charge density by way of a field effect, rather than a 
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mesomeric donating effect (Scheme 6). Nevertheless, this field effect did not interfere 
with the β-carbon. The bond between the α-carbon and the β-carbon is further polarized, 
creating a partial negative charge on the latter. Consequently, the β-carbon is no longer an 
appropriate place for a nucleophilic attack. 
SO2Ph
FR


 SO2Ph
FR
Inductive effectMesomeric effectSO2Ph
FR
 
Scheme 6. Inductive Effect Vs Mesomeric Effect for the α-Fluorovinyl Sulfone. 
The negative charge on the β-carbon does not have an effect on the charge of the 
γ-carbon. As an alternative, the hydrogen atom located on the β-carbon becomes a more 
positive species. The negative charge on the β-carbon could also be influenced by a 
mesomeric effect. In one of the likely mesomeric forms, an alkene is formed between the 
fluorine and the α-carbon, resulting in a negative charge on the β-carbon. However, when 
bond lengths between the α- and β-carbons are studied, no considerable changes are seen 
on the substitution by a fluorine atom, the changes being less than 0.01 a.u.75 On the other 
hand a mesomeric effect would cause lengthening to this bond. Lastly, Haemers tested 
the influence of α-fluorine on the activity of Michael acceptor cysteine protease inhibitors 
using Leishmania CPB cysteine protease. The reactivity of the addition might be 
improved if the electrophilicity of the β-carbon of the Michael acceptor is increased. 
Haemers used the vinyl phenylsulfone acceptor system and prepared reference compound 
64 and its α-fluoro derivative 65. They found that compound 64 is a potent inhibitor of 
the Leishmania cysteine protease CPB, while compound 65 was found to be a weak 
inhibitor. These in vitro observations confirmed the theoretical predictions that the 
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introduction of α-fluorine in a Michael acceptor such as vinyl sulfones should not result 
in increasing Michael acceptor properties of these enzymatic substrates. 
The fluorovinyl sulfone compounds 67 and 68 (Scheme 7) were found to be 
unreactive towards thiols and remained unchanged. Contrary to this lack of reactivity, the 
H-vinyl sulfone 66 reacted to completion with thiols within 45 minutes producing the 
desired addition at carbon β. Thus, there is lower reactivity of the sulfone as a Michael 
acceptor towards thiolate nucleophiles when α-fluorine was present in the vinyl sulfone 
moiety.  
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Scheme 7. Conjugated Addition of Thiolates to Vinyl Phenyl Sulfones. 
1.3.2.1. Vinyl Sulfones as Cysteine Protease Inhibitors. 
Cysteine proteases from malaria parasites are of great interest as therapeutic 
targets79 because of their role in parasite development.80 Plasmodium falciparum contains 
four cysteine proteases from the papain family known as falcipains, for example, 
falcipain-2 (FP-2)81  and falcipain-3 (FP-3)81b,82 which are widely used as therapeutic 
targets. Peptidyl vinyl sulfone, 72 (Figure 16), was found to be a potent irreversible 
inhibitor of falcipains, which acts as Michael acceptor for the catalytic cysteine residue.83 
Falcipain inhibitors are believed to inhibit the development of cultured erythrocytic 
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parasites by blocking the hydrolysis of the host hemoglobin. They also cure mice infected 
with lethal malaria infections.84 
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Figure 16. Structure of a Dipeptidyl Mu-Leu-hPhe-VSPh Containing Vinyl Sulfone.  
In regards to the use of protease inhibitors as antimalarials, the concern is that 
selection of drug-resistant strains will eventually occur.79 Parasites resistant to a 
dipeptidyl vinyl sulfone have been observed in Lopes' laboratory, although this resistance 
was somewhat limited.85 Dipeptidyl vinyl sulfones are good candidates for combination 
antimalarial therapy as a strategy to retard the development of resistance; as a result, 
Lopes designed artemisinin–vinyl sulfone hybrid molecules for the potential prevention 
of multi-drug resistance in P. falciparum. 
The structure activity relationship (SAR) data for the inhibition of FP-2 exposed 
that peptidyl vinyl sulfones containing a Leu residue at the P2 position and an hPhe 
(homophenylalanine) at the P1 position, 72, is very active. These vinyl sulfones have IC50 
values in the low-nM range.81a,82,86 Hybrid molecule 73 bearing an endoperoxide motif 
was also designed and synthesized (Figure 17). In this inhibitor the vinyl sulfone 
component is linked to the endoperoxide moiety via the N-terminus, using a 4-
hydroxymethylbenzoic acid linker. This hybrid molecule, 73, displays potent 
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antiplasmodial activity against a panel of P. falciparum chloroquine-sensitive and 
multidrug-resistant strains, with IC50 values ranging from 2 to 5 nM.  
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Figure 17. Structure of a Hybrid Vinyl Sulfone with Activity Towards P. falciparium. 
1.3.3. Selected Biological Properties of Vinyl Sulfoxide.  
The biological activity of sulfoxides is usually credited to their capability of either 
being reduced to the corresponding sulfides or oxidized to the corresponding sulfones. In 
tumor cells, the solid center is usually deprived of oxygen and is similar to a low oxygen 
tension (hypoxia) area resistant to both radiotherapy and chemotherapy. The use of 
bioreductive agents which are selectively toxic to hypoxic cells upon enzymatic reduction 
has been reported.87 For example, Sulindac which is marketed in the UK & U.S. by 
Merck as Clinoril ® as a non-steroidal anti-inflammatory drug of the arylalkanoic acid 
class with a methyl sufonyl group attached to the phenyl ring. Sulindac sulfone has 
cancer chemopreventive activity88 and inhibition of angiogenesis with sulindac or its 
sulfone metabolite may also contribute to their antineoplastic properties.89 
Santelli-Rouvier states that it could be deduced, from a comparison of sulfides 
and sulfoxides that sulfoxides are not sulfide prodrugs as their activity against human 
cancer cell lines are usually greater as compared to the corresponding sulfides because, 
sulfoxides can undergo redox type reactions. While the analogous sulfones are far less 
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active, this can be attributed to their low pKa values. Leaving group properties of the 
sulfoxides have also been correlated to their biological activity.90 Additionally, the 
antitumor activity of complexes of platinum containing substituted sulfoxides suggested 
that these complexes may act by binding to DNA with consequent loss of the sulfoxide 
ligand.91 Brefeldin A (BFA), is a lactone antibiotic produced by fungal organisms such as 
Eupenicillium brefeldianum. Brefeldin A has antitumor activity by inducing apoptosis in 
cancer cells although clinical use was prohibited because of undesirable pharmacokinetic 
properties. The sulfoxide derivatives present activities comparable to that of BFA. One 
was shown to be more active than BFA. The sulfide analogues were less active than the 
sulfoxides. This could be attributed to the ability of the sulfoxide and not the sulfide to 
undergo elimination, which leads to the regeneration of BFA.92 
1.3.4. Selected Biological Properties of Vinyl Sulfides. 
Not a lot of work has been performed in the cyclization of peptides bearing 
preconstructed vinyl sulfides unit within. Crescenza’s work showed that a vinyl sulfide 
could be formed by an elimination-addition of an enol triflate. The reaction occurred via 
an intermediate allene in the synthesis of a 7-membered dipeptide unit.93  The vinyl 
sulfide motif should possess properties to be used for conformational fine-tuning of 
structure activity relationships (SARs) for cyclic peptide analogues. Pharmacologically 
these vinyl sulfide ring systems should exhibit higher metabolic stability as well as higher 
affinity and full agonist properties in the AT1 receptor.94 
α-(Halo)vinyl sulfides were synthesized as potential targets from compounds 
containing the trifluoromethyl motif. For example, vinyl chloride 75a and vinyl bromide 
75b were obtained as the major products in good yields when the (Z)-1-stannyl-2-
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tributylstannyl-1-(4-methylphenylthio)ethene 74 was treated with CuCl2 or CuBr2 in the 
presence of Pd(OAc)2 catalyst (Scheme 8).95 
F3C SnBu3
STol
CuCl2 or CuBr2
Pd(OAc)2
F3C X
STol
74 75a X = Cl (74%)
75b X = Br (68%)  
Scheme 8. Synthesis of α-Bromo and α-Chlorovinyl Sulfides by Halodestannylation     
                  Reaction. 
 
Cyclization most often utilize disulfide or diamide bond formastion in a process 
which imposes conformational constraints.96 Hallberg’s group formulated methods to 
deliver active angiotensin II (Ang II) derivatives  that contain ring systems which have 
similar conformational properties to those of disulfide. However, there is a vinyl sulfide 
unit instead of the redox-sensitive disulfide bridge. The Ang II derivatives 76a and 76b 
were synthesized containing a 13-member ring with a cis and trans vinyl sulfide bridge, 
as a valuable tool in the search for Ang II conformation bioactivity.97 (Scheme 9). 
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Scheme 9. Vinyl Sulfide Analogues of Angiotensin II. 
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1.3.5. Selected Biological Properties of Vinyl Sulfonium Ions. 
Thioether S-methyltransferase (TEMTase) is a key enzyme in the metabolism of 
sulfur and selenium containing compounds in animals.98 Ethyl vinyl sulfide (EVS) was 
found to be a substrate for this enzyme yielding methyl ethyl vinyl sulfonium ion 
(MEVS+) upon reaction with S-adenosylmethionine. Studies revealed that MEVS+ is a 
substrate for TEMTase and can act as a possible suicide inhibitor (Scheme 10). MEVS+ is 
a very reactive species because of the ability of the sulfonium ions to stabilize the 
neighboring carbanion generated during the nucleophilic attack on the β-carbon of the 
vinyl motif.98 Scheme 10 exhibits the proposed mechanism of TEMTase inactivation 
caused by the methylation of EVS to form MEVS+ and subsequently, interaction of 
MEVS+ with nucleophilic amino acid residues in or around the active site of the enzyme.  
S
AdoMet AdoHcy
TEMTase
S
Nu
EVS, 77 MEVS
S
Nu
,78 79  
Scheme 10. Proposed Mechanism for Thioether S-Methyltransferase Inactivation by  
        Ethyl Vinyl Sulfide. 
 
Warner and Hoffman incubated TEMTase with EVS and AdoMet in order to test 
its ability to methylate dimethyl sulfide (DMS) to form the trimethyl sulfonium ion 
(TMS+). The data obtained demonstrated that TEMTase was inactivated by EVS in a 
time-dependent, pseudo-first-order process, which is a basic requirement for a suicide 
inhibitor. It was noted that activity of the TEMTase diminished logarithmically for 12 
min, but the loss of activity began to equilibrate after 15 min. No further loss of activity 
was seen after 30 min. Warner and Hoffman explained that this inability to attain further 
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inactivation was a result of the AdoHcy generated after 15 min by methylation of EVS 
with AdoMet, which acts as a feedback inhibitor of the remaining active TEMTase. The 
EVS has to bind initially to the active site of the enzyme to generate MEVS+. As stated, 
from the kinetics of inactivation dimethyl sulfide (DMS) should compete with EVS for 
this site and block inactivation by EVS. As a result, DMS was confirmed to be an 
effective competitor of EVS inactivation in a concentration-dependent manner.98 
1.4. Gemanium in Health and Chemistry. 
Germanium is a natural trace mineral with a wide range of health benefits. For 
example, propagermanium, which was released in Japan in 1994, boosts the immune 
system, heptoprotection, protects against viruses and has low toxicity.99a Orally 
administered organic germanium stimulates interferon production, while renovating the 
previously impaired immune response. Organogermanium compounds have been 
prepared for hypotensive, neurotropic, antitumor, radioprotective and immunomodulating 
properties.99b The natural element germanium has also been linked to the prevention of 
cancer and AIDS.99c In the organic form, germanium is considered as one of the most 
potent developments in the nutritional treatment of cancer. Germanium is a biological-
response modifier; it allows the organism to change its response to tumors. It does not 
directly attack cancer cells; instead it stimulates the body's immune system, making it 
effective in the treatment of cancer as well as other degenerative diseases.99a 
1.4.1. Organogermane alkenes: Synthesis and Reactivity.  
Since the chemistry and applications of organogermanes in the organic synthesis 
has been subject of recent reviews99 in the following chapter of my dissertation only 
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selected aspects of germane chemistry directly related to the goals of my dissertation will 
be addressed. 
Metals located in group 14 are crucial elements for cross-coupling reactions 
between organometallics and organic halides. In spite of the wide application of Stille 
(Sn)99d,e,100 and Hiyama (Si)99d,e,101 couplings, coupling involving organogermanes has 
received limited attention,102a even though the germanium element is situated between 
silicon and tin in the periodic table. The lack of popularity of germanium could be due to 
the challenge in the difficutly in synthesizing vinyl germanyl derivatives as well as the 
poorer reactivity of these compounds.102 The most significant route to vinylgermanes 
involves the hydrogermylation of alkynes; which can be done either by utilizing radical 
initiators or by using a transition metal complex as a catalyst. The end product is the 
formation of the three vinyl germane isomers (E, Z and gem) with selectivity determined 
by both electronic and steric properties of the alkynes and germane hydride substrates. 
For example, vinylgermanes, e.g. 81 and 82 can be obtained via hydrometalation 
of alkyne, 80 as illustrated in Scheme 11. Generally, transition metal-catalyzed 
hydrometalation is utilized as a mild protocol to obtain the cis-addition products, 82.103 
The trans-addition products can be achieved via Lewis acid catalyzed hydrometalations 
of C-C multiple bonds.104 Unfortunately, these methods exhibit low functional group 
tolerance.105 Thus, it is necessary to develope milder trans-selective general 
hydrometalation.106 Gevorgyan's group performed the first Lewis acid catalyzed 
hydrogermylation reaction, which not only showed a higher functional group tolerance 
when compared to the previously reported Lewis acid catalyzed hydrometalation 
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reactions but also displayed stereospecific trans-addition (81) for alkynes and cis-
addition for propiolates.105 
R2R1 HGeHGe
R2 = H, Alk, ArR2 = CO2R
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H
CO2R
Ge
H
R1
R2
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81 80 82  
Scheme 11. Lewis Acid Catalyzed Hydrogermylation of Alkynes. 
Hydrogermylation is a useful tool because it leads to the formation of 
vinylgermanes, which could be later transformed into the synthetically useful 
vinylhalides. As one might expect, halodegermylation of triethylgermanes 83 with NBS 
or NIS produced vinyl halides 84 and 85 in excellent yields (Scheme 12).106 
Iododegermylation of 86 under standard conditions occurred on efficiently, producing 
vinyl iodides 87 and 88 in good yields. It is worth noting that all halodegermylation 
reactions proceed with stereospecific retention of the double-bond geometry. 
Ph GeEt3
NBS or NIS
CH2Cl2, r.t. Ph X
83 84 X = Br, 92%
85 X = I,   99%
R1 CO2R2
GeEt3 NIS, AlCl3
CH2Cl2, 0 oC R
1 CO2R2
I
86 87 R1 = C5H11, R2 = Me, 88%
88 R1 = Ph,      R2 = Et,   85%  
Scheme 12. Halodegermylation Reaction of Vinyl Germanes with NBS and NIS with and  
        Without Lewis Acids. 
 
Since compounds like 1-fluoroalkynes are very unstable and nearly unknown,107 
techniques such as hydrogermylation are inapplicable for the synthesis of (α-
fluoro)vinylgermanes,108 The chemistry109 and biological activity of the 
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organogermanium compounds have already been reviewed.110 Wnuk and coworkers have 
developed stereoselective radical-mediated germyldesulfonylations of (α-fluoro)vinyl 
sulfones with germanium hydrides to provide access to (α-fluoro)vinyl germanes.110 Such 
an approach provides a means to synthesizing 1-fluoroalkenyl 
tris(trimethylsilyl)germanes, which were employed as substrates in Pd-catalyzed cross-
coupling reactions with aryl halides. Thus, treatment of vinyl phenyl sulfone 90a (E) with 
(TMS)3GeH/ AIBN gave the corresponding vinyl germane 91a (E) stereoselectively 
(Scheme 13). Analogous treatment of E vinyl sulfone 90 with Bu3GeH, Ph3GeH, and 
tri(2-furyl)germane produced the corresponding E germanes 91-94. Radical 
germyldesulfonylation of 89 also allowed the synthesis of the previously unknown (α-
fluoro)vinyl germanes 91'-94' in high yields with  retention of E stereochemistry. It was 
found that vinylgermanes bearing either a conjugated or an isolated double bond serve as 
versatile transmetalation reagents. The E-germanes could undergo coupling reactions 
with retention of stereochemistry under aqueous and anhydrous conditions. On the 
contrary, the coupling of Z-germanes occurs with less stereoselectivity to produce a 
mixture of E and Z isomers.110 
R1
R2 S
X
O O
89 X = F
90 X = H
R1
R2 GeR3
X
91 R = Me3Si,  X = H   91' R= Me3Si,  X = F
92 R = Bu,       X = H   92' R = Bu,       X = F
93 R = Ph,       X = H   93' R = Ph,       X = F
94 R = 2-fury,  X = H   94' R = 2-fury,  X = F
R3GeH/AIBN
Tol. 85 oC
 
Scheme 13. Radical Mediated Germyldesulfonylation Reaction of Vinyl Sulfones. 
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1.4.2. Germanium Containing Nucleosides. 
Previously, germaniums containing α-amino acids and peptides have been 
incorporated into biologically active decapeptides.111 The 6-trialkylgermyl-5-
fluorouridine derivatives are one of the very few known examples of germanium-
containing nucleoside analogues.112 Also, 5-trimethylgermyl-2'-deoxyuridine was shown 
to inhibit HSV-1 replication in vitro and blocked incorporation of thymidine into DNA of 
ovarian cancer cells.113  
Lithiation of uracil acyclonucleosides was employed recently to obtain 6-
substituted derivatives.113 Lukevics' group has investigated the lithiation of another type 
of nucleoside analogues N-1 tetrahydrofuryl derivatives.112 They decided to focus on an 
antitumor agent 1-(2-tetrahydrofuryl)-5-fluorouracil (95, Ftorafur)112 for the introduction 
of an organometallic substituent at the C-6 position of uracil.  Lithiation of Ftorafur was 
carried out in THF below -70 oC using 4.2 equiv. of lithium diisopropylamide (LDA) and 
after 1 h the C-6 lithiated Ftorafur was treated with the corresponding 
trialkylchlorogermane at -70 oC. The 6-substituted organogermanium, 96, isostructural 
derivative of Ftorafur, was obtained in moderate yield (Scheme 14). 
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Scheme 14. The Synthesis 6-Trimethylgermane-5-Fluorouracil Analogues. 
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The glycosyl bond length in compound 96 is slightly shorter than in other 
nucleoside structures reported114 and have the average value of 1.464 Å.115 It was found 
that atoms of the uracil ring in molecule of compound 96 deviate from the average plane 
and have the screw (1S2) conformation. The configuration of the THF ring in both 
compounds are C3'-exo-C4'-endo. It was also found that in 96 the uracil moiety exhibits a 
syn orientation with respect to the THF ring, while an anti conformation was found for 
compounds described.114a-d This could be the result of the introduction of bulky 
substituents in the 5-fluorouracil ring at C6. For instance, the large GeMe3 groups change 
molecular conformations and bond lengths. Careful analysis of the bond lengths for the 
compound indicated that the C6 Ge is significantly longer than Ge-C bonds with methyl 
groups' carbon. 
The results obtained from Lukevic's lab112 demonstrated the ability of the 
germanium-modified nucleoside analogues to interfere with transcription and, probably 
with the replication processes, because of the conformation changes induced by the 
presence of the germanium atom.  
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2.  RESEARCH OBJECTIVE 
The purpose of this dissertation is to design and to synthesize novel inhibitors of 
S-adenosyl-L-homocysteine hydrolase and S-adenosyl-L-methionine transferases.  The 
first targets were adenosine and uridine analogues with the C5' and sulfur atoms replaced 
by a fluoroalkenyl unit. The adenine analogues were expected to act as substrates for the 
"hydrolytic" activity of S-adenosyl-L-homocysteine hydrolase. These targets could be 
prepared via Negishi and other Pd-catalyzed cross-coupling reactions. Stereoselective Pd-
catalyzed monoalkylation of 5'-(bromofluoromethylene)-5'-deoxyadenosine with 
alkylzinc bromides derived from the homocysteine- like precursors could produce S-
adenosyl-L-homocysteine analogues with a 6'-(fluoro)vinyl motif. These novel vinylic 
adenine nucleosides were planned to be tested for time-dependent inactivation of the S-
adenosyl-L-homocysteine hydrolases. 
 The stannydesulfonylation reaction is a critical step in the synthesis of two 
nucleoside-based drug candidates bearing an exo-fluoro methylene unit at a ribofuranosyl 
ring. The first drug is E-fluorovinyl cytidine (Tezacitabine) which is a ribonucleoside 
reductase inhibitor with a potent anticancer activity. The second compound is 5'-deoxy-
5'-(fluoromethylene)adenosine which is a inhibitor of S-adenosyl-L-homocysteine 
hydrolase with potent antiviral activity. The critical step in the synthesis of these two 
compounds (drugs) was the removal of the auxiliary sulfonyl group employing a radical-
mediated stannyldesulfonylation reaction using tributyltin hydride. In order to eliminate 
the synthetic drawback associated with the toxicity of the tin reagent, the second aim of 
this dissertation was to develop a radical-mediated germyldesulfonylation utilizing less 
toxic germane hydrides. Radical-mediated substitution of the arylsulfonyl group with the 
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tributyl- or the triphenylgermanyl group at the vinylic carbon was expected to afford 
desired vinyl germanes. Moreover, the halodegermylation reaction should serve as an 
alternative approach for the synthesis of 5'-deoxy-5'-(halomethylene)nucleoside 
analogues.  
I was also planning to study radical-mediated thiodesulfonylation of the readily 
available vinyl and (α-fluoro) vinyl sulfones with aryl thiols in organic or aqueous 
medium. Such a procedure would provide a bench and environmentally friendly protocol 
to access both vinyl and the virtually unknown (α-fluoro)vinyl sulfides. The 
thioldesulfonylation was expected to proceed with controlled stereochemistry. These 
thiodesulfonylation reactions would provide an alternative methodology to the 
hydrothiolation of alkynes with thiols which occur under metal catalysis conditions. 
Since vinyl sulfide 2-(3-hydroxy-5-methoxyphenyl)-1-phenylthioethene is a potent 
antibacterial agent active against drug-resistant strains of tuberculosis and anthrax 
surrogates, I am planning to apply my methodology for the synthesis of its (α-fluoro) 
vinyl analogue. This would allow us to determine whether the incorporation of the 
fluorine atom into the vinyl sulfide unit would enhance its biological activity. I also 
intended to perform methylation to the vinyl or (α-fluoro)vinyl phenyl sulfide to get 
access to the corresponding vinyl or (α-fluoro)vinyl methyl phenyl sulfonium salts. These 
sulfonium ions were selected as possible methyl group donors during reactions with 
thiols, phenols or amino groups which are commonly present in natural amino acids.  
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3. RESULTS AND DISCUSSIONS 
3.1.   Design and Synthesis of S-Adenosyl-L-Homocysteine Analogues with the 
Carbon-5' and Sulfur Atoms Replaced by a Vinyl or Halo(vinyl) Unit via 
Cross-Coupling Reactions. 
The first targets of this dissertation were S-adenosyl-L-homocysteine analogues 
96 and 98 (Scheme 15). These compounds could serve as substrates for the "hydrolytic" 
activity of the enzyme, because they should form stable complexes with the enzyme and 
in turn help identify key binding groups at the active site. Such analogues (e.g. 96 and 98) 
should be resistant to elimination because the homocysteine-type unit is attached to C5' 
via an olefinic double bond. As a result, they can freeze the elimination steps catalyzed 
by AdoHcy hydrolase allowing the proteins in the active site of the enzyme to be 
identified. These unsaturated S-adenosyl-L-homocysteine analogues 96 and 98 could be 
synthesized from their corresponding vinyl halides 99 and dihalide 97 utilizing Negishi 
cross-coupling procedures. The Pd-catalyzed approaches extended my earlier attempts to 
synthesize AdoHcy analogues 96 or 98 employing metathesis and Wittig reaction 
methodology. 
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Cross Coupling O
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X
96 R = H or NH2
     X = Halogen
97 Y = X = Halogen
Halogenation-
dehydrohalogenation
O
OHHO
A
HO2C
R
98 R = H or NH2
Cross Coupling O
OHHO
A
Y
99 Y = Halogen  
Scheme 15. Retrosynthetic Analysis for the Synthesis of S-Adenosyl-L-Homocysteine  
        Analogues with C5' and Sulfur Atoms Replaced by Vinyl or Halovinyl Unit. 
 
3.1.1. Synthesis of Vinyl S-Adenosyl-L-Homocysteine Analogues. 
 Negishi cross-coupling reaction is a palladium catalyzed stereospecific carbon-
carbon bond formation between aryl or vinyl halides with zinc-derived organometallic 
reagents. After various optimization attempts which included testing different Pd-
catalyst, solvents, temperature and additives. I found that treatment of iodovinyl 
adenosine precursor, 100b(E) with 1.5 equivalent of EtO2C(CH2)3ZnBr in the presence of 
a catalytic amount of Pd(0) in benzene produced ethyl 1-(adenine-9-yl)-1,5,6,7,8,9-
hexadeoxy-2,3-O-isopropylidene-β-D-ribo-dec-5(E)-enofuranuronate (101b, Scheme 16) 
in excellent yields after purification. 1H NMR of the product 101b showed that coupling 
occurs with retention of stereochemistry (J6'-5' = 15.4 Hz), while the mass spectrum 
showed an ion at m/z 418 (MH+, 100) which corresponds to its molecular ion. Analogous 
treatment of the iodovinyl uridine, 100a, gave the desired uracil-based product 101b in 
good yields. 
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Deactonization of 101b with TFA/H2O at 0 oC for 30 minutes produced ethyl 1-
(adenine-9-yl)-1,5,6,7,8,9-hexadeoxy-β-D-ribo-dec-5(E)-enofuranuronate (102b, 49%) 
after column chromatography and recrystallization in MeOH. 1H NMR analysis showed 
the disappearance of methyl signals from the isopropyl unit and the mass spectrum 
indicated a molecular ion at m/z 378 (MH+, 100).  Analogously, the uridine analogue 
101a was deprotected to give 102a. Saponification of the ester, 102b, afforded 102c, a 
10-carbon AdoHcy analogue with C5' and sulfur atoms replaced by a vinyl unit.  
O
OO
B
I
100a B = Ura
100b B = Ade
BrZn
OEt
O
a
O
OO
B
101a B = Ura
101b B = Ade
EtO
O
b
O
OHHO
B
102a B = Ura
102b B = Ade
EtO
O
Reagents: (a) Tris(dibenzylideneacetone)-dipalladium/benzene
                 (b)  TFA/H2O (9:1); (c) NaOH/H2O
O
OHHO
B
102c B = Ade
HO
O
c
 
Scheme 16. Synthesis of S-Adenosyl-L-Homocysteine Analogues via Pd-catalyzed  
        Coupling Utilizing 5'-Deoxy-5'-(Iodomethylene)adenosine. 
 
It has to be mentioned that Andrei and Wnuk synthesized the target molecule in 
the adenosine series, 104, with an amino group at position C9'. 116 They employed a 
metathesis reaction between a 6 carbon amino acid (containing a terminal double bond) 
and 5'-deoxy-5'-methyleneadenosine, 103, in the presence of a Grubbs catalyst to obtain 
the desired product (104, Scheme 17).  
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Ru-catalyst
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EtO
O
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Scheme 17. Metathesis Approach for the Synthesis of S-Adenosyl-L-Homocysteine  
        Derivatives. 
 
3.1.2. Synthesis of 6,6'-Dihalo(homo)vinyl Adenosine Precursors. 
 The geminal dihalovinyl analogue 107 was envisioned to be a potential substrate 
for the Pd-catalyzed selective monoalkylation reaction.  Thus, a Moffat oxidation of the 
isopropylidene protected adenosine, 105, gave the crude aldehyde 106. A subsequent 
Wittig reaction with (bromofluoromethylene)triphenylphosphonate (generated in situ 
using CBr3F/Ph3P/Zn afforded bromo(fluoro)alkene 107 in 30% yield (Scheme 18). The 
19F NMR of 107 showed a mixture of E/Z (3:2) diastereomers. The two pairs of doublets 
at -64.28 ppm (JF-H5'(cis) = 10.7 Hz) and at -68.81 ppm (JF-H5'(trans) = 29.8 Hz) were 
diagnostic of the E/Z isomers. 
O
OO
A
HO
105
O
OO
A
O
106
O
OO
A
107
Br
F
a b
Reagents and conditions: (a) DCC/DMSO/Cl2CHCO2H; (b) Ph3P/CBr3F/Zn/CH2Cl2  
Scheme 18. Synthesis of 6',6"-Dihalovinyladenosine via Pd-Catalyzed Coupling  
        Utilizing 5'-Deoxy-5'-(Bromofluoromethylene)adenosine. 
 
3.1.3. Synthesis of 6'-Halovinyl S-Adenosyl-L-Homocysteine Analogues. 
Adenosine analogues with the 5',6'-halovinyl or vinyl motif 96 and 98 
incorporated in place of the C5' and sulfur atoms might act as substrates for the 
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"oxidative" and/or "hydrolytic" activity of AdoHcy hydrolase. For instance, enzyme-
mediated addition of water to 96 (X = F, R = H or NH2; Scheme 14) might occur at C5' or 
C6'. With the addition of water, this would generate a new species bearing a hydroxyl or 
keto (after β-elimination of HF) binding site within the enzyme. 
Andrei and Wnuk have synthesized the AdoHcy analogue bearing the amino 
moiety on C9' and an alkenyl unit between C5' and C6' employing metathesis 
approaches.116a Their attempts to install a halogen at C6' via bromination-
dehydrobromination methodology led however to the synthesis of 5'-bromo analogue 
109.  Thus, compound 104 was treated with pyridinium tribromide followed by 1,8-
diazobicyclo[5.4.0]undec-7-ene (DBU) to form 108 as a single isomer in 70% yield 
(Scheme 19). Deprotection of 108 with NH3/MeOH and TFA/H2O followed by 
saponification with NaOH and HPLC purification gave 109 (E, 54%).  
O
OO
ANBz2
104
EtO
O
NHBoc
O
OO
ANBz
108
EtO
O
NHBoc Br
a
b
O
OHHO
A
109
EtO
O
NHBoc Br
c
Reagents and conditions: (a) C5H5NH Br3; (b) i.DBU/THF ii. MeOH/NH3; (c) i. TFA. ii. NaOH
Scheme 19. Synthesis of 5'-Bromo(homo)vinyl S-Adenosyl-L-Homocysteine Analogues. 
In order to prepare the 6'-halovinyl analogue, 96, I turned my attention to the Pd-
catalyzed selective monoalkylation of 5'-deoxy-5'-(dihalomethylene) nucleoside 
precursor. Enlightened by the results obtained from the Negishi reactions between the 6'-
halovinyl nucleoside precursor and the commercially available Negishi reagent (alkylzinc 
bromide) I have targeted a selective monoalkylation of dihalovinyl nucleoside substrates 
(e.g., 107). It is noteworthy to mention that the mono cross-coupling reactions of 1,1-
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dihalovinyl electrophiles with Csp3 nucleophiles are very limited.117 Andrei and Wnuk 
developed Pd-catalyzed Negishi coupling of 1-fluoro-1 bromoalkenes with alkylzinc, 
which provided stereoselective access to the internal fluoroalkenes.116 After optimization 
of the coupling conditions, I discovered that treatment of the protected 5'-
(bromofluoromethylene)-5'-deoxyadenosine42 (107, E/Z, 3:2) with EtO2C(CH2)3ZnBr/ 
Pd(PPh3)4 in refluxing benzene produced fluorovinyl AdoyHcy, 110, (56%) as a mixture 
of geometric (E/Z, 2:3; Scheme 20) isomers. 19F NMR indicated the formation of both 
geometric isomers at δ -95.78 ('q', JF–H5';7';7'' = 21.8 Hz, 0.4, E), and -101.80 (dt, JF–H5' = 
35.5 Hz; JF–H7';7'' = 17.3 Hz, 0.6, Z); the mass spectrum showed a molecular ion at m/z 436 
(MH+, 100) as base peak. Selective acid-catalyzed deprotection of 110 gave the 
corresponding ester 111; 1H NMR proved deacetonization by the disappearance of the 
methyl groups at δ 1.36 (s, 3, CH3) and at 1.61 (s, 3, CH3). Saponification of the ester 
afforded a free carboxylic acid analogue, 112, a 10-carbon AdoHcy analogue with C5' 
and sulfur atoms replaced by 6'-fluorovinyl unit. 
O
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A
Br
107
O
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A
110
EtO
O
a
O
OHHO
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111
EtO
O
b
Reagents and conditions: (a)EtO2C(CH2)3ZnBr/Pd(PPh3)4/benzene/heat; 
                                         (b) TFA/H2O; (c) NaOH/H2O)
F F F
c
O
OHHO
A
112
HO
O F
 
Scheme 20. Synthesis of 6'-Halo(homo)vinyl S-Adenosyl-L-Homocysteine Analogues. 
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3.1.4. Inactivation of the S-Adenosyl-L-Homocysteine Hydrolase. 
The homovinyl adenine nucleosides were tested against human AdoHcy 
hydrolase using a protocol involving a 0.5 or a 4 h preincubation with the enzyme 
followed by a 12 min incubation that measured the residual enzyme activity (Table 1).116 
Esters 101b and 111 were found to be unstable either by chemically or enzymatically 
under the assay conditions. These compounds had also very similar activity toward the 
Trypanosoma cruzi AdoHcy hydrolase. Interestingly, the most active inhibitors were 
found to be the 10-carbon, 102b and 102c, vinylic analogues. With a 30 min 
preincubation, ester 102b was found to be more active than the corresponding acid 102c. 
The 6'-fluoro vinylic analogues 111 and 112 were expected to have higher activity 
against the enzyme; but instead they showed a lower activity than the non-halogenated 
derivatives 102b and 102c, perhaps in accordance with the fact that 5'-deoxy-5'-
(fluoromethylene) adenosine showed the lowest enzyme inactivation efficiency among all 
of the 5'-halomethylene derivatives.118 The 5'-bromovinylic analogue, 109, with the 
amino group located at C9' also showed a lower enzyme inhibition compared to 102b. 
The analogues 109 and 112 bearing a free carboxylic group produced similar time-
dependent inactivation of the human (Table 1) and T. cruzi AdoHcy hydrolases.  No 
further enzymatic studies have been performed on these compounds. 
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Table 1. Inhibition of S-Adenosyl-L-Homocysteine Hydrolase by 5',6'-Vinylic Adenosine  
   Derivatives. 
a AdoHcy hydrolase (204 nM) was incubated with the inhibitors (281 uM) at 37 oC
   for 12 min and the remaining enzyme activity was assayed as described152
b Data are the averages of duplicate determinations
c Preincubation time of the inhibitors with the enzyme
d Esters  were not tested with 4 h preincubation time due to chemical instability in the 
   enzymatic assay.
Compound                                           % of enzyme inhibitiona,b
0.5 hc                                        4 hc
101bd                                                  81
102c                                                  28.5                             92.4     
109                                                    14.5                             44.6  
111d                                                  14.1   
112                                                   15.2                             35.2
 
3.2.  Application of the Germyldesulfonylation Reactions to the Synthesis of 
Germanium-Containing Nucleosides. 
3.2.1. Synthesis of 6'-Vinyl Germane Nucleosides. 
Radical-mediated replacement of an arylsulfonyl group with a tributylstannyl 
group at the vinylic carbon is an important approach for the synthesis of various 
nucleoside and amino acid analogues bearing an α-halo vinyl functionality. For example, 
McCarthy and coworkers used a radical-mediated stannyldesulfonylation protocol (113a 
→ 113b) for the synthesis of (E)-fluorovinyl cytidine 113c (Tezacitabine; an inhibitor of 
ribonucleoside reductases with potent anticancer activity), from the protected (α-
fluoro)vinyl sulfone 113a (Figure 18).109,118  
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O
HO
HO
C
F
X
113a X = PhSO2
113b X = Bu3Sn
113c X = H
O
OHHO
AX
O
OHHO
A
X
114a X = (4-CH3)PhSO2
114b X = Bu3Sn
114c X = I, Br, Cl, F
115a  X = PhS
115b  X = Bu3Sn
115c  X = I, Br, Cl, F  
Figure 18. Nucleoside Analogues Synthesized via Tin Radical-Mediated Extrusion of    
                  Sulfur Atom.   
 
Also, a radical mediated stannyldesulfonylation of the vinyl 6'-sulfone analogue 
of adenosine 114a was achieved using a radical initiator and Bu3SnH. Subsequent 
halodestannylation of the resulting vinyl 6'-stannanes 114b afforded 5'-deoxy-5'-
(halomethylene)adenosine 114c. These 6'-halovinyladenosine analogues  were found to 
be potent inhibitors of S-adenosyl-L-homocysteine (AdoHcy) hydrolase and valuable 
probes to study the "hydrolytic" activity of the enzyme.35,38,116 The 
stannyldesulfonylation/protiodestannylation of the (α-fluoro)vinyl sulfones and 
stannyldesulfonylation/halodestannylation of the vinyl sulfones procedures allowed for 
the synthesis of various 5'-deoxy-5'-(halomethylene)nucleoside analogues derived from 
uridine,111 L-adenosine,120 3'-deoxyadenosine,41 6-N-cyclopropyladenosine121 and 5'-
deoxy-5'-(halomethylene)ribose derivatives.122 Moreover, the replacement of the sulfide 
group from 115a with tributyltin hydride has been elaborated for the synthesis of the 
known 4',5'-unsaturated-5'-haloadenosine analogue 115c (a potent AdoHcy hydrolase 
inhibitor) employing halodestannylation of the intermediary vinyl stannane 115b.123  
I envisioned the possibilities for the removal of the toxicity factors associated 
with tributyltin hydride reagent in a stannyldesulfonylation reaction by developing a 
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stereoselective and chemoselective radical-mediated germyldesulfonylation of vinyl and 
(α-fluoro)vinyl sulfones with less toxic germanium hydrides to produce 116 (Figure 19)30 
O
OHHO
AX
O
OHHO
AR3Ge
116
O
OHHO
APhO2S
27 93  
Figure 19. Germyldesulfonylation an Approach for the Synthesis of Novel  
      Vinyl Germane Nucleosides. Application Towards Synthesis of 5'-Deoxy-5'-    
      Halo(methylene)adenosines. 
 
In order to prepare the 2',3'-O-isopropylidiene protected uridine/adenosine 
(117a/b), the sugar was dissolved in acetone and treated with 1 equivalent of p-
toluenesulfonic acid monohydrate and 4 equivalents of ethyl orthoformate.  
Crystallization of the crude product from methanol gave the 2',3'-O-
isopropylidieneadenosine/uridine (105/118) in more than 95% yields (Scheme 21). 
Moffatt oxidation of the 5'-OH group in (105/118) with 3 equivalents of 
dicyclohexylcarbodiimide (DCC) in DMSO and half an equivalent of dichloroacetic acid 
at ambient temperature gave the crude 5'-aldehyde. Treatment of the 5'-aldehyde with 1.1 
equivalents of (p-toluenesulfonylmethylene)triphenylphosphorane produced a less polar 
product in an exothermic reaction.  The 6'-tosylvinyluridine, 119a, and 6'-
tosylvinyladenine, 119b, were obtained in good yields (~80%) after purification in silica 
gel. 1H NMR spectrum for 119b confirmed the structure and was diagnostic to establish 
trans configuration (J6'-5' = 15.1 Hz).  Two doublets at δ 7.29 (d, J = 8.2 Hz, Ar, 2H) and 
7.62 (d, J = 8.3 Hz, Ar, 2H) indicated the presence of the p-toluenesulfonyl group located 
at C6' (Figure 19). 
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  Reflux of 119a in toluene with tributylgermanium hydride in the presence of 
AIBN effected germanyldesulfonylation via a radical process to give 5'-
(tributylgermyl)methylene-5'-deoxyuridine, 120a, as a single (E)-isomer (J 5'-6'(trans) = 18.5 
Hz) in 57% yield. Sulfone 96b also underwent a germyldesulfonylation reaction with 
Bu3GeH to yield the vinyl germane (E)-121a (46%). The analogous 
stannyldesulfonylation of 119a and 119b with Bu3SnH produced the corresponding 
(E/Z)-5'-(tributylstannyl)methylene-5'-deoxyuridine111 and adenosine35 derivatives in 
87% and 61% yields, respectively. Thus, treatment of 119a and 119b with 
triphenylgermane hydride gave (E)-5'-deoxy-5'-(triphenylgermyl)methylene nucleosides 
correspondingly gave 120b (72%) and 121b (42%). The desulfonylation reaction was 
performed on both purine and pyrimidine nucleoside analogues using either trialkyl- or 
triarylgermanes. I found that the yields were significantly higher for the uridine 
analogues. This is similar to what was observed in the case of the stannyldesulfonylation 
reactions.35,111  Unlike the stannyldesulfonylation reactions,35 the germyldesulfonylations 
of the vinyl sulfones derived from the sugar modified nucleosides are stereoselective 
since the analogous (Z)-isomers of vinyl germanes 120 or 121 were not isolated from the 
crude reaction mixtures. The germyldesulfonylation reactions most probably occurs via 
the radical addition-elimination mechanism, similarly to the silyl- and 
stannyldesulfonylation reactions.118 
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119b B = A
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120b B = U, R = Ph
121a B = A, R = Bu
121b B = A, R = Ph
122a R' = H
122b R' = Ac
123a R = Ph, R' = Ac
123b R = Ph, R' = H
124a R = Bu, R' = Ac
124b R = Bu, R' = H
125 B = U, X = I, RR = CMe2
126 B = A, X = Br, RR = CMe2
127 B = A, X= R = H
a b c
d or e
ff
g h
h
 Reagents and conditions: (a) Ethyl orthoformate/acetone/p-toluenesulfonic acid; (b) (i) DCC/DMSO/ Cl2CHO2H, (ii) 
Ph3P=CHTs; (c) Bu3GeH or Ph3GeH/AIBN/PhCH3/heat; (d) NIS or NBS; (e) TFA/H2O; 
 (f) Bu3GeH/ACCN/HOCH2CH2SH/PhCH3/heat; (g) DMAP/Ac2O; (h) NH3/MeOH
c
 
Scheme 21. Synthesis of 6'-Vinylgermyluridine and Adenosine Analogues. 
I found that stereoselective iododegermylation reaction of tributylgermane, 120a, 
and N-iodosuccinimide (NIS) gave 5'-deoxy-5'-(iodomethylene) uridine, [(E)-125, 92%]. 
Similarly the tributylgermane, 121a, reacts with N-bromosuccinimide (NBS) to yield the 
5'-deoxy-5'-(bromomethylene)adenosine (E)-126 (81%) with retention of double bond 
geometry.  It is worth noting, that treatment of triphenylgermanes 120b and 121b with 
either NBS or NIS did not produce the corresponding halomethylene nucleosides 125 or 
126, giving instead the recovered vinyl triphenylgermanes 120b and 121b.  Even 
halodegermylation of the triphenylgermane, 120b, with iodine (CH2Cl2/-78 ◦C to room 
temperature for 14 hours) did not give the desired halosubstituted product, 125, only 
recovered starting materials. In the literature,124 iododestannylation reactions are known 
for vinyl triaryltin derivatives. I believe that the strength of the Ge-Csp2 bond depends on 
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the nature of the substituents on the germanium atom;125 most importantly it seems that 
Csp2-Ge(alkyl)3 bonds are more stable than that of the Csp2-Ge(aryl)3 bonds. I also 
observed same patterns of different reactivity for the protiodegermylation reactions of 
vinyl triarylgermanes and trialkylgermanes. For instance, treatment of the 
tributylgermane, 121a, with aqueous trifluoroacetic acid (TFA) affected simultaneous 
protiodegermylation and deacetonization to afford 5'-deoxy-5'-methyleneadenosine, 127. 
In contrast when triphenylgermane, 120b, was treated with TFA only the isopropylidene 
protection group was removed affording germanonucleoside, 123b.  
I was, however, able to synthesize deprotected trialkylgermane, 124b, using a 
base-labile protection strategy. For instance, treatment of 2',3'-O-diacetyl sulfone, 122b, 
with Bu3GeH/AIBN gave  124a  in 49% yield. Interestingly, germyldesulfonylation 
reaction performed in the presence of 2-mercaptoethanol, as a radical carrier,117 and 1,1'- 
azobis(cyclohexanecarbonitrile), (ACCN) as a radical initiator also produced 124a in 
even higer yield (58%). Treatment of 124a with methanolic ammonia affected 
deacylation yielding the vinyl tributylgermane, 124b (72%). The synthesis of the vinyl 
triphenylgermane, 123b (65% overall yield), was analogously developed by 
germyldesulfonylation of 2',3'-O-acetyl protected uridine, 122b with Ph3GeH, followed 
by deacetylation of the resulting 123a. 
3.2.2.   Synthesis of 2'-Vinyl Germane Nucleosides. 
 I also developed the germyldesulfonylation reaction for the removal of the vinyl 
sulfonyl group located on C2' of the nucleosides in Wnuk laboratory.119 Thus, treatment 
of the protected 2'-ketouridine, 128, with a sulfonyl-stabilized enolate derived from 
diethyl (phenylsulfonyl)methylphosphonate gave the Horner-Wittig-type  vinyl 2'-
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phenylsulfone, 129, as a single (Z)-isomer (Scheme 22). The Z stereochemistry was 
established by NOESY NMR experiments as well as by comparing my results with the 
data of McCarthy’s work that utilized the fluoro(phenylsulfonyl)methylphosphonate 
reagent.108 Germyldesulfonylation reactions of 129 with Ph3GeH produced the 2'-deoxy-
2'-[(triphenylgermyl)methylene]uridine, 130 (51%) as a single (Z)-isomer. The 
triphenylgermanyl protected nucleoside 130 was desilylated with TBAF affording the 
vinyl triphenylgermane 131 in 73% yield. 
O
U
ORO
RO O
U
RO
RO
SO2PH
O
U
RO
RO
GePh3
a b,c
128 R= TIPS 129 R= TIPS 130 R= TIPS
131 R = H
   Reagents and conditions: (a) PhSO2CH2PO(OEt)2/LHDMS/THF; (b) Ph3GeH/AIBN/ PhCH3/heat;       
                                            (c)TBAF/THF.
Scheme 22. Synthesis of 2'-Vinylgermyluridine Analogues. 
I have demonstrated that germyldesulfonylation reactions with trialkyl- and 
triarylgermane hydrides affect the removal of the sulfonyl group from the exomethylene 
and isolated double bonds of the sugar moieties of nucleosides. However, treatment of 
130 with the more reactive tris(trimethylsilyl)germane [(TMS)3GeH] provided the 
corresponding vinyl (TMS)3Ge-uridine derivatives in relatively small yields (≤ 15%, 1H 
NMR) despite numerous attempts. Therefore, no further efforts were made to optimize 
the germyldesulfonylation reactions utilizing the (TMS)3GeH reagent, although the vinyl 
tris(trimethylsilyl)germanes could serve as precursors for further modifications via Pd-
catalyzed couplings reactions.110,126 
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3.3. Radical-Mediated Thiodesulfonylation of Vinyl Sulfones 
3.3.1. Synthesis of Vinyl Sulfones and α-(Fluoro)vinyl Sulfones 
The vinyl and α-(fluoro)vinyl sulfones were prepared following literature 
methodology utilizing Horner-Emmons-Woodward reactions.110 Thus, the condensation 
reaction of the sulfonyl-stabilized enolates generated from diethyl (phenylsulfonyl)- 
methylphosphonate with aliphatic and aromatic aldehydes and ketones 132a–g gave the 
corresponding vinyl sulfones 133a–f and cyclic vinyl sulfone 133g (72–95%, Scheme 
22).   It is important to note that these condensations produced the corresponding E 
isomers as either the major or the sole products with only traces of the Z sulfones 
observed in the crude 1H NMR or gas chromatographic analysis.  
Analogous condensations utilizing the sulfonyl-stabilized enolates generated from 
diethyl fluoro(phenylsulfonyl)methylphosphonate with aliphatic and aromatic aldehydes 
and ketones 132a–h afforded the corresponding α-(fluoro)vinyl sulfones 134a–h 
(Scheme 23). Unlike the vinyl sulfones, the α-(fluoro)vinyl sulfones are obtained mostly 
as unseparable mixtures of E/Z isomers.127 
SR1
R X
O
R1
R
PhSO2CHXPO(OEt)2
HMDS/THF/-78 oC
132 133 X = H, 134 X = F
        R                            R'
a      C6H5                            
b      4-(CH3)C6H4               
c      4-(CF3)C6H4                
d      3,4-(MeO)2C6H3         
e      C6H5CH2CH2              
f       c-C6H11                       
g                     -(CH2)5-
h      C6H5                           CH3
series:
O
O
H
H
H
H
H
H
 
Scheme 23. Synthesis of E-Vinyl and (E/Z)-(α-Fluoro)vinyl Sulfones. 
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3.3.2. Thiodesulfonylation of Vinyl Sulfones: Synthesis of Vinyl Sulfides. 
After several attempts to identify the conditions for radical replacement of the 
sulfonyl group with thiol groups at sp2 hybridized carbon, I was fortunate to discover that 
the reaction between the conjugated vinyl sulfone E-133a with benzenethiol (2 equiv) in 
the presence of ACCN as a radical initiator in refluxing toluene (12 h) produced the vinyl 
sulfide 135a (61%; Scheme 24; Table 2, entry 1).127 This type of radical 
thiodesulfonylation reaction was also successful in an aqueous medium. For instance, 
treatment of E-133a with benzenethiol/ ACCN or AIBN in water (100 oC) produced vinyl 
sulfide 135a in 71% and 65% yields (entry 2). When a polar protic solvent was used such 
as methanol or ethanol, I produced a homogenous reaction mixture which effected 
thiodesulfonylation (entry 3). The thiodesulfonylation reactions were not markedy 
influenced by the nature of the substituents. Thus, the alkyl (series b), electron-
withdrawing (CF3, series c), or electron-donating (MeO, series d) groups on the phenyl 
ring attached to the double bond had only modest effect on rate and yield of 
thiodesulfonylation reactions with benzenethiol (entries 11–15, 18–20). 
a      C6H5                            
b      4-(CH3)C6H4               
c      4-(CF3)C6H4                
d      3,4-(MeO)2C6H3         
e      C6H5CH2CH2              
f       c-C6H11                       
g                     -(CH2)5-
h      C6H5                           CH3
H
H
H
H
H
H
SR1
R
SR1
R
R2
HS R2
Method A, B or C
        R                            R'
133 135 R2 = H
136 R2 = CH3
137 R2 = NH2
138 R2 = CO2Me
O
O
 
Scheme 24. Thiodesulfonylation of Vinyl Sulfones and Synthesis of Vinyl Sulfides. 
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Treatment of the unconjugated vinyl sulfones derived from aliphatic aldehydes 
(series e and f) with benzenethiol/AIBN or ACCN under protic and aprotic conditions did 
not yield the corresponding vinyl sulfides (entries 21 and 22). Interestingly, dialkyl 
alkenyl sulfone, 133g, derived from cyclohexanone, underwent a thiodesulfonylation 
reaction affording vinyl sulfide, 135g (entries 23 and 24), demonstrating that the 
thiodesulfonylation can serve as a convenient method for the synthesis of the 
trisubstituted vinyl sulfides. 
The thermal reaction of E-133a with benzenethiol without any radical initiator 
produced 135a but in significantly lower yield (10%, entry 2) than when an initiator was 
used. Similarly, the replacement of benzenethiol with phenyl disulfide also effected the 
conversion of the sulfone 133a to the vinyl sulfide 135a in lower yield (20%, entry 4); 
The reaction proceed required longer time and subsequent addition of radical initiator. 
However, reaction of 133a with phenyl disulfide without radical initiator failed to 
produce the corresponding vinyl sulfide 135a by using any of the three approaches. 
Treatment of E-132a with 4-methylbenzenethiol or 4-aminobenzenethiol in 
H2O/ACCN produced the corresponding vinyl sulfides 136a (61%) and 137a (55%) 
(entries 5 and 6). Analogously, E-133c was reacted with 4-methylbenzenethiol or 4-
aminobenzenethiol in H2O/ACCN to produce the corresponding vinyl sulfides 136c and 
137c (entries 16 and 17). Thiodesulfonylation of E-133a with 4-mercaptobenzoic acid 
(R1 = CO2H) in methanol afforded the methyl ester 138a (85%; entry 7). Thus, I could 
assume that thiodesulfonylation protocol is compatible with amino and carboxylate 
derivative functional groups, which are vulnerable to oxidative and reductive procedures.  
I also attempted thiodesulfonylation reactions on 133a and 133c, with alkanethiols (2-
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mercaptoethanol, 1-propanethiol or thioacetic acid) under radical conditions but the 
corresponding vinyl sulfides were not formed. Instead I only recovered the starting 
sulfones. 
Table 2. Synthesis of E-Vinyl Sulfides via Thiodesulfonylation of Vinyl Sulfones. 
Entry Sulfone (E/Z) Methoda  Productb (E/Z)c            Yieldd 
   1  133a (E) A   135a  95:5  61 
   2 133a (E)  B 135a  95:5   71e, 65e,f, 10e.g  
   3  133a (E) C  135a  95:5  70e 
   4  133a (E) C  135a  95:5  20e,k   
   5  133a (E) B  136a  95:5  61 
   6  133a (E) B  137a  98:2  55 
   7  133a (E) C  138a  95:5  85 
   8  133a (Z)   A  135a  95:5  65e 
   9  133a (Z)   B  135a  95:5  95e 
   10  133a (Z)   C  135a  95:5  70, (80e) 
   11  133b (E) A  135b  85:15  55e 
   12  133b (E) B  135b  85:15  54, (63e) 
   13  133c (E) A  135c  95:5   59, (70e), 5e,g 
   14 133c (E) B  135c  95:5    85e, 80e,f, 50g                          
   15 133c (E) C  135c  95:5  94e, (96e,i) 
   16  133c (E) B  136c  95:5  58                   
   17  133c (E) B  137c  95:5  40, (55e) 
   18 133d (E) A  135d  75:25  55 
   19 133d (E) B  135d  75:25  64e 
   20  133d (E) C  135d  85:15  70e 
   21  133e (E) A,B,C  135e    n.r 
   22 133f (E) A,B,C  135f    n.r.  
   23 133g  B  135g    55 
   24 133g  C  135g    76e 
   25 133g  C  136g    62 
            
a Method A: thiol/ACCN/toluene/110 oC/12 h; Method B: thiol/ACCN/water/100 oC/10 h; Method C: 
thiol/ACCN/MeOH/65 oC/10 h. b Reactions were performed on 0.1-1.0 mmol scale of sulfones (0.05 mM) 
with 1.25-2.00 equiv. of thiols and 0.25-0.50 equiv. of AACN or AIBN. c Determined by GC-MS and/or 1H 
NMR. d Isolated yield.  e Based on GC-MS.  f AIBN instead of ACCN. g Without ACCN. h Disulfide instead 
of thiol, 16 h. i In EtOH. 
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Radical-mediated thiodesulfonylation of the vinyl sulfone 133 occurred mainly 
with retention of the E stereochemistry although small amounts of the Z isomers were 
detectable by GC–MS and 1H NMR of the crude reaction mixtures (Table 2). In order to 
study the stereochemical outcome of the thiodesulfonylation reactions I also prepared 
pure Z-vinyl sulfone as a starting precursor. 
SHS+
NaOH
EtOH
135E/Z: 5/95
S
133 Z-isomer
   AcOH
30% H2O2
PhSH, AIBN
Method A,B or C
S
135 E/Z: 95/5
O O
139 140
 
Scheme 25. Synthesis of the Z-Vinyl Phenyl Sulfone and its Thiodesulfonylation. 
The Z-vinyl sulfone 133a was prepared by anti-Markovnikov addition of PhSH to 
phenylacetylene in the presence of NaOH (139, Scheme 25). Subsequent oxidation of the 
resulting (Z)-2-phenyl-1-phenylthioethene 135 gave the corresponding sulfone Z-133a as 
described in the literature.128 The magnitude for the vicinal olefinic coupling constant 
was J = 12.1 Hz indicating Z stereochemistry (the E isomer has J = 15.1 Hz). This 
sulfone, Z-133a was later treated with PhSH in aqueous or organic medium to produce 
the vinyl sulfide 135a in very good yields with inversion of stereochemistry (E/Z, 95:5; 
entries 8–10). Thus, I concluded that the vinyl sulfides were formed predominantly with 
E stereochemistry independent of the stereochemistry of the starting vinyl sulfones. 
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3.3.3. Thiodesulfonylation of α-(Fluoro)vinyl Sulfones: Synthesis of α-(Fluoro)vinyl 
Sulfides. 
Reactions involving radical-mediated thiodesulfonylation provided me access to 
the synthesis of the virtually unknown (α-fluoro)vinyl sulfides 142-145 in relatively good 
yields (Scheme 26). I started with the reactions of 141a (E/Z, 96:4) with benzenethiol in 
organic or aqueous medium in the presence of the radical initiator, ACCN, which formed 
the (α-fluoro)vinyl sulfide, E/Z-142a, in good to excellent yields with the "overall" 
retention of stereochemistry (Table 3, entries 1 and 2).127 Similarly, for unfluorinated 
compounds, thiodesulfonylation appeared fairly general since sulfones 141b, 141c and 
141d bearing alkyl (Me), electron-withdrawing (CF3), or electron-donating (MeO) 
substituents on the phenyl ring attached to the double bond also produced (α-fluoro)vinyl 
sulfides (entries 4–6, 9, and 10).  
a      C6H5                            
b      4-(CH3)C6H4               
c      4-(CF3)C6H4                
d      3,4-(MeO)2C6H3         
e      C6H5CH2CH2              
f       c-C6H11                       
g                     -(CH2)5-
h      C6H5                           CH3
H
H
H
H
H
H
        R                            R'
SR1
R
R2HS R
2
Method A, B or C
142 R2 = H
143 R2 = CH3
144 R2 = NH2
145 R2 = CO2Me
SR1
R F
141
F
O
O
series:
 
Scheme 26. Thiodesulfonylation of (E/Z)-(α-Fluoro)vinyl Sulfones and Synthesis of  
        (E/Z)-(α-Fluoro)vinyl Sulfides. 
 
Treatment of the unconjugated sulfone 141e or 141f with benzenethiol produced 
the vinyl sulfide 142e or 142f in low yields (entries 11 and 12). Careful analysis of the 
crude reaction mixture indicated, however, that only the Z-141e or the Z-141f isomer of 
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the starting sulfones were consumed during reactions to produce primarily E-sulfides, 
while the E-sulfones remained mostly unreacted. These indicated the lack of reactivity of 
E-133e and E-133f vinyl sulfones since only the Z sulfone was consumed during 
reactions. Cyclohexylidiene sulfone 141g was the only nonconjugated sulfone that gave 
promising results.  It produced the tetrasubstituted vinyl sulfide, 141g upon treatment 
with benzenethiol (entry 13).  
Reactions involving sulfone 141h (E/Z, 57:43) derived from acetophenone with 
benzenethiol also afforded tetrasubstituted (α-fluoro)-vinyl sulfide 142h (E/Z, 50:50; 
entries 14 and 15). I later tested the stereospecificity of the thiodesulfonylation reactions 
by testing thiodesulfonylation with pure E/Z isomers of some (α-fluoro)vinyl sulfones. I 
observed that thiodesulfonylation is not stereospecific since reactions of pure E-141h or 
Z-141h with benzenethiol each gave 142h as mixture of both E/Z-isomers (entries 16 and 
17). The E product is the predominant isomer, most probably due to its greater 
thermodynamic stability (Scheme 26). 
Thiodesulfonylation also occurred with other aromatic thiols such as 4-
methylbenzenethiol, 4-aminobenzenethiol and with 4-mercaptobenzoic acid yielding 
various vinyl sulfides (entries 3, 7 and 8, 18–20). It is noteworthy that transmetalation of 
the carboxylate group to methyl ester occurred in MeOH. My methodology is particularly 
important for the synthesis of (α-fluoro)vinyl sulfides since the 1-fluoroalkynes are 
unstable and virtually unknown in literature, therefore, the hydrothiolation approaches are 
inapplicable. It is also worth emphasizing that my thiodesulfonylation methodology can 
be viewed as as reductive deoxygenation of sulfones to the corresponding sulfides—a 
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transformation which requires harsh conditions incompatible with most functional 
groups.127 
Table 3. Synthesis of (-Fluoro)vinyl Sulfides via Thiodesulfonylation of (- 
   Fluoro)vinyl Sulfones. 
Entry Sulfone (E/Z) Methoda  Productb E/Zc             Yieldd 
1 141a  (96:4) A  142a  92:8  92 
2 141a  (96:4) B  142a  94:6  65e 
3 141a  (96:4) A  144a  83:17  50 
4 141b (86:14) A  142b  93:7  82, 62f 
5 141b (86:14) B  142b  92:8  56 
6 141b (86:14) C  142b  92:8  92f 
7 141b (86:14)   C  143b  92:8  90 
8 141b (86:14)   C  144b  94:6  69f 
9 141c (90:10) B  142c  93:7  60f,72 
10 141d (97:3) B  142d  93:7  73 
11 141e (90:10)  B  142e  70:30  10g   
12 141f (86:14) C  142f                 70:30  12h  
13 141g  B  142g    65 
14 141h (57:43) B  142h  50:50  58 
15 141h (57:43) C  142h  50:50  68 
16 141h (100:0) C  142h  50:50  85 
17 141h (0:100) C  142h  33:67  70 
18 141h (100:0) C  143h  64:36  96 
19 141h (57:43) B  143h  50:50  59 
20 141h (57:43) C  145h  55:45  42 
 
a Method A: thiol/ACCN/toluene /110 oC/6 h; Method B: thiol/ACCN/ H2O /100 oC/6 h; Method C: 
thiol/ACCN/MeOH/65 oC/5 h. b Reactions were performed on 0.1-0.5 mmol scale of sulfones (0.05 mM) 
with 1.25-2.0 equiv. of thiols and 0.25-0.50 equiv. of AACN or AIBN. c Determined by GC-MS and 1H or 
19F NMR. d Isolated yield. e Reaction with phenyl disulfided gave 142a (55%, Method B or C). f AIBN 
instead of ACCN. g 83% based on Z-141e. h 75% based on Z-141f.  
 
3.3.4. Kinetics of Thiodesulfonylation Reaction.  
The relative kinetics for the thiodesulfonylation reaction of vinyl sulfone and α-
fluorovinyl sulfone were studied using 4-methylphenyl vinyl sulfone 133b and its α-
fluorovinyl counterpart 141b as convenient starting materials. Thus, equivalent amounts 
of sulfones 133b (0.5 eq) and 141b (0.5 eq) were mixed together with one or two 
equivalent of benzenethiol. The progress of the reaction was followed by analyzing 
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aliquots by GC-MS and 1HNMR (see Table 4 for results). For example, treatment of α-
fluoro sulfone 141b (E/Z, 84:16; 0.5 equiv) with PhSH (2.0 equiv; Method C) in the 
presence of the parent α-H sulfone E-133b (0.5 equiv) demonstrated that the 
thiodesulfonylation of α-fluorovinyl sulfone occurs at a faster rate than its nonfluorinated 
counterpart.127 Differentiation of reactivity between vinyl and α-fluorovinyl sulfones 
towards thiodesulfonylation reactions with aryl thiols was more evident when only one 
equivalent of benzenethiol was used resulting in a 3-fold difference after 2 h (70% yield 
of 142b vs 25% yield of 135b). 
Table 4. Relative Kinetics of Thiodesulfonylation Reactions. 
Time (min)
30 min                              20%            50%
1 h                                    25%            65%
2h                                     25%            70%
3h                                     10%            75%
4h                                      5%             75%
5h                                      5%             80%
Yield       135b         142b
                                  35%           70%
                                  45%            88%
                                   48%            95%
                                   40%            98%
                                   35%            99%
                                   25%            99%
Yield        135b        142b
SO2Ph SPh
X
PhSH (1or 2 eq)
AIBN, MeOH
   E-133b, 0.5 eq. E/Z 135b X = H
E/Z 142b X = F
SO2Ph
F
E/Z 141b, 0.5 eq.
Yield with 1 eq.  thiol Yield with 2 eq.  thiol
 
3.3.5. Synthesis of the Antibacterial Agent with (α-Fluoro)vinyl Sulfide Unit. 
Next I applied my radical-mediated thiodesulfonylation procedure for the 
synthesis of the (E/Z)-1-fluoro-2-(3-hydroxy-5-methoxyphenyl)-1-phenylthioethene 
151a. The latter compound was expected to have enhanced biological activity when 
compared to its nonfluorinated analogue, 2-(3-hydroxy-5-methoxyphenyl)-1-
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phenylthioethene 151b, which is active against drug resistant strains of tuberculosis and 
anthrax surrogates.129 
I proposed the synthesis of 151a by starting with suitably protected 3,5-
dihydroxybenzaldehyde into (α-fluoro)vinyl sulfone utilizing the Wittig-Horner reaction 
followed by replacement of sulfonyl group with benzenthiol employing my radical 
mediated thiodesulfonylation methodology. In order to prepare the required 3-hydroxy-5-
methoxybenzaldehyde substrate, 147, the commercially available 3,5-
dimethoxybenzaldehde, 146, was selectively demethylated with propanethiol in the 
presence of sodium hydride at reflux following literature procedure129b (Scheme 27). 
Subsequent protection of the free hydroxyl group in 147 was performed by dissolving the 
compound in anhydrous pyridine and treating it with 3 equivalents of tert-
butylchlorodimethylsilane to yield 148 (53%).  
Treatment of the aldehyde, 148 with the Wittig reagent generated from diethyl 
fluoro(phenylsulfonyl)methylphosphonate and lithium bis(trimethylsilyl) amide in THF 
gave (E/Z)-1-fluoro-2-(3-methoxy-5-tert-butyldimethylsilyloxyphenyl)-1-phenylsulfonyl-
ethene, 149, in 80% yield (E/Z: 89/11) after column chromatography (hexane/EtOAc; 
9:1). 1H NMR and 19F NMR showed a vicinal coupling constant of 3J = 34.3 Hz, and 3J = 
21.9 Hz for E and Z isomers, respectively. Thiodesulfonylation reaction of the (α-
fluoro)vinyl sulfone, 149, with benzenethiol at 100 oC (oil bath) for 1.5 hours in MeOH 
produced the corresponding (α-fluoro)vinyl sulfide, 150, in 90% yield after purification 
in silica gel as a mixture of E/Z isomers as conveniently judged by NMR and GC/MS (tR 
= 28.60 min, E, tR = 27.31 min, Z). Desilylation of 150 with tetra-butylammonium 
fluoride in THF at 0 oC in an ice-bath for 25 minutes afforded (E/Z)-1-fluoro-2-(3-
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hydroxy-5-methoxyphenyl)-1-phenylthioethene, 151a, in 98% yield. 1HNMR showed the 
disappearance of the signals from the silyl protection at 0.21 and 0.98 ppm. The GC-MS 
spectrum indicated a molecule ion at m/z 276 (M+, 100; tR = 25.39 min, Z, tR = 26.64 min, 
E).  
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Scheme 27. Synthesis of (E/Z)-1-Fluoro-2-(3-Methoxy-5-Hydroxyphenyl)-1- 
        Phenylthioethene and its Sulfone and Sulfoxide Derivatives. 
 
I also synthesized the corresponding 3-hydroxy-5-methoxy-(α-fluoro)vinyl 
sulfoxide 154 and sulfone 152 derivatives to test if the oxidization state of sulfur will 
enhance antibacterial activity. Thus, (α-fluoro)vinyl sulfide, 150, was dissolved in 
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methylene dichloride and treated with a solution of m-CPBA in CH2Cl2  for 1 hour to 
produce (E/Z)-1-fluoro-2-(3-methoxy-5-tert-butyl-dimethylsilyloxyphenyl)-1-phenyl-
sulfinylethene, 153 in good yield (85%) after column chromatography. The 19F NMR 
showed a doublet at δ -121.61 (d, J = 36.7 Hz, 1F) and the GC–MS analysis showed a 
molecular ion at m/z 406 (M+; tR = 30.62 min, E). Desilylation of 153 with TBAF in THF 
at 0 oC (ice-bath) for 25 minutes afforded (α-fluoro)vinyl sulfoxide, 154 (90%). The 19F 
NMR in CDCl3 showed δ -121.61 (d, J = 36.7 Hz, 1F) and the GC–MS showed an ion 
peak at m/z 292 (M+; tR = 28.95 min, E). Standard desilylation of 149 with TBAF 
provided the (α-fluoro)vinyl sulfone 152 (94%) after purification on silica gel column. 
It was demonstrated in earlier literature reports129 that in order for the vinyl 
sulfide to possess antibacterial activity the styryl group is required to have a meta 
hydroxyl/methoxy pattern. Therefore, I also prepared 3,5-dimethoxystyryl (α-fluoro)vinyl 
sulfide, 146b to check for the existing pattern of reactivity. Thus, readily available 
aldehyde 146 underwent a Wittig reaction with diethyl fluoro(phenylsulfonyl)-
methylphosphonate in the presence of lithium bis(trimethylsilyl)amide in THF to give 
(E/Z)-1-fluoro-2-(3,5-dimethoxy)-1-phenylsulfonylethene, 146a, in 80% yield (E/Z: 
78/22) after column chromatography (hexane/EtOAc; 85:15). 1H NMR and 19F NMR 
showed a vicinal coupling constant of 3J = 34.2 Hz, and 3J = 21.8 Hz for E and Z isomers, 
respectively. Thiodesulfonylation of (α-fluoro)vinyl sulfone, 146a, with benzenethiol at 
100 oC (oil bath) for 1.5 hours in MeOH produced the corresponding (α-fluoro)vinyl 
sulfide, 146b (75%) as a mixture of E/Z isomers; 1H NMR and 19F NMR showed a 
vicinal coupling constant of 3J = 32.0 Hz, and 3J = 16.9 Hz for E and Z isomers, 
respectively.  
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3.3.5.1. Biological Activity of the (α-Fluoro)vinyl Sulfide, Sulfoxide and Sulfone  
Analogues 
Table 5 summarizes the in vitro cytotoxic activity of 3-hydroxy-5-methoxy-(α-
fluoro)vinyl sulfone 152, sulfoxide 154, and sulfide 151a  as well as 3,5-dimethoxy-(α-
fluoro)vinyl sulfide 146b  against three different gram positive bacterial lines. Tests were 
performed in the laboratory of Professor A. Monte at University of Wisconsin La Crosse. 
The minimum inhibitory concentration IC50 values were determined as an average of at 
least three experiments with standard error of the mean. It was found that (α-fluoro)vinyl 
sulfide 151a showed activity against M. smegmatis, the surrogate for tuberculosis, at the 
similar level129c as the nonfluorinated analogue 151b (Table 5). Sulfone 152 and 
sulfoxide 154 have no cytotoxic activity as compared to 151a for both S. aureus and B. 
cereus. The 3,5-dimethoxy-(α-fluoro)vinyl sulfide 146b also showed no activity 
reinforcing the literature finding that m-hydroxy/methoxy pattern is required for 
antibacterial activity. 
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Table 5.  Antibacterial Activity of the (α-Fluoro)vinyl Sulfone, Sulfoxide and Sulfide          
                Analogues Against Gram Positive Bacteria.a 
 
Compound 
Staphylococcus 
aureus  Bacillus cereus 
Mycobacterium 
smegmatis 
    >512 
>128 >128 >128 
  146b >128 >128 >128 
mean >128 >128 >128 
    128 
16 32 128 
151a 16 32 128 
mean 16b 32c 128d 
    256 
128 128 >128 
152 128 128 >128 
mean 128 128 >128 
>128 >128 256 
>128 >128 >128 
154       >128 
mean >128 >128 >128 
 
a Minimum inhibitory concentration IC50 values in µg/mL. b Corresponds to IC50 of  58 µM. c Corresponds 
to IC50 of  116 µM. d  Corresponds to IC50 of  464 µM. 
 
3.3.6. Synthesis of Vinyl and α-(Fluoro)vinyl Methyl Phenyl Sulfonium Ions. 
3.3.6.1. Attempted Transfer of a Methyl Group to Alkyl or Aryl Thiols, Phenols and  
Amino Groups 
Methyl group transfers (e.g., from SAM) catalyzed by methyltransferases are one 
of the most fundamental reactions catalyzed by proteins. These processes are frequently 
used for the alkylation (methylation) of viral RNA fragments and/or different amino acid 
residues to alert their natural activity. I envisioned that in Wnuk lab (α-fluoro)vinyl 
sulfides synthesized can be converted to the corresponding sulfonium salt (i.e. 155 or 
156); which in turn could act as (a) methyl group donor to the amino acid functionalities 
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such as hydroxyphenol (present in tyrosine), sulfhydryl (cysteine/homocysteine), amino 
(lysine/histidine) or hydroxyl (serine) groups (path a, Scheme 28) or alternatively might 
act as a (b) powerful Michael acceptor to induce covalent inhibition of the protein 
proximal amino acid residues prior to transferring CH3 group (path b, Scheme 28, 
157a/b). 
E/Z 155 X = H
E/Z 156 X = F
X
S Ph
E/Z 135a X = H
E/Z 142a X = F
X
S Ph
Path a
Path b
E/Z 157a X = H
E/Z 157b X = F
X
S Ph
Nu
E-Nuc
E-Nuc
E-
E-Nu-CH3
E-Nuc E-Nuc-CH3
 
Scheme 28. Possible Dual Reactivity of Vinyl Sulfonium Ion with Enzyme-bound  
        Nucleophiles. 
 
Pathway (a) resembles a typical methylation reaction catalyzed by various 
transferases enzyme, while pathway (b) was demonstrated by Warner and Hoffman who 
reported98 a nucleophilic addition of the enzyme-bound protein to the β position of the 
MEVS+ (see Scheme 10). They reported that vinyl sulfonium ions act as an inhibitor for 
thioether methyltransferase (TEMTase)98 postulating that ethyl methyl vinyl sulfonium 
ion inactivates the enzymes activity by covalently modifying TEMTase.  
In order to check my hypothesis, and to examine a possible dual reactivity of 
vinyl sulfonium ions with nucleophiles, I converted vinyl 135a and (α-fluoro)vinyl 142a 
sulfides to the corresponding methyl phenyl styryl or (β-fluoro)styryl sulfonium salts 155 
and 156, respectively. The (β-fluoro)styryl sulfonium ion, 156, will also allow me to 
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determine the effect of the fluorine substituent on the reactivity of vinyl sulfonium 
substrates. Thus, treatment of 135a or 142a with iodomethane and silver 
tetrafluoroborate129d yielded quantitatively the alkenyl or (α-fluoro)alkenyl methyl phenyl 
sulfonium salts 155 and 156, respectively (Scheme 29). 1H NMR and 19F NMR analysis 
showed that methylation of the sulfide occurred with retention of the E stereochemistry at 
the alkenyl unit. 
E/Z 155 X = H
E/Z 156 X = F
X
S Ph
E/Z 135a X = H
E/Z 142a X = F
X
S Ph AgBF4
CH3I
 
Scheme 29. Synthesis of Vinyl and α-Fluorovinyl Sulfonium Ions. 
Vinyl sulfonium salts, 155 and 156, were treated with an array of nucleophiles 
mimicking functionalities present in natural amino acid (Scheme 30). Thus treatment of 
the sulfonium salt 155 with propanethiol in DMF in the presence of triethylamine (TEA) 
resulted in a quick disapearance of the substrate and formation of the corresponding 
sulfide 135a. Treatment of 155 with phenol, thiophenol and/or imidazole also resulted in 
a rapid formation of the vinyl sulfide 135a. Analogous treatment of propanethiol, 
thiophenol, phenol and imidazole with β-styryl fluorinated sulfonium salt 156 also 
resulted in a quick formation of the corresponding fluorovinyl sulfide 142a.  Treatment of 
156 with p-toluenethiol in DMF with TEA also led to the formation of the vinyl sulfide 
142a and the new minor product whose structure was tentatively assigned as the β-
addition adduct of type 158. These results indicated an efficient transfer of the methyl 
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group from substrate 155/156. However, treatment of 156 with protected N-Boc-Hcy-
COtBu under analogous conditions led to the formation of complex reaction mixture.   
The preliminary kinetic result of the methylation reactions reveals that the transfer 
of a methyl group from the fluorinated sulfonium salt precursor 56 occurs only slightly 
faster than from the corresponding unfluorinated methyl sulfonium counterpart, 55.  
 
E/Z 155 X = H
E/Z 156 X = F
X
S Ph
SH
N NH
OH
SH
DMF, NaH/TEA
DMF, NaH/TEA
DMF, NaH/TEA
DMF, NaH/TEA
E/Z 135a X = H
E/Z 142a X = F
X
S Ph
S
O
S
N N
R R
158F
S Ph
S
 
Scheme 30. Reaction of Vinyl and α-Fluorovinyl Sulfonium Ions with Selected Amino  
        Acid Residues. 
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4. EXPERIMENTAL SECTION 
4.1. General Procedure 
 Melting points were obtained with a capillary apparatus and are uncorrected. UV 
spectra were measured in MeOH using a Shimadzu UV-2101 PC scanning spectrometer. 
1H (Me4Si) at 400 MHz and 13C (Me4Si) at 100.6 MHz were recorded on a Bruker 
Avance NMR spectrometer with solutions in CDCl3, unless otherwise specified. Mass 
spectra were obtained by atmospheric pressure chemical ionization (APCI) technique 
using a Finnigan navigator LC/MS and MeOH as a solvent. Gas chromatography data 
was obtained by a Hewlett Packard HP6890 series GC system equipped with a 5973 
Mass Selective Detector and a 7683 Series Injector. Evaporation was effected with a 
Büchi rotary evaporator under water aspirator or mechanical oil pump at < 35 oC. 
Elemental analysis was determined at Galbraith Laboratories, Knoxville, TN. Merck 
Kiselgel 60-F254 sheets were used for Thin Layer Chromatography (TLC) and products 
were detected with a 254 nm light. Merck Kiselgel 60 (230-400 mesh) was used for 
column chromatography. Unless otherwise specified solvents used for column 
chromatography and TLC were as follows: (S1) CHCl3/MeOH (9:1); (S2) CHCl3/MeOH 
(95:5); (S3) CHCl3); (S4) EtOAc; (S5) EtOAc/hexane (1:1); (S6) EtOAc/hexane (7:3); 
(S7) EtOAc/hexane (3:7); (S8) EtOAc/hexane (1:9); (S9) SSE [the upper phase of 
EtOAc/i-PrOH/H2O (4:1:2)]. Reagent grade chemicals were used for reactions. Solvents 
were dried by reflux over and distillation from CaH2 under argon except THF which was 
dried with a VAC Atmospheres Co. solvent purifier. Sonication was performed with a 
Branson 5200 ultrasound bath. 
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4.2. Synthesis 
Ethyl 5(E)-(5'-deoxy-2',3'-O-isopropylideneuridin-5'-ylidene)pentanoate 
(101a). Procedure A Tris(dibenzylideneacetone)dipalladium (9.2 mg, 0.01 mmol) was 
added to a solution of (E)-100a111 (40 mg, 0.1 mmol) in benzene (2 mL) followed by 
dropwise addition of EtO2C(CH2)3ZnBr (0.5 M/THF, 0.3 mL, 0.15 mmol) via syringe at 
ambient temperature under N2. The resulting mixture was heated at 55 oC for 8 h 
[additional EtO2C(CH2)3ZnBr (0.1 mL, 0.05 mmol) was added after 5 h] and progress of 
the reaction was monitored (TLC) by the formation of slightly more polar compound. 
The volatiles were evaporated and the brown residue was partitioned (EtOAc/H2O). The 
organic layer was washed (brine), dried (Na2SO4), evaporated, and the residue was 
column chromatographed (EtOAc/hexane, 85:15) to give 101a (28 mg, 72%); 1H NMR δ 
1.25 (t, J = 7.1 Hz, 3, CH3), 1.38 (s, 3, CH3), 1.58 (s, 3, CH3), 1.72 (quint, J = 7.6 Hz, 2, 
H8',8''), 2.12 (q, J = 7.1 Hz, 2, H7',7''), 2.32 (t, J = 7.6 Hz, 2, H9'), 4.14 (q, J = 7.1 Hz, 2, 
CH2), 4.50 (dd, J = 4.3, 7.8 Hz, 1, H4'), 4.74 (dd, J = 4.4, 6.2 Hz, 1, H3'), 5.02 (dd, J = 
1.7, 6.5 Hz, 1, H2'), 5.60 (d, J = 1.6 Hz, 1, H1'), 5.62 (dd, J = 8.0, 14.6 Hz, 1, H5'), 5.73 
(d, J = 8.2 Hz, 1, H5), 5.82 (dt, J = 6.8, 14.6 Hz, 1, H6'), 7.28 (d, J = 8.2 Hz, 1, H6), 9.40 
(s, 1, NH); 13C NMR δ 14.25 (CH3), 24.03 (C8'), 25.32 and 27.16 (CMe2), 31.53 (C7'), 
33.62 (C9'), 60.35 (CH2), 84.22 (C3'), 84.84 (C2'), 88.63 (C4'), 94.29 (C1'), 102.45 (C5), 
114.57 (CMe2), 128.57 (C6'), 131.96 (C5'), 142.23 (C6), 149.77 (C2), 163.03 (C4), 
173.45 (C10'); MS m/z 395 (100, MH+); HRMS calcd for C19H27N2O7 [M+H]+ 395.1818, 
found 395.1811. 
Ethyl 5(E)-(5'-deoxy-2',3'-O-isopropylideneadenosin-5'-ylidene)pentanoate 
(101b) Coupling of (E)-100b35 (41 mg, 0.1 mmol) with EtO2C(CH2)3ZnBr (0.5 M/THF, 
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0.4 mL, 0.2 mmol) by procedure A [column chromatography (1→2% MeOH/EtOAc)] 
gave 101b (27 mg, 68%); 1H NMR (600 MHz) δ 1.25 (t, J = 7.2 Hz, 3, CH3), 1.28 (s, 3, 
CH3), 1.42 (s, 3, CH3), 1.68 (quint, J = 7.5 Hz, 2, H8',8''), 2.04 (q, J = 7.2 Hz, 2, H7',7''), 
2.28 (t, J = 7.5 Hz, 2, H9',9''), 4.08 (q, J = 7.1 Hz, 2, CH2), 4.65 (dd, J = 3.3, 7.5 Hz, 1, 
H4'), 4.98 (dd, J = 3.5, 6.2 Hz, 1, H3'), 5.51 (dd, J = 1.9, 6.3 Hz, 1, H2'), 5.59 (ddt, J = 
1.2, 7.6, 15.4 Hz, 1, H5'), 5.72 (dt, J = 15.4, 6.6 Hz, 1, H6'), 5.90 (br s, 2, NH2), 6.09 (d, J 
= 1.9 Hz, 1, H1'), 7.91 (s, 1, H2), 8.38 (s, 1, H8); MS m/z 418 (100, MH+); HRMS calcd 
for C20H28N5O5 [M+H]+ 418.2090, found 418.2082. 
 Ethyl 5(E)-(5'-deoxyuridin-5'-ylidene)pentanoate (102a)  Procedure B. A 
solution of 101a (70 mg, 0.78 mmol) with TFA/H2O (9:1, 2.5 mL) was stirred at 0 oC 
(ice-bath) for 1 h. The volatiles were evaporated under vacuum (< 15 oC) and co-
evaporated (3 x) with toluene. The residue was column chromatographed (1→6% 
MeOH/CHCl3) to give 102a (45 mg, 72%): mp 102–104 oC dec; UV max 262 nm (ε 
9200), min 230 nm (ε 2100); 1H NMR (Me2SO-d6/D2O) δ 1.18 (t, J = 7.1 Hz, 3, CH3), 
1.62 ('quint', J = 7.3 Hz, 2, H8',8''), 2.08 (q, J = 6.8 Hz, 2, H7',7''), 2.32 (t, J = 7.4 Hz, 2, 
H9',9''), 3.81 (t, J = 5.3 Hz, 1, H3'), 4.04–4.10 (m, 3, H2',CH2), 4.15 ('t', J = 6.4 Hz, 1, 
H4'), 5.57–5.72 (m, 4, H1',5,5',6'), 7.58 (d, J = 8.1 Hz, 1, H6); 13C NMR (Me2SO-d6) δ 
14.91 (CH3), 24.60 (C8'), 31.75 (C7'), 33.68 (C9'), 60.60 (CH2), 73.73 (C3'), 74.40 (C2'), 
84.81 (C4'), 89.62 (C1'), 102.79 (C5), 129.58 (C6'), 134.44 (C5'), 141.89 (C6), 151.49 
(C2), 163.95 (C4), 173.61 (C10'); MS m/z 355 (100, MH+). Anal. Calcd for C16H22N2O7 
(354.36): C, 54.23; H, 6.26; N, 7.91. Found: C, 54.34; H, 6.28; N, 7.68. 
Ethyl 5(E)-(5'-deoxyadenosin-5'-ylidene)pentanoate (102b) Treatment of 101b 
(27 mg, 0.065 mmol) with TFA/H2O by procedure B gave 102b (15 mg, 61%). 
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Purification on HPLC (10 → 60% CH3CN/H2O for 1 h, tR = 43 min) and recrystallization 
(MeOH) gave white crystals: mp 91–93 oC dec; UV max 260 nm (ε 12,700), min 230 nm 
(ε 1840); 1H NMR (MeOH-d6, 600 MHz) δ 1.05 (t, J = 7.2 Hz, 3, CH3), 1.55 (quint, J = 
7.3 Hz, 2, H8',8''), 1.98 (q, J = 7.0 Hz, 2, H7',7''), 2.16 (t, J = 7.4 Hz, 2, H9',9''), 3.94 (q, J 
= 7.0 Hz, 2, CH2), 4.04 (t, J = 5.2 Hz, 1, H3'), 4.25 (dd, J = 5.4, 6.6 Hz, 1, H4'), 4.59 (t, J 
= 4.8 Hz, 1, H2'), 5.58 (dd, J = 6.8, 15.4 Hz, 1, H5'), 5.65 (dt, J = 15.4, 6.4 Hz, 1, H6'), 
5.84 (d, J = 4.5 Hz, 1, H1'), 8.08 (s, 1, H2), 8.10 (s, 1, H8); 13C NMR (Me2SO-d6)  
14.90 (CH3), 24.46 (C8'), 31.57 (C7'), 33.62 (C9'), 60.74 (CH2), 73.54 (C3'), 74.69 (C20), 
85.40 (C4'), 88.33 (C1'), 119.76 (C5), 129.64 (C6'), 133.98 (C5'), 140.95 (C8), 150.11 
(C4), 153.53 (C2), 156.56 (C6), 173.97 (C10'); MS m/z 378 (100, MH+). Anal. Calcd for 
C17H23N5O5•H2O (395.41): C, 51.64; H, 6.37; N, 17.71. Found: C, 51.53; H, 6.42; N, 
17.37. 
5(E)-(5'-Deoxyadenosin-5'-ylidene)pentanoic acid (102c) NaOH/H2O (1 M, 
0.35 mL) was added to a solution of 102b (10 mg, 0.026 mmol) in MeOH (2.5 mL) and 
stirring was continued at ambient temperature overnight. The resulting mixture was 
neutralized with AcOH to pH ~ 7. Volatiles were evaporated and the residue was purified 
on HPLC (10 → 30% CH3CN/H2O for 50 min, tR = 28 min) to give 102c (7.5 mg, 82%); 
1H NMR (MeOH-d4) δ 1.74 ('quint', J = 7.4 Hz, 2, H8',8''), 2.15 (q, J = 7.1 Hz, 2, H7',7''), 
2.32 (t, J = 7.4 Hz, 2, H9',9''), 4.21 (t, J = 5.2 Hz, 1, H3'), 4.43 (dd, J = 5.5, 6.8 Hz, 1, 
H4'), 4.72 (t, J = 4.9 Hz, 1, H2'), 5.75 (dd, J = 7.0, 15.4 Hz, 1, H5'), 5.83 (dt, J = 15.5, 6.5 
Hz, 1, H6'), 6.01 (d, J = 4.5 Hz, 1, H1'), 8.16 (s, 1, H2), 8.22 (s, 1, H8); 13C NMR 
(MeOH-d4) δ 25.37 (C8'), 32.64 (C7'), 34.32 (C9'), 75.12 (C3'), 75.70 (C2'), 86.43 (C4'), 
90.14 (C1'), 120.10 (C5), 129.76 (C6'), 135.18 (C5'), 141.28 (C8), 150.66 (C4), 153.93 
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(C2), 157.36 (C6), 177.59 (C10'); MS m/z 350 (100, MH+); HRMS calcd for C15H20N5O5 
[M+H]+ 350.1464, found 350.1469. 
Ethyl 5-fluoro-5-(5'-deoxy-2',3'-O-isopropylideneadenosin-5'-ylidene)pentan-
oate (110) Pd(PPh3)4 (25.6 mg, 0.022 mmol) was added to a solution of 10742 (E/Z, 
~60:40; 80 mg, 0.2 mmol) in benzene (5 mL) followed by dropwise addition of 
EtO2C(CH2)3ZnBr (0.5 M/THF, 0.88 mL, 0.44 mmol) via syringe at ambient temperature 
under N2. The resulting mixture was heated at 55 oC for 8 h. The volatiles were 
evaporated and the brown residue was partitioned (EtOAc/NaHCO3/H2O). The organic 
layer was washed (brine), dried (Na2SO4), evaporated, and the residue was column 
chromatographed (1→ 3% MeOH/CHCl3) to give 110 (49 mg, 56%; E/Z, ~40:60); 19F 
NMR δ -95.78 ('q', JF–H5';7';7'' = 21.8 Hz, 0.4, E), -101.80 (dt, JF–H5' = 35.5 Hz; JF–H7';7'' = 
17.3 Hz, 0.6, Z); MS m/z 436 (MH+); HRMS calcd for C20H27FN5O5 [M+H]+ 436.1996, 
found 436.1991. (Z)-87 had: 1H NMR δ 1.23 (t, J = 7.1 Hz, 3, CH3), 1.36 (s, 3, CH3), 161 
(s, 3, CH3), 1.84 ('quint', J = 7.3 Hz, 2, H8',8''), 2.15 (dt, J = 17.1, 7.7 Hz, 2, H7',7''), 2.30 
(t, J = 7.5 Hz, 2, H9',9''), 4.09 (q, J = 7.2 Hz, 2, CH2), 4.85 (dd, J = 9.2, 35.5 Hz, 1, H5'), 
4.97 ('dd', J = 3.3, 6.2 Hz, 1, H3'), 5.15 (dd, J = 3.1, 9.2 Hz, 1, H4'), 5.54 (dd, J = 1.9, 6.2 
Hz, 1, H2'), 5.88 (br s, 2, NH2), 5.98 (d, J = 1.7 Hz, 1, H1'), 7.86 (s, 1, H2), 8.34 (s, 1, 
H8). (E)- 110 had: 1H NMR δ 1.21 (t, J = 7.1 Hz, 3, CH3), 1.35 (s, 3, CH3), 160 (s, 3, 
CH3), 1.74 ('quint', J = 7.2 Hz, 2, H8',8''), 2.26 (t, J = 7.4 Hz, 2, H9',9''), 2.35 (dt, J = 
23.3, 7.3 Hz, 2, H7',7''), 4.11 (q, J = 7.2 Hz, 2, CH2), 4.75 (ddd, J = 1.8, 3.2, 10.1 Hz, 1, 
H4'), 4.97 ('dd', J = 3.3, 6.2 Hz, 1, H3'), 5.30 (dd, J = 10.1, 19.6 Hz, 1, H5'), 5.50 (dd, J = 
1.7, 6.3 Hz, 1, H2'), 5.88 (br s, 2, NH2), 5.97 (d, J = 1.5 Hz, 1, H1'), 7.84 (s, 1, H2), 8.34 
(s, 1, H8). 
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Ethyl 5-fluoro-5-(5'-deoxyadenosin-5'-ylidene)pentanoate (111) Treatment of 
110 (40 mg, 0.092 mmol; E/Z, 40:60) with TFA/H2O by procedure B and HPLC 
purification (15 →50% CH3CN/H2O, tR = 49 min) gave 111 (32 mg, 88%; E/Z, ~35:65): 
19F NMR (MeOH-d4) δ -94.73 ('q', JF–H5';7;7' = 20.5 Hz, 0.35, E), -102.14 (dt, J F–H5' = 35.9 
Hz; JF–H7';7'' = 17.7 Hz, 0.65, Z); MS m/z 396 (100, MH+); HRMS calcd for C17H23FN5O5 
[M+H]+ 396.1678, found 396.1680. (Z)-111 had: 1H NMR (MeOH-d4) δ 1.24 (t, J = 7.1 
Hz, 3, CH3), 1.86 ('quint', J = 7.4 Hz, 2, H8',8''), 2.32 ('dt', J = 17.6, 7.3 Hz, 2, H7',7''), 
2.40 (t, J = 7.4 Hz, 2, H9',9''), 4.13 (q, J = 7.1 Hz, 2, CH2), 4.23 (t, J = 4.7 Hz, 1, H3'), 
4.86 ('t', J = 4.4 Hz, 1, H2'), 4.94 (dd, J = 4.5, 9.2 Hz, 1, H4'), 5.20 (dd, J = 9.2, 36.5 Hz, 
1, H5'), 5.99 (d, J = 4.8 Hz, 1, H1'), 8.24 (s, 1, H2), 8.26 (s, 1, H8); 13C NMR (MeOH-d4) 
 14.50 (CH3), 22.34 (C8'), 31.99 (d, J = 27.2 Hz, C7'), 33.87 (C9'), 61.55 (CH2), 74.89 
(C2'), 76.29 (C3'), 79.34 (d, J = 6.5 Hz, C4'), 90.38 (C1'), 106.01 (d, J = 11.3 Hz, C5'), 
120.82 (C5), 141.69 (C8), 150.62 (C4), 153.90 (C2), 157.37 (C6), 163.50 (d, J = 260.9 
Hz, C6'), 174.86 (C10'). (E)-111 had: 1H NMR (MeOH-d4) δ 1.24 (t, J = 7.1 Hz, 3, CH3), 
1.84 ('quint', J = 7.4 Hz, 2, H8',8''), 2.39 (t, J = 7.3 Hz, 2, H9',9''), 2.43–2.55 (m, 2, 
H7',7''), 4.12 (q, J = 7.1 Hz, 2, CH2), 4.28 (t, J = 5.5 Hz, 1, H3'), 4.60 (ddd, J = 1.9, 5.8, 
9.8 Hz, 1, H4'), 4.72 (dd, J = 4.0, 5.1 Hz, 1, H2'), 5.44 (dd, J = 9.7, 19.9 Hz, 1, H5'), 6.00 
(d, J = 3.6 Hz, 1, H1'), 8.25 (s, 1, H2), 8.23 (s, 1, H8); 13C NMR (MeOH-d4) δ 14.50 
(CH3), 22.34 (C8'), 28.56 (d, J = 27.2 Hz, C7'), 33.78 (C9'), 61.55 (CH2), 75.21 (C2'), 
76.11 (C3'), 81.03 (d, J = 14.4 Hz, C4'), 90.57 (C1'), 106.83 (d, J = 24.4 Hz, C5'), 120.70 
(C5), 141.31 (C8), 150.54 (C4), 153.94 (C2), 157.37 (C6), 165.42 (d, J = 255.3 Hz, C6'), 
174.89 (C10'). 
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5-Fluoro-5(E)-(5'-deoxyadenosin-5'-ylidene)pentanoic acid (112) Treatment of 
111 (8 mg, 0.020 mmol; E/Z, 35:65) with NaOH as described for 102c and HPLC 
purification (5 →50% CH3CN/H2O for 1 h, tR = 42 min) gave 112 (6 mg, 82%; E/Z, 
45:55); 19F NMR (MeOH-d4) δ -97.8 ('q', JF–H5';7';7'' = 23.9 Hz, 0.45, E), -105.0 ('dt', JF–H5' 
= 35.6 Hz; JF–H7';7'' =17.6 Hz, 0.55, Z); MS m/z 368 (100, MH+); HRMS calcd for 
C15H19FN5O5 [M+H]+ 368.1370, found 368.1375. (Z)-112 had: 1H NMR (MeOH-d4) δ 
1.85 ('quint', J = 7.4 Hz, 2, H8',8''), 2.32 (dt, J = 17.3, 7.4 Hz, 2, H7',7''), 2.38 (t, J = 7.3 
Hz, 2, H9',9''), 4.23 (t, J = 4.8 Hz, 1, H3'), 4.83 ('t', J = 5.0 Hz, 1H, H2'), 4.92 (dd, J = 4.7, 
9.3 Hz, 1, H4'), 5.20 (dd, J = 9.2, 36.0 Hz, 1, H5'), 6.01 (d, J = 5.2 Hz , 1, H1'), 8.24 (s, 1, 
H2), 8.27 (s, 1H, H8); 13C NMR (MeOH-d4) δ 23.02 (C8'), 32.05 (d, J = 27.4 Hz, C7'), 
33.82 (C9'), 74.91 (C2'), 76.27 (C3'), 79.34 (d, J = 6.6 Hz, C4'), 90.27 (C1'), 105.90 (d, J 
= 11.0 Hz, C5'), 120.46 (C5), 141.36 (C8), 150.60 (C4), 153.88 (C2), 157.34 (C6), 
163.30 (d, J = 258.6 Hz, C6'), 177.09 (C10'). (E)-112 had: 1H NMR (MeOH-d4) δ 1.84 
('quint', J = 7.4 Hz, 2H, H8',8''), 2.39 (t, J = 7.3 Hz, 2, H9',9''), 2.45 (dt, J = 23.7, 7.3 Hz, 
1, H7'), 2.46 (dt, J = 23.7, 7.3 Hz, 1, H7''), 4.28 (t, J = 5.6 Hz, 1, H3'), 4.60 (ddd, J = 1.8, 
5.8, 9.7 Hz, 1, H4'), 4.72 (dd J = 4.0, 5.2 Hz, 1, H2'), 5.44 (dd, J = 9.8, 19.9 Hz, 1, H5'), 
6.00 (d, J = 3.7 Hz, 1, H1'), 8.23 (s, 1, H2), 8.25 (s, 1, H8); 13C NMR (MeOH-d4) d 22.45 
(C8'), 28.65 (d, J = 26.9 Hz, C7'), 33.82 (C9'), 75.17 (C2'), 76.12 (C3'), 81.04 (d, J = 14.8 
Hz, C4'), 90.58 (C1'), 106.73 (d, J = 24.7 Hz, C5'), 120.53 (C5), 141.68 (C8), 150.49 
(C4), 153.91 (C2), 157.34 (C6), 165.88 (d, J = 258.6 Hz, C6'), 177.09 (C10'). 
1-[6-(Tributylgermyl)-5,6-dideoxy-2,3-O-isopropylidene-β-D-ribohex-5(E) 
enofuranosyl]uracil (120a) A suspension of 119a (48 mg, 0.11 mmol) in toluene (2 mL) 
was deoxygenated (N2, 1 hour), and then Bu3GeH (49 mg, 0.052 mL, 0.20 mmol) was 
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added. Deoxygenation was continued for 30 minutes, and AIBN (8.2 mg, 0.05 mmol) 
was added. The resulting solution was refluxed for 14 hours [additional AIBN (16.4 mg, 
0.1 mmol) in degassed toluene (1 mL) was added to the reaction mixture periodically]. 
Volatiles were evaporated (TLC analysis showed a formation of the less polar product) 
and the residue was partitioned (CHCl3//H2O/NaHCO3). The organic layer was washed 
with brine, dried (MgSO4) and was evaporated. The residue was column 
chromatographed [EtOAc/hexane (7:3)] to give 120a (33 mg, 57%) as a syrup: 1H NMR 
δ 0.72–0.78 (m, 6H, Bu), 0.84–0.88 (m, 9H, Bu), 1.24–1.33 (m, 12H, Bu), 1.39 (s, 3, 
CH3), 1.56 (s, 3, CH3), 4.52 ("dd", J = 4.0, 6.0 Hz, 1, H4'), 4.69 (dd, J = 4.3, 6.4 Hz, 1, 
H3'), 4.92 (dd, J = 2.0, 6.4 Hz, 1, H2'), 5.70 (dd, J = 1.5, 8.2 Hz, 1, H5), 5.72 (d, J = 2.1 
Hz, 1, H1'), 5.95 (dd, J = 6.3, 18.5 Hz, 1, H5'), 6.14 (dd, J = 1.1, 18.5 Hz, 1, H6'), 7.20 (d, 
J = 8.1 Hz, 1, H6), 8.75 (br s, 1, NH); 13C NMR δ 12.71 (Bu), 13.77 (Bu), 25.37 (CMe2), 
26.42 (Bu), 27.15 (CMe2), 27.29 (Bu), 83.99 (C3'), 84.83 (C2'), 89.79 (C4'), 93.47 (C1'), 
102.41 (C5), 114.65 (CMe2), 134.02 (C6'), 140.60 (C5'), 141.64 (C6), 149.77 (C2), 
162.96 (C4); MS m/z 525 (100, MH+, 74Ge), 523 (70, MH+, 72Ge), 521 (50, MH+, 70Ge); 
HRMS calcd for C25H4374GeN2O5 [M+H]+ 525.2384, found 525.2385. 
1-[5,6-Dideoxy-2,3-O-isopropylidene-6-(triphenylgermyl)-β-D-ribo-hex-5(E) 
enofuranosyl]uracil (120b) Treatment of 119a (48 mg, 0.11 mmol) with Ph3GeH (60 
mg, 0.20 mmol; as described for 120a) gave 120b (46 mg, 72%) as a foam: 1H NMR δ 
1.26 (s, 3, CH3), 1.50 (s, 3, CH3), 4.61 (ddd, J = 1.2, 4.2, 5.6 Hz, 1, H4'), 4.71 (dd, J = 
4.1, 6.3 Hz, 1, H3'), 4.90 (dd, J = 1.9, 6.4 Hz, 1, H2'), 5.55 (d, J = 8.1 Hz, 1, H5), 5.64 (d, 
J = 1.9 Hz, 1, H1'), 6.12 (dd, J = 5.7, 18.3 Hz, 1, H5'), 6.52 (dd, J = 1.3, 18.3 Hz, 1, H6'), 
7.10 (d, J = 8.1 Hz, 1, H6), 7.26–7.33 (m, 9H, Ph), 7.36–7.42 (m, 6H, Ph), 8.65 (br s, 1, 
83 
 
 
 
NH); 13C NMR δ 25.34 & 27.11 (CMe2), 84.14 (C3'), 84.69 (C2'), 89.48 (C4'), 93.92 
(C1'), 102.61 (C5), 114.63 (CMe2), 128.35, 128.53, 129.26, 135.03 (Ph), 135.64 (C6'), 
141.80 (C5'), 145.00 (C6), 149.75 (C2), 162.99 (C4); MS m/z 585 (100, MH+, 74Ge), 583 
(70, MH+, 72Ge), 581 (50, MH+, 70Ge); HRMS calcd for C31H3174GeN2O5 [M+H]+ 
585.1485, found 585.1447. 
9-[6-(Tributylgermyl)-5,6-dideoxy-2,3-O-isopropylidene-β-D-ribo-hex-5(E)-
enofuranosyl]adenine (121a) Treatment of 119b (50 mg, 0.11 mmol) with Bu3GeH (47 
mg, 0.050 mL, 0.19 mmol; as described for 120a) gave 121a (27 mg, 46%) as a syrup: 
1HNMR δ 0.66–0.71 (m, 6H, Bu), 0.85–0.89 (m, 9H, Bu), 1.26–1.34 (m, 12H, Bu) 1.42 
(s, 3, CH3), 1.62 (s, 3, CH3), 4.71 (dd, J = 3.1, 5.0 Hz, 1, H4'), 5.02 (dd, J = 3.1, 6.2 Hz, 
1, H3'), 5.57 (dd, J = 1.8, 6.3 Hz, 1, H2'), 5.64 (br s, 2, NH2), 5.95 (dd, J = 5.1, 18.6 Hz, 
1, H5'), 6.01 (d, J = 18.5 Hz, 1, H6'), 6.12 (d, J = 1.8 Hz, 1, H1'), 7.88 (s, 1, H2), 8.35 (s, 
1, H8); 13C NMR δ 12.69 (Bu), 13.85 (Bu), 26.54 (Bu), 26.63 & 27.26 (CMe2), 27.38 
(Bu), 84.70 (C3'), 85.39 (C2'), 90.63 (C4'), 91.27 (C1'), 114.97 (CMe2), 120.99 (C5), 
133.70 (C6'), 140.89 (C5'), 142.02 (C8), 150.44 (C4), 154.05 (C2), 156.36 (C6); MS m/z 
548 (100, MH+, 74Ge), 546 (70, MH+, 72Ge), 544 (50, MH+, 70Ge); HRMS calcd for 
C26H4474GeN5O3 [M+H]+ 548.2656, found 548.2650. 
9-[5,6-Dideoxy-2,3-O-isopropylidene-6-(triphenylgermyl)-β-D-ribo-hex-5(E)-
enofuranosyl]adenine (121b) Treatment of 119b120 (50 mg, 0.11 mmol) with Ph3GeH 
(57 mg, 0.19 mmol; as described for 120a) gave 121b (28 mg, 42%) as a foam: 1H NMR 
δ 1.39 (s, 3, CH3), 1.62 (s, 3, CH3), 4.83 (ddd, J = 1.3, 3.2, 5.8 Hz, 1, H4'), 5.09 (dd, J = 
3.2, 6.3 Hz, 1, H3'), 5.55 (dd, J = 1.9, 6.3 Hz, 1, H2'), 5.61 (br s, 2, NH2), 6.11 (d, J = 1.9 
Hz, 1, H1'), 6.20 (dd, J = 5.9, 18.3 Hz, 1, H5'), 6.46 (dd, J = 1.4, 18.3 Hz, 1, H6'), 7.31–
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7.40 (m, 15H, Ph), 7.85 (s, 1, H2), 8.11 (s, 1, H8); 13C NMR δ 25.44 & 27.11 (CMe2), 
84.13 (C3'), 84.81 (C2'), 89.75 (C4'), 90.74 (C1'), 114.38 (CMe2), 120.13 (C5), 127.96, 
128.26, 129.13, 134.95 (Ph), 135.67 (C6'), 140.03 (C5'), 145.44 (C8), 149.44 (C4), 
153.04 (C2), 155.31 (C6) MS m/z 608 (100, MH+, 74Ge), 606 (68, MH+, 72Ge), 604 (50, 
MH+, 70Ge); HRMS calcd for C32H3274GeN5O3 [M+H]+ 608.1717, found 608.1722. 
1-[2,3-Di-O-acetyl-5,6-dideoxy-6-(p-toluenesulfonyl)-β-D-ribo-hex-5(E)-
enofuranosyl]uracil (122b) DMAP (5 mg, 0.04 mmol) was added to a stirred solution of 
122a130(80 mg, 0.18 mmol) in Ac2O (4 mL) at ambient temperature. After 14 hours, 
MeOH (10 mL) was added and stirring was continued for 1 hour. Volatiles were 
evaporated and the residue was co-evaporated with MeOH (2 × 5 mL). The crude product 
was partitioned (CHCl3//H2O/HCl) and the organic layer was washed with NaHCO3/H2O, 
brine, dried (MgSO4) and was evaporated to give 122b (83 mg, 96%) of sufficient purity 
to be used in next step: 1HNMR δ 2.05 (s, 3H, Ac), 2.08 (s, 3H, Ac), 2.38 (s, 3, CH3), 
4.64 (ddd, J = 1.6, 4.6, 6.0 Hz, 1, H4'), 5.24 (t, J = 6.1 Hz, 1, H3'), 5.36 (t, J = 5.5Hz, 1, 
H2'), 5.70 (d, J = 8.1 Hz, 1, H5), 5.86 (d, J = 4.8 Hz, 1, H1'), 6.62 (dd, J = 1.6, 15.1 Hz, 
1, H6'), 6.98 (dd, J = 4.4, 15.1 Hz, 1, H5'), 7.18 (d, J = 8.1 Hz, 1, H6), 7.28 (d, J = 8.2 
Hz, 2H, Ar), 7.71 (d, J = 8.3 Hz, 2H, Ar), 9.45 (br s, 1, NH); 13C NMR δ 20.39 (2×) & 
21.65 (CH3 & 2 × Ac), 72.16 (C3'), 72.39 (C2'), 79.17 (C4'), 89.35 (C1'), 103.68 (C5), 
127.94 (Ar), 129.78 (Ar), 133.33 (C6'), 136.47 (Ar), 138.66 (C5'), 140.21 (C6), 145.01 
(Ar), 149.98 (C2), 162.67 (C4), 169.44 & 169.58 (2 × Ac); MS m/z 479 (100, MH+). 
1-[2,3-Di-O-acetyl-5,6-dideoxy-6-(triphenylgermyl)-β-D-ribo-hex-5(E) 
enofuranosyl]uracil (123a) Treatment of 122b (90 mg, 0.19 mmol) with Ph3GeH (104 
mg, 0.34 mmol; as described for 120a) gave 123a (81 mg, 68%) as an amorphous solid: 
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1HNMR δ 2.09 (s, 3H, Ac), 2.11 (s, 3H, Ac), 4.66 (ddd, J = 1.5, 5.2, 5.4 Hz, 1, H4'), 5.27 
(t, J = 5.2 Hz, 1, H3'), 5.32 (t, J = 5.4 Hz, 1, H2'), 5.65 (d, J = 8.1 Hz, 1, H5), 6.10 (d, J = 
5.1 Hz, 1, H1'), 6.17 (dd, J = 5.4, 18.3 Hz, 1, H5'), 6.73 (dd, J = 1.4, 18.3 Hz, 1, H6'), 
7.18 (d, J = 8.2 Hz, 1, H6), 7.37–7.43 (m, 9H, Ph), 7.45–7.50 (m, 6H, Ph), 8.98 (br s, 1, 
NH); 13C NMR δ 20.43 & 20.54 (2 × Ac), 72.55 (C2'), 72.96 (C3'), 83.18 (C4'), 87.43 
(C1'), 103.47 (C5), 128.48, 129.44, 134.96, 135.21 (Ph), 131.02 (C6'), 139.34 (C6), 
142.87 (C5'), 150.22 (C2), 162.63 (C4), 169.61 (2 × Ac); MS m/z 629 (100, MH+, 74Ge), 
627 (70, MH+, 72Ge), 625 (50, MH+, 70Ge); HRMS calcd for C32H3174GeN2O7 [M+H]+ 
629.1343, found 629.1335. 
1-[5,6-Dideoxy-6-(triphenylgermyl)-β-D-ribo-hex-5(E)-enofuranosyl]uracil 
(123b) Method A. A solution of 123a (32 mg, 0.05 mmol) in NH3/MeOH (2 mL) was 
stirred at ~0◦C for 2 hours, and was evaporated and co-evaporated (MeOH). The residue 
was column chromatographed (EtOAc/hexane, 4:1) to give 123b (26 mg, 96%) as a white 
powder: 1HNMRδ 4.01 (t, J = 5.5 Hz, 1, H3'), 4.19 (dd, J = 3.5, 5.0 Hz, 1, H2'), 4.62 ("t", 
J = 5.5 Hz, 1, H4'), 5.20 (br s, 2, 2 × OH), 5.58 (d, J = 8.1 Hz, 1, H5), 5.82 (d, J = 3.2 Hz, 
1, H1'), 6.20 (dd, J = 5.3, 18.4 Hz, 1, H5'), 6.71 (dd, J = 1.4, 18.3 Hz, 1, H6'), 7.32–7.46 
(m, 16H, Ph & H6), 8.92 (br s, 1, NH); 13C NMR δ 73.82 (C3'), 75.10 (C2'), 85.81 (C4'), 
91.11 (C1'), 102.52 (C5), 128.43, 128.87, 130.98, 134.85 (Ph), 136.36 (C6'), 139.54 (C6), 
144.29 (C5'), 151.21 (C2), 163.69 (C4); MS m/z 545 (100, MH+, 74Ge), 543 (75, MH+, 
72Ge), 541 (45, MH+, 70Ge); HRMS calcd for C28H2774GeN2O5 [M+H]+ 545.1132, found 
545.1132. 
Method B. A solution of 120b (29 mg, 0.05 mmol) in TFA/H2O (9:1, 1.5 mL) was 
stirred at ~0◦C for 1 hour. The volatiles were evaporated, co-evaporated (3×) with toluene 
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and the residue was column chromatographed (EtOAc) to give 123b (18 mg, 66%) with 
data identical as above. 
1-[2,3-Di-O-acetyl-6-(tributylgermyl)-5,6-dideoxy-β-D-ribo-hex-5-(E) 
enofuranosyl]-uracil (124a) Method A. Treatment of 122b (39 mg, 0.08 mmol) with 
Bu3GeH (39 mg, 0.041 mL, 0.16 mmol; as described for 120a) gave 124a (22 mg, 49%) 
as a foam: 1HNMRδ 0.78–0.92 (m, 15H, Bu), 1.26–1.38 (m, 12H, Bu), 2.08 (s, 3H, Ac), 
2.10 (s, 3H, Ac), 4.52 ("t", J = 5.5 Hz, 1, H4'), 5.22 (t, J = 5.3 Hz, 1, H3'), 5.30 (t, J = 5.4 
Hz, 1, H2'), 5.75 (d, J = 8.1 Hz, 1, H5), 5.95 (dd, J = 5.7, 18.5 Hz, 1, H5'), 6.02 (d, J = 
5.2 Hz, 1, H1'), 6.26 (dd, J = 1.2, 18.5 Hz, 1, H6'), 7.26 (d, J = 8.1 Hz, 1, H6), 8.27 (s, 1, 
NH); 13C NMR δ 12.71 (Bu), 13.73 (Bu), 26.35 (Bu), 27.32 (Bu), 20.42 & 20.49 (2 × 
Ac), 72.78 (C3'), 72.91 (C2'), 83.57 (C4'), 87.73 (C1'), 103.24 (C5), 135.65 (C6'), 138.84 
(C5'), 139.50 (C6), 149.89 (C2), 162.27 (C4); 169.56 & 169.57 (2 × Ac); MS m/z 569 
(100, MH+, 74Ge), 567 (72, MH+, 72Ge), 565 (51, MH+, 70Ge); HRMS calcd for 
C26H4374GeN2O7 [M+H]+ 569.2282, found 569.2289. 
Method B. A suspension of 122b (29 mg, 0.06 mmol) in toluene (4 mL) was degassed 
(N2, 1 hour), and then Bu3GeH (29 mg, 0.031 mL, 0.12 mmol) was added and 
deoxygenation was continued for an additional 1 hour. The 2-mercaptoethanol (2 mg, 2 
μL, 0.02 mmol) and ACCN (14.5 mg, 0.06 mmol) were added and the resulting solution 
was refluxed for 20 hours. The aqueous work-up and column chromatography (as 
described for 120a) gave 124a (20 mg, 58%) with data as reported above. 
1-[6-(Tributylgermyl)-5,6-dideoxy-β-D-ribo-hex-5-(E)-enofuranosyl]uracil 
(124b) Treatment of 124a (23 mg, 0.04 mmol) with NH3/MeOH (2 mL; as described for 
123a) gave 124b (14 mg, 72%) as a white powder: 1H NMR (MeOH-d4) δ 0.83–0.97 (m, 
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15H, Bu), 1.30–1.46 (m, 12H, Bu), 3.96 ("t", J = 5.7 Hz, 1, H3'), 4.18 (dd, J = 3.8, 5.3 
Hz, 1, H2'), 4.35 (t, J = 5.8 Hz, 1, H4'), 5.69 (d, J = 8.1 Hz, 1, H5), 5.83 (d, J = 3.8 Hz, 1, 
H1'), 6.11 (dd, J = 5.3, 18.5 Hz, 1, H5'), 6.20 (d, J = 18.6 Hz, 1, H6'), 7.55 (d, J = 8.1 Hz, 
1, H6); 13C NMR (MeOH-d4) δ 13.71 (Bu), 14.09 (Bu), 27.46 (Bu), 28.56 (Bu), 75.12 & 
75.13 (C2'/3'), 87.08 (C4'), 92.09 (C1'), 102.78 (C5), 133.15 (C6'), 142.39 (C5'), 143.20 
(C6), 152.22 (C2), 166.08 (C4); MS m/z 485 (100, MH+, 74Ge), 483 (77, MH+, 72Ge), 481 
(52, MH+, 70Ge); HRMS calcd for C22H3974GeN2O5 [M+H]+ 485.2071, found 485. 2065. 
1-[5,6-Dideoxy-6-iodo-2,3-O-isopropylidene-β-D-ribo-hex-5(E)-enofuranosyl]- 
uracil (125) A solution of NIS (22 mg, 0.10 mmol) in CHCl3/CH2Cl2 (1:1, 5 mL) was 
added dropwise to a stirred solution of 120a (48 mg, 0.09 mmol) in CHCl3/CH2Cl2 (1:1, 5 
mL) at 0◦C. After 1 hour (TLC showed exclusive formation of a more polar product), the 
pink reaction mixture was treated with NaHSO3/H2O and the separated organic layer was 
washed with brine, dried (MgSO4) and was evaporated. Purification on a short silica gel 
column (CHCl3/MeOH, 30:1) gave 125 (34 mg, 92%) with data as reported.138 
9-[6-Bromo-5,6-dideoxy-2,3-O-isopropylidene-β-D-ribo-hex-5(E) 
enofuranosyl]adenine (126) A solution of NBS (18 mg, 0.10 mmol) in CHCl3/CH2Cl2 
(1:1, 5 mL) was added dropwise to a stirred solution of 121a (50 mg, 0.09 mmol) in 
CHCl3/CH2Cl2 (1:1, 5 mL) at 0◦C. After 6 hours, the reaction mixture was washed with 
NaHCO3/H2O and brine and the separated organic layer was dried (Na2SO4) and was 
evaporated. Purification on a short silica gel column (CHCl3/MeOH, 20:1) gave 126 (28 
mg, 81%) with data as reported.37 
9-(5,6-Dideoxy-β-D-ribo-hex-5-enofuranosyl)adenine[5'-deoxy-5'-methylene-
adenosine] (127) A solution of 121a (22 mg, 0.04 mmol) in CF3CO2H/H2O (9:1, 1 mL) 
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was stirred at 0◦C for 1 hour. The volatiles were evaporated and the residue was co-
evaporated (2×) with toluene. The residue was column chromatographed (1 → 5% 
MeOH/EtOAc) to give 127  (8 mg, 76%): 1H NMR (MeOH-d4) δ 4.25 (t, J = 5.1 Hz, 1, 
H3'), 4.48 (dd, J = 5.3, 6.5 Hz, 1, H4'), 4.74 (t, J = 4.9 Hz, 1, H2'), 5.26 ("dt", J = 1.4, 
10.5 Hz, 1, H6"), 5.41 ("dt", J = 1.5, 17.1 Hz, 1, H6'), 6.04 (d, J = 5.0 Hz, 1, H1'), 6.11 
("ddd", J = 6.6, 10.5, 17.1 Hz, 1, H5'), 8.23 (s, 1, H2), 8.26 (s, 1, H8). 
2'-Deoxy-3',5'-O-(1,1,3,3-tetraisopropyl-1,3-disiloxanyl)-2'-[(phenylsulfonyl)- 
methylene] uridine [129 (Z)] Lithium bis(trimethylsilyl)amide (1 M/THF; 0.18 mL, 
0.18 mmol) was added dropwise to a stirred solution of diethyl 
(phenylsulfonyl)methylphosphonate (53 mg, 0.18 mmol) in THF (2 mL) at -78◦C under 
nitrogen. After 30 minutes, ketone 128131(78 mg, 0.16 mmol) was added and the resulting 
solution was allowed to warm up to -30◦C over 2 hours and then to ~0◦C over 15 minutes. 
NH4Cl/H2O (0.5 mL) was added and the volatiles were evaporated. The residue was 
partitioned (CHCl3//H2O/NaHCO3) and the organic layer was washed with brine, dried 
(MgSO4) and was evaporated. Column chromatography (30→40% EtOAc/hexane) gave 
129 (62 mg, 62%) as a pale-yellow powder: 1H NMR δ 0.97–1.05 (m, 28H, 4 × i-Pr), 
3.62 (ddd, J = 3.0, 4.2, 8.7 Hz, 1, H4'), 3.99 (dd, J = 3.0, 12.8 Hz, 1, H5'), 4.06 (dd, J = 
4.2, 12.8 Hz, 1, H5''), 5.35 (dt, J = 2.1, 8.5 Hz, 1, H3'), 5.70 (d, J = 8.0 Hz, 1, H5), 6.43 
("t", J = 1.8 Hz, 1, H1'), 6.48 ("t", J = 2.3 Hz, 1, H2"), 7.27 (d, J = 8.1 Hz, 1, H6), 7.51 
("t", J = 7.4 Hz, 2H, Ph), 7.60 ("tt", J = 1.3, 7.4 Hz, 1H, Ph), 7.68 ("dd", J = 1.4, 7.1 Hz, 
2H, Ph), 8.30 (s, 1, NH); 13CNMR δ 12.58 (CH), 16.86, 16.94, 17.05, 17.13, 17.20, 
17.21, 17.23, 17.35 (CH3), 61.21 (C5'), 73.02 (C3'), 81.38 (C4'), 85.83 (C1'), 102.06 
89 
 
 
 
(C5), 124.17 (C2"), 126.57, 129.56, 134.02, 140.57 (Ph), 145.08 (C6), 148.65 (C2), 
156.65 (C2'), 162.91 (C4); MS m/z 623 (100, MH+). 
2'-Deoxy-3',5'-O-(1,1,3,3-tetraisopropyl-1,3-disiloxanyl)-2'-[(triphenylgermyl) 
methylene]uridine [130 (Z)] Treatment of 129 (43 mg, 0.07 mmol) with Ph3GeH (40 
mg, 0.13 mmol; as described for 120a) gave 130 (28 mg, 51%) as a white powder: 1H 
NMR δ 0.91–0.97 (m, 24H, 8 × CH3), 1.03 (s, 4H, 4 × CH), 3.50 (dt, J = 3.2, 8.7 Hz, 1, 
H4'), 3.86 (dd, J = 3.2, 12.1 Hz, 1, H5'), 3.91 (dd, J = 3.6, 12.1 Hz, 1, H5''), 4.88 (''dt'', J = 
2.2, 8.4 Hz, 1, H3'), 5.15 (d, J = 8.1 Hz, 1, H5), 5.83 (t, J = 1.7 Hz, 1, H1'), 6.29 (d, J = 
8.1 Hz, 1, H6), 6.77 (t, J = 2.1 Hz, 1, H2''), 7.20–7.26 (m, 9H, Ph), 7.30–7.36 (m, 6H, 
Ph), 8.28 (s, 1, NH); 13C NMR δ 12.60, 12.66, 13.05, 13.65 (CH), 16.92, 17.02, 17.22, 
17.24, 17.27, 17.31, 17.36 (CH3), 61.31 (C5'), 73.50 (C3'), 82.12 (C4'), 85.37 (C1'), 
102.24 (C5), 122.63 (C2''), 128.62, 129.53, 134.63, 135.29 (Ph), 141.17 (C6), 149.03 
(C2), 155.27 (C2'), 162.21 (C4); MS m/z 787 (50, MH+, 74Ge), 785 (35,MH+, 72Ge), 783 
(25,MH+, 70Ge); HRMS calcd for C40H5374GeN2O6Si2 [M+H]+ 787.2654, found 
787.2663. 
2'-Deoxy-2'-[(triphenylgermyl)methylene]uridine [131 (Z)] Bu4NF (1 M/THF, 
0.12 mL, 0.12 mmol) was added to a solution of 130 (31 mg, 0.04 mmol) in THF (2 mL) 
and the resulting mixture was stirred at ~0◦C for 3 hours. Volatiles were evaporated and 
the residue was partitioned between diethyl ether and water. The aqueous layer was 
evaporated and the oily residue was column chromatographed (EtOAc) to give 131 (16 
mg, 73%) as an amorphous solid: 1H NMR (MeOH-d4) δ 3.66–3.73 (m, 2, H4',5'), 3.83–
3.89 (m, 1, H5''), 4.77 (dt, J = 2.2, 8.0 Hz, 1, H3'), 5.32 (d, J = 8.0 Hz, H5), 6.14 (t, J = 
1.7 Hz, 1, H1'), 6.86 (t, J = 2.2 Hz, 1, H2''), 7.04 (d, J = 8.0 Hz, 1, H6), 7.37–7.43 (m, 9H, 
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Ph), 7.49–7.52 (m, 6H, Ph); 13C NMR MeOH-d4) δ 62.33 (C5'), 73.43 (C3'), 85.44 (C4'), 
86.93 (C1'), 102.93 (C5), 124.67 (C2''), 129.65, 130.54, 135.76, 136.76 (Ph), 143.85 
(C6), 151.61 (C2), 159.02 (C2'), 166.01 (C4); MS m/z 545 (50, MH+, 74Ge), 543 (35, 
MH+, 72Ge), 541 (25, MH+, 70Ge); HRMS (ESI) calcd for C28H2674GeN2NaO5 [M+Na]+ 
567.0951, found 567.0960. 
The vinyl sulfones 2a117, 2b132, 2c132 2e117, 2f133, 2g134, 2h117 and (α-fluoro)vinyl sulfones 
3a134, 3d134, 3e134, 3f135, 3g117, 3h117were prepared as reported. 
(E)-2-(3,4-dimethoxyphenyl)-1-phenylsulfonylethene (133d). LHDMS (1.0M; 
1.12 mL, 1.12 mmol) was added dropwise to a stirred solution of diethyl 
(phenylsulfonyl)-methylphosphonate110 (292 mg, 1.0 mmol) in THF (10 mL) under N2 at 
-78 oC.  After 30 minutes, 132d (186 mg, 1.12 mmol) was added and the yellow reaction 
mixture was allowed to warm to -40 oC over 2 h. Saturated NH4Cl/H2O (~ 4 mL) was 
added and the volatiles were evaporated. The residue was partitioned (H2O//CHCl3) and 
the organic layer was washed (brine), dried (MgSO4), evaporated and column 
chromatographed (hexane/EtOAc; 9:1) to give 133d (358 mg, 47%): 1H NMR δ 3.78 (s, 
3H), 3.82 (s, 3H), 6.73 (d, J = 15.3 Hz, 1H), 6.79 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 2.0 Hz, 
1H), 7.03 (dd, J = 2.0, 8.3 Hz, 1H), 7.46 ("tt", J = 1.3, 8.3 Hz, 2H), 7.52 ("dt" J = 1.4, 8.7 
Hz, 1H), 7.57 (d, J = 15.3 Hz, 1H), 7.88 ("dt", J = 1.5, 8.6 Hz, 2H); 13C NMR δ 55.9 
(CH3), 56.0 (CH3), 110.1 (C2), 111.1 (Cα), 123.5 (C5), 124.7 (C6), 125.2 (C1), 127.5 
(C2'), 129.3 (C3'), 133.2 (Cβ), 141.2 (C4'), 142.6 (C1'), 149.3 (C4), 151.9 (C3); GC-MS 
m/z 272 (M+; tR = 26.47 min, E, tR = 26.12 min, Z). MS m/z 304.8 (100, MH+).  
(E/Z)-1-Fluoro-2-(4-methylphenyl)-1-phenylsulfonylethene (134b). Treatment 
of diethyl fluoro(phenylsulfonyl)methylphosphonate (515 mg, 1.66 mmol) in THF (10 
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mL) with 132b (0.22 mL, 1.86 mmol) as described for 133d gave 134b (358 mg, 70%; 
E/Z, 86:14): 1H NMR δ 2.38 (s, 3  0.86H), 2.40 (s, 3  0.14H), 6.90 (d, J = 22.5 Hz, 
0.14H), 7.05 (d, J = 34.2 Hz, 0.86H), 7.22 (d, J = 7.9 Hz, 2  0.86H), 7.40 (d, J = 7.9 Hz, 
2  0.14H), 7.48 (d, J = 8.0 Hz, 2  0.86H), 7.55 (d, J = 7.9 Hz, 2  0.14H), 7.61 ("t", J = 
7.4 Hz, 2  0.86H), 7.70 ("t", J = 6.9 Hz, 0.86H), 7.93 (d, J = 7.9 Hz, 2  0.14H), 8.05 (d, 
J = 7.9 Hz, 2  0.86H); 13C NMR (for E-134b) δ 21.4 (CH3), 119.2 (J = 18.7 Hz, Cβ), 
126.7 (C4'), 128.6 (C2), 128.7 (C4), 129.4 (C3), 129.7 (C3'), 130.2 (C2'), 137.7 (C1'), 
140.9 (C1), 153.0 (d, J = 302.9 Hz, Cα); 19F NMR δ -112.45 (d, J = 22.0 Hz, 0.14F), -
125.85 (d, J = 34.0 Hz, 0.86F); GC-MS m/z 276 (M+; tR = 24.20 min, E, tR = 22.58 min, 
Z). 
(E/Z)-1-Fluoro-2-(4-trifluoromethylphenyl)-1-phenylsulfonylethene (134c). 
Treatment of diethyl fluoro(phenylsulfonyl)methylphosphonate (467 mg, 1.6 mmol) in 
THF (10 mL) with 132c (0.24 mL, 1.8 mmol) as described for 133d gave 134c (475 mg, 
95%; E/Z, 9:1): 1H NMR δ 6.89 (d, J = 20.6 Hz, 0.07H, H1), 7.07 (d, J = 33.9 Hz, 0.93H, 
H1), 7.57-7.72 (m, 7H), 8.01 (d, J = 8.7 Hz, 2H); 13C NMR δ 113.8 (Cβ), 125.9 (CF3), 
127.8 (C4'), 128.7 (C4), 128.8 (C3), 129.5 (C2), 130.3 (C3'), 130.4 (C2'), 134.7 (C1), 
137.0 (C1'), 155.2 (J = 308.6 Hz, Cα); 19F NMR δ -62.82  (s, 0.07), -63.06 (s, 0.93F)  -
109.2 (d, J = 20.7 Hz, 0.07 F), -121.2 (d, J = 33.9 Hz, 0.93 F); MS m/z 329 (100, MH-);  
GC-MS m/z 330 (M+; tR = 24.53 min, Z, tR = 26.13 min, E);  
General Procedure for Thiodesulfonylation.  Method A. The vinyl sulfones 133a-g or 
(α-fluoro)vinyl sulfones 134a-h (0.10 mmol) were dissolved in toluene (2 mL) under a 
nitrogen atmosphere in a sealed tube. The reaction mixture was degassed for 1 h at 
ambient temperature, and then thiol (0.20 mmol) and the radical initiator (ACCN or 
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AIBN; 0.031 mmol) were added. The resulting solution was heated at 115 oC (oil bath) 
for 8 h and then was evaporated. The resulting brownish residue was partitioned between 
CHCl3/brine. The separated organic layer was dried (MgSO4), evaporated and purified by 
column chromatography (hexane) to give the corresponding sulfides 135-138(a-g) or (α-
fluoro)vinyl sulfides 142-145(a-h). 
Method B. The vinyl sulfones 133a-g or (α-fluoro)vinyl sulfones 134a-h (0.10 
mmol) were suspended in H2O (2 mL) under a nitrogen atmosphere in a sealed tube. The 
reaction mixture was degassed for 1 h at ambient temperature, and then thiol (0.20 mmol) 
and radical initiator (ACCN or AIBN; 0.031 mmol) was added to the heterogenous 
solution and the reaction mixture was heated at 105 oC (oil bath) for 8 hrs. The resulting 
brownish residue was partitioned (CHCl3//H2O/brine), and the organic layer was dried 
(MgSO4), evaporated and purified by column (hexane/EtOAc, 9:1) to give the 
corresponding sulfides 135-138(a-g) or (α-fluoro)vinyl sulfides 142-145(a-h). 
Method C. The vinyl sulfones 133a-g or (α-fluoro)vinyl sulfones 134a-h (0.10 
mmol) were dissolved in MeOH (2 mL) under a nitrogen atmosphere in a sealed tube. 
The reaction mixture was degassed for 1 h at ambient temperature, and then thiol (0.20 
mmol) and the radical initiator (ACCN or AIBN; 0.031 mmol) were added. The resulting 
solution was heated at 85 oC (oil bath) for 8 hrs and then evaporated. The resulting 
brownish residue was partitioned between (CHCl3/brine). The separated organic layer 
was dried (MgSO4), evaporated and purified by column chromatography (hexane) to give 
the corresponding sulfides 135-138(a-g) or (α-fluoro)vinyl sulfides 142-145(a-h). 
(E/Z)-2-phenyl-1-phenylthioethene (135a). Treatment of 133a (20 mg, 0.08 
mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 mmol) by method B [AIBN (3.9 mg, 
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0.024 mmol)] gave 135a (10.5 mg, 61%: E/Z, 95:5) 1H NMR δ 6.48 (d, J = 10.8 Hz, 
0.10H), 6.58 (d, J = 10.8 Hz, 0.10H), 6.72 (d, J = 15.5 Hz, 0.90H), 6.87 ((d, J = 15.5 Hz, 
0.90H), 7.20-7.42 (m, 10H); GC-MS m/z 212 (M+; tR = 20.20 min, E, tR = 20.10 min, Z). 
Treatment of 133a (20mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 
mmol) by method B [ACCN (5.8 mg, 0.024 mmol)] gave 135a (12 mg, 71%: E/Z, 95:5). 
Treatment of 133a (20mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 
mmol) by method B [no initiator] gave 135a (1.7 mg, 10%: E/Z, 95:5). 
Treatment of 133a (20mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 
mmol) by method A [ACCN (5.8 mg, 0.024 mmol)] gave 135a (9.3 mg, 55%: E/Z, 95:5). 
 Treatment of 133a (20mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 
mmol) by method C [AIBN (3.9 mg, 0.024 mmol), EtOH or MeOH (2 mL)] gave 135a 
(12 mg, 70%: E/Z, 95:5). 
(Z)-2-phenyl-1-phenylthioethene [135a (Z)]. Treatment of 133a (Z) (20mg, 0.08 
mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 mmol) by method A [AIBN (3.9 mg, 
0.024 mmol)] gave 135a (10.2 mg, 60%: E/Z, 95:5). 
Treatment of 133a (Z) (20mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 
0.16 mmol) by method B [AIBN (3.9 mg, 0.024 mmol)] gave 135a (16.1 mg, 95%: E/Z, 
95:5). 
Treatment of 133a (Z) (20mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 
0.16 mmol) by method C [AIBN (3.9 mg, 0.024 mmol), EtOH (2 mL)] gave 135a 
(13.6mg, 80%: E/Z, 95:5). 
 (E/Z)-2-(4-methylphenyl)-1-phenylthioethene (135b). Treatment of 133b (22.1 
mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 mmol) by method B [ACCN 
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(5.8 mg, 0.024 mmol)] gave 135b (11.4 mg, 63%: E/Z, 85:15): 1H NMR δ 2.25 (s, 3 × 
0.85H), 2.27 (s, 3 × 0.15H), 6.36 (d, J = 11.0 Hz, 0.15H), 6.50 (d, J = 11.0 Hz, 0.15H), 
6.66 (d, J = 16.1 Hz, 0.85H), 6.76 ((d, J = 16.1 Hz, 0.85H), 7.05 (d, J = 8.0 Hz, 1H), 
7.12-7.27 (m, 6H), 7.31-7.43 (m, 2H); GC-MS m/z 226 (M+; tR = 21.72 min, E, tR = 21.53 
min, Z). 
Treatment of 133b (22.1mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 
mmol) by method A [AIBN (3.9 mg, 0.024 mmol)] gave 135b (10 mg, 55%: E/Z, 85:15). 
2-(4-Trifluoromethylphenyl)-1-phenylthioethene (135c). Treatment of 133c (25 
mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 mmol) by method A [AIBN 
(3.9 mg, 0.024 mmol)] gave 135c (13 mg, 59%: E/Z, 95:5): 1H NMR δ 6.56 (d, J = 10.8 
Hz, 0.05H), 6.62 (d, J = 15.5 Hz, 0.95H), 6.64 (d, J = 10.8 Hz, 0.05H), 7.01 (d, J = 15.6 
Hz, 0.95H),7.28-7.62 (m, 9H);  13C NMR δ; GC-MS m/z 280 (M+; tR = 20.55 min, Z, tR = 
20.82 min, E). 
 Treatment of 133c (25 mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 
mmol) by method B [AIBN (3.9 mg, 0.024 mmol)] gave 135c (19 mg, 85%: E/Z, 95:5). 
 Treatment of 133c (25 mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 
mmol) by method C [AIBN (3.9 mg, 0.024 mmol)] gave 135c (21 mg, 95%: E/Z, 95:5). 
(E/Z)-2-(3,4-dimethoxyphenyl)-1-phenylthioethene (135d). Treatment of 133d 
(24.3 mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 mmol) by method A gave 
135d (12 mg, 55%: E/Z, 83:17): 1H NMR (CDCl3) δ 3.86 & 3.87 (s, 2 × 3H, 0.83H), 3.88 
& 3.92 (s, 2 × 3H, 0.17H), 6.36 (d, J = 10.6 Hz, 0.17H), 6.52 (d, J = 10.6 Hz, 0.17H), 
6.72 (s, 0.83H), 6.88 (s, 0.83H), 7.21-7.47 (m, 8H); GC-MS m/z 272 (M+; tR = 26.55 min, 
E, tR = 26.21 min, Z). 
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Treatment of 133d (24.3 mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 
mmol) by method B gave 135d (9.6 mg, 44%: E/Z, 54:45). 
Treatment of 133d (24.3 mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 
mmol) by method C gave 135d (10.9 mg, 50%: E/Z, 85:15). 
(Cyclohexylidene)methyl phenyl sulfide (135g). Treatment of 133g (18.9 mg, 
0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 mmol) and ACCN (5.8 mg, 0.024 
mmol) by Method B gave 135g (5.8 mg, 35%): 1H NMR δ 1.55-1.63 (m, 6H), 2.24 ("t", J 
= 5.7 Hz, 2H), 2.39 ("t", J = 5.7 Hz, 2H), 5.86 ("s", 1H), 7.18-7.31 (m, 4H), 7.49 (m, 1H); 
GC-MS m/z 204 (M+; tR = 21.95 min). 
Treatment of 133g (18.9 mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 
mmol) by method C gave 135g (12 mg, 74%). 
2-(4-Methylphenyl)-1-(cyclohexylidene)methyl phenyl sulfide (136g). 
Treatment of 133g (18.9 mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 mmol) 
and AIBN (3.9 mg, 0.024 mmol) by Method C gave 136g (10.5 mg, 60%): 1H NMR δ 
1.54-1.59 (m, 6H), 2.20 ("t", J = 5.5 Hz, 2H), 2.29 (s, 3H), 2.36 ("t", J = 5.5 Hz, 2H), 
5.86 ("s", 1H), 7.05 (d, J  = 8.1 Hz, 2H), 7.19 (d, J = 8.2 Hz, 2H); GC-MS m/z 218 (M+; 
tR = 20.11 min). 
2-Phenyl-1-(4-aminophenylthio)ethene (137a). Treatment of 133a (20 mg, 0.08 
mmol) with 4-aminobenzenethiol (20 mg, 0.16 mmol) by method B  gave 137a (10 mg, 
55%: E/Z, 65:35): 1H NMR δ 3.79 (bs, 2H), ), 6.36 (d, J = 11.7 Hz, 0.35H), 6.41 (d, J = 
15.4 Hz, 0.65H), 6.42 (d, J = 11.8 Hz, 0.35H), 6.80 (d, J = 15.5 Hz, 0.65H) 7.15-7.29 (m, 
9H); GC-MS m/z 227 (M+; tR = 29.20 min, E, tR = 30.24 min, Z). 
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4-Trifluoromethylphenyl-1-(4-aminophenylthio)ethene (137c). Treatment of 
133c (25 mg, 0.08 mmol) with 4-aminobenzenethiol (20 mg, 0.16 mmol) by method B  
gave 137c (4.7 mg, 20%: E/Z, 70:30): 1H NMR δ 3.82 (bs, 2H), 6.31 (d, J = 15.4 Hz, 
0.7H), 6.41 (d, J = 11.0 Hz, 0.3H), 6.51 (d, J = 10.8 Hz, 0.3H), 6.93 (d, J = 15.6 Hz, 
0.7H) 7.25-7.32 (m, 2H), 7.45-7.66 (m, 6H);  19F NMR δ; -62.7 Hz; GC-MS m/z 295 
(M+; tR = 28.74 min, E, tR = 28.56 min, Z). 
      (E/Z)-1-Fluoro-2-phenyl-1-phenylthioethene (142a). Treatment of 134a (22.1 
mg, 0.08 mmol; E/Z, 96:4) with thiophenol (14.4 mg, 13.4 μL, 0.16 mmol) by method B 
[AIBN (3.9 mg, 0.024 mmol)] gave 142a (12 mg, 65%: E/Z, 94:6): 1H NMR δ 6.28 (d, J 
= 32.5 Hz, 0.94H), 6.76 (d, J = 16.3 Hz, 0.06H), 7.26-7.37 (m, 6H), 7.44-7.53 (m, 4H); 
13C NMR (for E-142a) δ 117.9 (d, J = 12.7 Hz, Cβ), 127.2 (C4'), 127.6 (C2), 128.2 (C4), 
128.7 (C3), 129.3 (C3'), 129.9 (C2'), 132.2 (C1'), 137.1 (C1), 152.2 (d, J = 310 Hz, Cα); 
19F NMR δ -80.33 (d, J = 16.3 Hz, 0.06F), -85.55 (d, J = 32.4 Hz, 0.94F). GC-MS m/z 
230 (M+; tR = 20.3 min, E; tR = 19.3 min, Z).  
Treatment of 134a (22.1 mg, 0.08 mmol, E/Z, 96:4) with thiophenol (14.4 mg, 
13.4 μL, 0.16 mmol) by method A [AIBN (3.9 mg, 0.024 mmol)] gave 142a (17 mg, 
92%: E/Z, 92:8). 
Treatment of 134a (22.1 mg, 0.08 mmol; E/Z, 96:4) with phenyl disulfide (35 mg, 
0.16 mmol) method B and C [no thiol, AIBN (3.9 mg, 0.024 mmol)] afforded 142a 
(55%).  Analogous reaction without AIBN gave unchanged 134a (~95%). 
 (E/Z)-1-Fluoro-2-(4-methylphenyl)-1-phenylthioethene (142b). Treatment of 
134b (22.1 mg, 0.08 mmol; E/Z, 86:14) with thiopheniol (14.4 mg, 13.4 μL, 0.16 mmol) 
by method B [ACCN (5.8 mg, 0.024 mmol)] gave 142b (11 mg, 56%: E/Z, 92:8): 1H 
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NMR δ 2.20 (s, 3H), 6.15 (d, J = 32.6 Hz, 0.92H), 6.64 (d, J = 16.3 Hz, 0.08H), 7.15 (d, J 
= 8.0 Hz, 2H), 7.25-7.35 (m, 3H), 7.40-7.46 (m, 4H); 13C NMR (for E-142b) δ 21.2 
(CH3), 118.3 (d, J = 13.4 Hz, Cβ), 127.4 (C4'), 128.2 (C2), 128.2 (C4), 129.2 (C3), 129.3 
(C3'), 129.6 (C2'), 132.6 (C1'), 138.3 (C1), 151.5 (d, J = 309.0 Hz, Cα); 19F NMR δ -
81.33 (d, J = 16.3 Hz, 0.08F), -86.45 (d, J = 32.6 Hz, 0.92F); GC-MS m/z 244 (M+; tR = 
19.95 min, Z; tR = 21.01 min, E).  
Treatment of 134b (22.1 mg, 0.08 mmol, E/Z, 86:14) with thiopheniol (14.4 mg, 
13.4 μL, 0.16 mmol) by method A [AIBN (3.9 mg, 0.024 mmol] gave 142b (11 mg, 
82%: E/Z, 93:7). 
Treatment of 3b (22.1 mg, 0.08 mmol, E/Z; 86:14) with thiopheniol (14.4 mg, 
13.4 μL, 0.16 mmol) by method C [AIBN (3.9 mg, 0.024 mmol)] gave 142b (18 mg, 
92%: E/Z, 92:8). 
(E/Z)-1-Fluoro-2-(4-trifluoromethylphenyl)-1-phenylthioethene (142c). 
Treatment of 134c (25 mg, 0.08 mmol; E/Z, 9:1) with thiophenol (14.4 mg, 13.4 μL, 0.16 
mmol) by method B [AIBN (3.9 mg, 0.024 mmol)] gave 142c (17 mg, 72%: E/Z, 93:7): 
1H NMR δ 6.24 (d, J = 32.1 Hz, 0.93H), 6.72 (d, J = 15.7 Hz, 0.07H), 7.18-7.38 (m, 5H), 
7.48 ("dd", J = 1.4, 7.5 Hz, 2H), 7.58 (s, 2H);  13C NMR δ 115.2 (d, J =12.3 Hz, Cβ), 
125.5 (CF3), 127.2 (C4'), 127.6 (C3'), 128.2 (C4), 128.8 (C2), 128.9 (C3), 129.1 (C2'), 
129.4 (C1), 130.8 (C1'), 137.6 (d, J = 324.0 Hz, Cα); 19F NMR δ -77.14 (d, J = 15.6 Hz, 
0.07F), -82.8 (d, J = 32.0 Hz, 0.93F); MS m/z 299 (100, MH+); GC-MS m/z 298 (M+; tR = 
23.09 min, E, tR = 23.18 min, Z). 
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(E/Z)-1-Fluoro-2-(3,4-dimethoxyphenyl)-1-phenylthioethene (142d). 
Treatment of 134d (25.8 mg, 0.08 mmol; E/Z, 97:3) with thiophenol (14.4 mg, 13.4 μL, 
0.16 mmol) by method B [ACCN (5.8 mg, 0.024 mmol)] gave 142d (17 mg, 73%: E/Z, 
93:7): 19F NMR δ -81.5 (d, J = 16.3 Hz, 0.07F), -88.2 (d, J = 32.4 Hz, 0.93F); HRMS 
calcd for C16H15FNaO2S [M+Na]+: 313.0675; found: 313.0687; GC-MS (EI) m/z 290  
(M+; tR = 29.32 min, E, tR = 30.04 min, Z).  E-142d had: 1H NMR (CDCl3) δ 3.86 (s, 3H), 
3.88 (s, 3H), 6.24 (d, J = 32.4 Hz, 0.93H), 6.82 (d, J = 8.4 Hz, 0.07H), 7.04 (dd, J = 2.1, 
8.4 Hz, 1H), 7.15 (d, J = 1.7 Hz, 1H), 7.24-7.35 (m, 3H), 7.42-7.46 (m, 2H); 13C NMR δ 
55.8 & 55.9 (CH3), 110.1 (C5), 111.6 (d, J = 10.1 Hz, C2), 118.3 (d, J = 13.2 Hz, Cβ), 
122.2 (d, J = 7.5 Hz, C6), 125.9 (d, J = 6.0 Hz, C1), 127.5 (C4'), 129.3 (C3'), 129.5 (C4), 
132.6 (d, J = 3.7 Hz, C1'), 148.8 (C4), 149.1 (d, J = 3.1 Hz, C3), 150.6 (d, J = 301.7 Hz, 
Cα);  Z-142a had: 1H NMR  δ 6.74 (d, J = 16.4 Hz). 
 (E/Z)-1-Flouro-4-(phenylbutyl)-1-phenylthioethene (142e). Treatment of 134e 
(22.3 mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 mmol) by methods B and 
C [AIBN (3.9 mg, 0.024 mmol)] gave 142e (2 mg, 10%:  E/Z, 70:30): Note: I observed 
that only the (Z)-sulfone reacts to form the corresponding (E/Z)-sulfide; 1H NMR δ 2.47 
("dq", J = 5.1, 10.8 Hz, 0.7H), 2.52 (m, 0.3H), 2.64 (t, J = 8.9 Hz, 0.3H), 2.67 (t, J = 10.4 
Hz, 0.3H), 5.38 (dt, J = 7.6, 30.3 Hz, 0.7H), 5.68 (dt, J = 7.8, 14.2 Hz, 0.3H), 7.11-7.44 
(m, 10H); 19F NMR δ -85.76 (d, J = 14.1 Hz, 0.3F), -91.78 ("dt", J = 2.14, 30.68 Hz, 
0.7F); MS m/z 258 (100, MH+). 
[(Cyclohexylidene)(fluoro)]methyl phenyl sulfide (142g). Treatment of 134g 
(20.3 mg, 0.08 mmol) with thiophenol (14.4 mg, 13.4 μL, 0.16 mmol) and AIBN (3.9 
mg, 0.024 mmol) by Method B gave 142g (11.6 mg, 65%): 1H NMR δ 1.50-1.63 (m, 3H), 
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2.35-2.43 (m, 2H), 7.16-7.33 (m, 4H), 7.49 (dd, J = 1.5,8.0 Hz, 1H); 13C NMR δ 26.9, 
27.0 (C5), 27.2, 27.3 (C3), 27.6, 27.7 (C4), 126.4, 128.0, 129.1, 137.0 (Ar), 132.2 (d, J = 
17.9 Hz, Cβ), 143.4 (d, J = 285.4 Hz, Cα); 19F NMR δ -96.81 (s,1F); MS m/z 221 (100, 
MH-). 
(E/Z)-1-Fluoro-2-methyl-2-phenyl-1-phenylthioethene (142h). Treatment of 
134h (22.1 mg, 0.08 mmol; E/Z, 57:43) with thiopheniol (14.4 mg, 13.4 μL, 0.16 mmol) 
by method B [AIBN (3.9 mg, 0.024 mmol)] gave 142h (11.3 mg, 58%; E/Z, 50:50): 1H 
NMR δ 2.19 (d, J = 4.4 Hz, 1.5H), 2.27 (d, J = 4.2 Hz, 1.5H), 7.19-7.51 (m, 10H); 13C 
NMR δ 18.0, 18.1 (CH3), 126.0, 126.1 (d, J = 15.6 Hz, Cβ), 126.9, 127.0(C4'), 127.7, 
127.8 (C2), 128.1 (C4), 128.1, 128.2 (C3), 128.7, 128.8 (C3'), 129.2, 129.3 (C2'), 133.0, 
133.5 (C1'), 139.0, 139.5 (C1), 147.9, 148.3 (d, J = 295.0 Hz, Cα); 19F NMR δ -89.77 (q, 
J = 4.3, 8.8 Hz, 0.5F), -89.90 ("q", J = 1.8 Hz, 0.5F); GC-MS m/z 244 (M+; tR = 20.61 
min, E, tR = 19.30 min, Z).  
Analogous treatment of the E-134h (15 mg, 0.05 mmol) with thiophenol (9.0 mg, 8.4 
μL, 0.10 mmol) by Method C [AIBN (2.5 mg, 0.015 mmol)] gave 142h (3.1 mg, 85%; 
E/Z, 1:1). 
Analogous treatment of the Z-134h (18 mg, 0.065 mmol) with thiophenol (11.6 
mg, 10.8 μL, 0.13 mmol) by Method C [AIBN (3.2 mg, 0.02 mmol)] gave 142h (3.4mg, 
70%; E/Z, 67:33). 
 (E/Z)-1-Fluoro-2-(4-methylphenyl)-1-(4-methylphenylthio)ethene (143b). 
Treatment of 134b (44.2 mg, 0.16 mmol; E/Z, 86:14) with p-toluenethiol (59.6 mg, 0.48 
mmol) and AIBN (7.8 mg, 0.024 mmol) by Method C gave 143b (37.1 mg, 90%: E/Z, 
92:8): 1H NMR δ 2.32 (s, 3H), 2.34 (s, 3H), 6.26 (d, J = 32.8 Hz, 0.92H), 6.72 (d, J = 
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16.5 Hz, 0.08H), 7.10 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 7.34-7.42 (m, 4H); 
13C NMR δ 21.1 (CH3), 23.4 (CH3), 117.2 (J = 13.1 Hz, Cβ), 128.6 (C2), 128.8 (C4), 
129.3 (C3), 129.6 (C3'), 130.1 (C2'), 134.3 (C4'), 136.9 (C4), 137.3 (C1'), 137.9 (C1), 
152.2 (d, J = 309.2 Hz, Cα); 19F NMR δ -81.6 (d, J = 16.3 Hz, 0.08F), -86.6 (d, J = 32.6 
Hz, 0.92F); GC-MS m/z 258 (M+; tR = 22.13, Z, tR =  23.20 min, E). 
(E/Z)-1-Fluoro-2-methyl-2-phenyl-1-(4-methylphenylthio)ethene (143h). 
Treatment of 134h (22.1 mg, 0.08 mmol; E/Z, 57:43) with p-toluenethiol (29.8 mg, 0.24 
mmol) and AIBN (3.9 mg, 0.024 mmol) by method B gave 143h (12.0 mg, 59%: E/Z, 
50:50): 1H NMR δ 2.15 (d, J = 4.4 Hz, 0.5H), 2.27 (d, J = 3.2 Hz, 0.5H), 2.30 (s, 3H), 
2.32 (s, 3H), 7.08-7.43 (m, 9H); 13C NMR δ 17.96, 18.00 (CH3),  20.04, 21.06 (CH3), 
125.06 (d, J = 15.4 Hz, Cβ), 127.57, 127.63 (C4'), 128.04, 128.09 (C2), 128.12, 128.17 
(C4), 128.27, 128.31 (C3), 129.49, 129.62 (C3'), 129.93, 130.04 (C2'), 137.14, 137.31  
(C1'), 139.38, 139.43 (C1), 148.40, 148.82 (d, J = 291.8 Hz, Cα); 19F NMR δ -89.74 (q, J 
= 4.1, 8.3 Hz, 0.5F), -89.89 (d, J = 1.5 Hz, 0.5F). GC-MS m/z 258 (M+; tR = 20.74 min, 
E, tR = 22.06 min, Z). 
Analogous treatment of the E-134h (15 mg, 0.05 mmol) with p-toluenethiol (18.6 
mg, 0.15 mmol) by Method C [AIBN (2.5 mg, 0.015 mmol)] gave 143h (12.4 mg, 96%; 
E/Z, 64:36). 
  (E/Z)-1-Fluoro-2-phenyl-1-(4-aminophenylthio)ethene (144a). Treatment of 
134a (22.1 mg, 0.08 mmol; E/Z, 96:4) with 4-mercaptoaniline (30 mg, 0.24 mmol) and 
AIBN (3.9 mg, 0.024 mmol) by method C gave 144a (9 mg, 50%: E/Z, 83:17): 1H NMR 
δ 3.76 (s, 2H), 6.07 (d, J = 33.3 Hz, 0.83H), 6.53 (d, J = 16.9 Hz, 0.17H), 6.64 (d, J = 8.6 
Hz, 2H), 7.18-7.34 (m, 5H), 7.44 (d, J = 8.7 Hz, 2H); 13C NMR (for E-144a) δ 114.0 (d, J 
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= 12.4 Hz, Cβ), 127.6 (C4'), 127.7 (C2), 128.2 (C4), 128.5 (C3), 128.6 (C3'), 128.8 (C2'), 
129.1 (C1'), 129.3 (C1), 152.3 (d, J = 310 Hz, Cα); 19F NMR δ -81.40 (d, J = 16.9 Hz, 
0.17F), -86.51 (d, J = 33.2 Hz, 0.83F); GC-MS m/z 245 (M+; tR = 24.95 min, Z, tR = 25.05 
min, E); HRMS calcd for C14H13FN1S [M+H]+: 246.0753; found: 246.0755. 
  (E/Z)-1-Fluoro-2-(4-methylphenyl)-1-(4-carboxyphenylthio)ethene (145b). 
Treatment of 134b (22.1 mg, 0.08 mmol; E/Z, 86:14) with 4-mercaptobenzoic acid (36.9 
mg, 0.24 mmol) and AIBN (5.8 mg, 0.024 mmol) by method C and recrystallized in 
MeOH gave 145b (16 mg, 69%: E/Z, 94:6): 1H NMR δ 2.35 (s, 3H), 6.36 (d, J = 32.5 Hz, 
0.94H), 6.9 (d, J = 15.9 Hz, 0.06H), 7.31-7.59 (m, 7H), 8.12 (d, J = 8.2 Hz, 1H); 19F 
NMR δ -81.92 (d, J = 16.0 Hz, 0.06F), -87.25 (d, J = 32.3 Hz, 0.94F). 
 (E/Z)-1-Fluoro-2-methyl-2-phenyl-1-(4-carboxyphenylthio)ethene (145h). 
Treatment of 134h (22.1 mg, 0.08 mmol; E/Z, 57:43) with 4-mercaptobenzoic acid (36.9 
mg, 0.24 mmol) and AIBN (3.9 mg, 0.024 mmol) by method C gave 145h (10.2 mg, 
42%: E/Z, 55:45): 1H NMR δ 2.22 (d, J = 4.4 Hz, 3 × 0.55H), 2.27 (d, J = 3.3 Hz, 3 × 
0.45H), 3.86 (s, 3 × 0.55H, 3.87 (s, 3 × 0.45H), 7.22-7.47 (m, 7H), 7.91-7.97 (m, 2H); 19F 
NMR δ -90.51 ("q" J = 4.1, 8.5 Hz, 0.55H), -90.57 (d, J = 1.9 Hz, 0.45H); GC-MS (tR = 
24.60 min, E; tR = 25.84 min, Z). 
(E/Z)-1-Fluoro-2-(3,5-dimethoxy)-1-phenylsulfonylethene (146a).  Treatment 
of 146 (181 mg, 1.09 mmol) with diethyl fluoro(phenylsulfonyl)-methylphosphonate (250 
mg, 0.08 mmol) in THF (5 mL) as described for 134b gave 146a (285 mg, 81%; E/Z, 
78:22): 19F NMR (CDCl3) δ -111.05 (d, J = 21.8 Hz, 0.22F), -123.58 (d, J = 34.2 Hz, 
0.78F); E-146a had: 1H NMR (CDCl3) δ 3.76 (s, 6H, 6.48 (t, J = 2.2 Hz, 1H), 6.69 
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 (s, 1H), 6.71 (s, 1H), 6.97 (d, J = 34.3 Hz, 1H), 7.49-7.60 (m, 2H), 7.64-7.71 (m, 1H), 
7.99 ("d", J = 7.5 Hz, 2H); Z-149 had: 1H NMR δ 6.82 (d, J = 21.8 Hz). 
(E/Z)-1-Fluoro-2-(3-5-dimethoxy)-1-phenylthioethene (146b). Treatment of 
146a (E/Z, 78:22, 103 mg, 0.32 mmol) with thiophenol (57.6 mg, 53.6 μL, 0.64 mmol) by 
method B gave 146b (E/Z, 90:10, 70 mg, 75%): 19F NMR (CDCl3) δ -79.6 (d, J = 16.4 
Hz, 0.10F), -84.3 (d, J = 32.1 Hz, 0.90F); GC–MS (EI) m/z 290 (M+; tR = 24.49 min, Z, 
tR = 25.84 min, E). E-146b had: 1H NMR (CDCl3) δ 3.80 (s, 3H), 6.24 (d, J = 32.0 Hz, 
1H), 6.43 (t, J = 2.2 Hz, 1H), 6.71 (s, 1H), 6.72 (s, 1H), 6.49 ("t", J = 1.6 Hz, 1H), 7.28-
7.32 (m, 1H), 7.34-7.39 (m, 2H), 7.49 ("d", J = 7.5 Hz, 2H); 13C NMR (CDCl3) δ 55.3 (2 
x OCH3), 100.3 (C4), 106.8 (C2), 107.0 (C6), 117.6 (d, J = 12.2 Hz, Cβ), 127.7 (C4'), 
130.0 (C2'), 131.9 (d, J = 2.9 Hz, C1), 134.5 (d, J = 5.6 Hz, C1), 134.4 (d, J = 5.8 Hz, 
C1), 152.5 (d, J = 310.9 Hz, Cα), 160.8 (C3/C5). Z-146b had: 1H NMR δ 6.70 (d, J = 
16.8 Hz). 
E/Z)-1-Fluoro-2-(3-methoxy-5-tert-butyldimethylsilyloxyphenyl)-1-
phenylsulfonylethene (149).  Treatment of diethyl fluoro(phenylsulfonyl)-
methylphosphonate (135 mg, 0.044 mmol) in THF (5 mL) with 148136 (157 mg, 0.59 
mmol) as described for 134b gave 149 (136 mg, 75%; E/Z, 89:11): 19F NMR (CDCl3) δ -
111.1 (d, J = 21.9 Hz, 0.11F), -123.9 (d, J = 34.2 Hz, 0.89F); GC–MS (EI) m/z 422 (M+; 
tR = 29.21 min, Z, tR = 30.89 min, E). E-149 had: 1H NMR (CDCl3) δ 0.16 (s, 6H), 0.95 
(s, 9H), 3.74 (s, 3H), 6.42 (t, J = 2.2 Hz, 1H), 6.66 ("t", J = 1.7 Hz, 1H), 6.71 ("t", J = 1.8 
Hz, 1H), 6.94 (d, J = 34.3 Hz, 1H), 7.50-7.60 (m, 2H), 7.62-7.70 (m, 1H), 7.99 ("d", J = 
7.5 Hz, 2H); 13C NMR (CDCl3) δ -4.4 (SiCH3), 18.2 [C(CH3)3], 25.7 [C(CH3)3], 55.4 
(OCH3), 108.5 (d, J = 7.7 Hz, C2'), 108.7 (C4'), 114.5 (d, J = 7.6 Hz, C6'), 118.7 (d, J = 
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20.3 Hz, Cβ), 128.7 (C2), 129.5 (C3), 130.8 (d, J = 3.7 Hz, C4), 134.4 (C1'), 137.5 (C1), 
153.8 (d, J = 305.9 Hz, Cα), 157.0 (C5'), 160.9 (C3'). Z-149 had: 1H NMR δ 6.80 (d, J = 
21.9 Hz). 
(E/Z)-1-Fluoro-2-(3-methoxy-5-tert-butyldimethylsilyloxyphenyl)-1-
phenylthioethene (150). Treatment of 149 (E/Z, 89:11, 135 mg, 0.32 mmol) with 
thiophenol (50.4 mg, 47.2 μL, 0.56 mmol) by method C gave 150 (E/Z, 90:10, 101 mg, 
81%): 19F NMR (CDCl3) δ -79.6 (d, J = 16.3 Hz, 0.10F), -84.6 (d, J = 32.1 Hz, 0.90F); 
GC–MS (EI) m/z 390 (M+; tR = 27.31 min, Z, tR = 28.60 min, E). E-150 had: 1H NMR 
(CDCl3) δ -0.20 (s, 6H), 0.78 (s, 9H), 3.54 (s, 3H), 6.00 (d, J = 32.0 Hz, 1H), 6.15 (t, J = 
2.2 Hz, 1H), 6.44 ("t", J = 1.6 Hz, 1H), 6.49 ("t", J = 1.6 Hz, 1H), 7.06-7.11 (m, 1H), 
7.12-7.17 (m, 2H), 7.21-7.29 (m, 2H); 13C NMR (CDCl3) δ -4.4 (SiCH3), 18.2 [C(CH3)3], 
25.7 [C(CH3)3], 55.3 (OCH3), 106.1 (C2'), 107.4 (d, J = 8.1 Hz, C4'), 113.3 (d, J = 7.6 
Hz, C6'), 117.6 (d, J = 12.0 Hz, Cβ), 127.6 (C4), 129.3 (C3), 130.0 (C2), 132.1 (C1), 
134.4 (d, J = 5.8 Hz, C1), 152.6 (d, J = 310.9 Hz, Cα), 156.8 (C5'), 160.6 (C3'). Z-150 
had: 1H NMR δ 6.71 (d, J = 16.3 Hz). 
 (E/Z)-1-Fluoro-2-(3-methoxy-5-hydroxyphenyl)-1-phenylthioethene (151a). 
Compound 150 (40 mg, 0.10 mmol) was dissolved in THF (1.5 mL) and placed in an ice-
bath at 0 oC for 10 minutes. Add TBAF (1M/THF; 71 µL, 0.071 mmol) and stir for an 
additional 25 minutes at 0 oC. The volatiles were evaporated in vacuo and the residue was 
partitioned (CHCl3//H2O/NaHCO3). The organic layer was washed (brine), dried 
(MgSO4), evaporated and purified on column chromatography (CHCl3) to give 151a (27 
mg, 98%, E/Z, 90:10): 19F NMR (CDCl3) δ -79.4 (d, J = 16.5 Hz, 0.10F), -84.0 (d, J = 
32.0 Hz, 0.90F); GC–MS (EI) m/z 276 (M+; tR = 25.39 min, Z, tR = 26.64 min, E). E-
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151a had: 1H NMR (CDCl3) δ 3.71 (s, 3H), 6.13 (d, J = 31.9 Hz, 1H), 6.32 (t, J = 2.2 Hz, 
1H), 6.60 ("t", J = 1.9 Hz, 2H), 7.22-7.27 (m, 1H), 7.28-7.33 (m, 2H), 7.36-7.44 (m, 2H); 
13C NMR (CDCl3) δ 55.4 (OCH3), 101.7 (C4'), 107.2 (d, J = 7.7 Hz, C2'), 108.3 (d, J = 
8.6 Hz, C6'), 117.2 (d, J = 12.3 Hz, Cβ), 127.8 (C4), 129.3 (C3), 130.1 (C2), 131.9 (d, J = 
3.0 Hz, C1), 134.8 (d, J = 5.7 Hz, C1), 152.9 (d, J = 311.0 Hz, Cα), 156.7 (C5'), 160.9 
(C3'). Z-151a had: 1H NMR δ 6.63 (d, J = 16.7 Hz). 
(E/Z)-1-Fluoro-2-(3-methoxy-5-hydroxyphenyl)-1-phenylsulfonylethene 
(152).  Desilylation of 149 (E/Z, 89:11, 35 mg, 0.083 mmol) in THF (1 mL) with TBAF 
(1M/THF; 59 µL, 0.059 mmol) as described for 151 gave 152 (24 mg, 94%, E/Z, 91:9): 
19F NMR (CDCl3) δ -111.0 (d, J = 21.8 Hz, 0.09F), -123.5 (d, J = 34.0 Hz, 0.91F); 1H 
NMR (CDCl3) δ 3.72 (s, 3H), 6.44 (t, J = 2.3 Hz, 1H), 6.64 ("t", J = 2.1 Hz, 1H), 6.66 
("t", J = 2.0 Hz, 1H), 6.92 (d, J = 34.2 Hz, 1H), 7.49-7.60 (m, 2H), 7.63-7.70 (m, 1H), 
7.98 ("d", J = 7.4 Hz, 2H); 13C NMR (CDCl3) δ  55.4 (OCH3), 108.5 (C2'), 108.3 (d, J = 
7.3 Hz, C4'), 109.7 (d, J = 7.6 Hz, C6'), 118.7 (d, J = 19.8 Hz, Cβ), 128.7 (C2), 129.5 
(C3), 131.0 (C1'), 134.5 (C4), 137.3 (C1), 153.7 (d, J = 305.0 Hz, Cα), 157.2 (C5'), 161.1 
(C3'); Z-152 had: 1H NMR δ 6.78 (d, J = 21.8 Hz). 
(E)-1-Fluoro-2-(3-methoxy-5-tert-butyldimethylsilyloxyphenyl)-1-
phenylsulfinylethene (153). Compound 150 (E/Z, 90:10, 50 mg, 0.13 mmol) was 
dissolved in CH2Cl2 and cooled to -40 oC. m-CPBA (11.01 mg, 0.064 mmol) dissolved in 
CH2Cl2 was added to the sulfide solution at -40 oC with continuous stirring. Additional 
portion of m-CPBA (11.0 mg, 0.064 mmol) solution was added dropwise and continued 
stirring for 30 mins at -40 oC. The solution was washed with Na2S2O4, aqueous NaHCO3 
and water, giving after silica gel column chromatography (CHCl3) pure 153 (44 mg, 
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85%):  19F NMR (CDCl3) δ -121.61 (d, J = 36.7 Hz, 1F); GC–MS (EI) m/z 406 (M+; tR = 
30.62 min, E). 1H NMR (CDCl3) δ 0.16 (s, 6H), 0.95 (s, 9H), 3.74 (s, 3H), 6.37 (t, J = 2.2 
Hz, 1H), 6.53 (d, J = 36.7 Hz, 1H), 6.62 ("t", J = 1.6 Hz, 1H), 6.69 ("t", J = 1.7 Hz, 1H), 
7.51-7.56 (m, 6H), 7.72-7.77 (m, 2H); 13C NMR (CDCl3) δ -4.4 (SiCH3), 18.2 [C(CH3)3], 
25.6 [C(CH3)3], 55.3 (OCH3), 107.6 (C2'), 107.9 (C4'), 108.0 (C6'), 113.9 (d, J = 7.0 Hz, 
Cβ), 125.4 (C3), 129.5 (C2), 131.9 (C1'), 132.1 (C4), 140.6 (C1), 156.9 (C5'), 158.8 (d, J 
= 319.7 Hz, Cα), 160.8 (C3'). 
  (E)-1-Fluoro-2-(3-methoxy-5-hydroxyphenyl)-1-phenylsulfinylethene (154). 
Desilylation of 153 (44 mg, 0.11 mmol) with TBAF (1M/THF; 44 µL, 0.044 mmol) in 
THF (1 mL) as described for 151 gave 154 (29 mg, 90%): 19F NMR (CDCl3) δ -121.61 
(d, J = 36.7 Hz, 1F); GC–MS (EI) m/z 292 (M+; tR = 28.95 min, E). 1H NMR (CDCl3) δ 
3.72 (s, 3H), 6.42 (t, J = 2.1 Hz, 1H), 6.54 (d, J = 36.4 Hz, 1H), 6.61 ("t", J = 1.5 Hz, 
1H), 6.74 ("t", J = 1.6 Hz, 1H), 7.00 (s, 1H), 7.49-7.55 (m, 6H), 7.71-7.74 (m, 2H); 13C 
NMR (CDCl3) δ 55.4 (OCH3), 103.1 (C4'), 107.4 (d, J = 7.2 Hz, C4'), 109.3 (d, J = 6.9 
Hz, C6'), 112.9 (s, Cβ), 125.5 (C3), 129.6 (C2), 131.8 (C1'), 132.3 (C4), 139.7 (C1), 
157.7 (C5'), 157.9 (d, J = 319.7 Hz, Cα), 161.1 (C3'). 
Methyl phenyl styryl sulfonium ion (155). To a solution of silver 
tetrafluoroborate (647 mg, 3.29 mmol) compound 135a (100 mg, 0.47 mmol) was added 
in dry 1,2-dichloroethane (15 mL) at room temperature under a nitrogen atmosphere. To 
the resulting mixture, a solution of methyl iodide (456 mg, 200 µL, 3.29 mmol) in 1,2-
dichloroethane (5 mL) was added dropwise via syringe, whereupon the reaction mixture 
became cloudy and a yellow solid (silver iodide) slowly precipitated out. The 
heterogeneous mixture was stirred at ambient temperature for 2 days. The mixture was 
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filtered off using a fritted Buchner funnel to remove AgI. The yellow solid was washed 
with 1,2-dichloroethane (2 x 10 mL) and the combined filtrates were dried over MgSO4, 
filtered, and the solvent was removed under reduced pressure to yield 155 (102 mg, 
70%): 1H NMR δ 1.24 (s, 3H), 6.84 (d, J = 15.4 Hz, 1H), 7.66 (d, J = 15.4 Hz, 1H), 7.38-
8.10 (m, 10H). 
Methyl (β-fluorostyryl) phenyl sulfonium ion (156). Treatment of 142a (100 
mg, 0.44 mmol) with silver tetrafluoroborate (524 mg, 3.1 mmol), as described for 155, 
gave 156 (117 mg, 80%): 1H NMR δ 1.18 (s, 3H), 7.28 (d, J = 37.5 Hz, 1H), 7.61-7.74 
(m, 6H), 7.90-7.96 (m, 4H); 19F NMR δ -121.13 (d, J = 36.0 Hz, 1F). 
Attempted methylation of selected nucleophiles with methyl phenyl styryl 
sulfonium ion (155). 
A solution of propanethiol (2.8 mg, 3 µL, 0.03 mmol) containing TEA (2.8 mg,  3 
µL, 0.03 mmol) in DMF (0.25 mL) was added to a stirred solution of 155 (5 mg, 0.017 
mmol) in DMF (0.3 mL).  The reaction mixture was stirred at ambient temperature for 15 
minutes to give vinyl sulfide 135a as judged by T.L.C., 1H NMR and GC/MS analysis. 
Analogous treatment of phenol (2.8 mg, 3 µL, 0.03 mmol) with 155 (5 mg, 0.017 
mmol) afforded vinyl sulfide 135a as judged by TLC, 1H NMR and GC/MS. 
Treatment of imidazole (2.0 mg, 0.03 mmol) containing NaH (1.0 mg, 0.03 
mmol) in DMF (0.25 mL) with 155 (5 mg, 0.017 mmol) dissolved in DMF (0.3 mL) at 
ambient temperature for 15 minutes yielded vinyl sulfide 135a as judged by TLC, 1H 
NMR and GC/MS. 
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Attempted methylation of selected nucleophiles with methyl (β-fluorostyryl) 
phenyl sulfonium ion (156). 
A solution of propanethiol (5.7 mg, 7 µL, 0.075 mmol) containing NaH (2.0 mg, 
0.075 mmol) in DMF (0.25 mL) was added to a stirred solution of 156 (15 mg, 0.05 
mmol) in DMF (0.3 mL).  The reaction mixture was stirred at ambient temperature for 15 
minutes to afford α-(fluoro)vinyl sulfide 142a as judged by TLC, 1H NMR, 19F NMR and 
GC/MS. 
Analogous treatment of benzenethiol (3.4 mg, 2 µL, 0.06 mmol) with 156 (10 mg, 
0.03 mmol) in DMF (0.3 mL) afforded α-(fluoro)vinyl sulfide 142a as judged by TLC, 
1H NMR, 19F NMR and GC/MS. The thioanisole (MeSPh) was also detected from the 
reaction mixture with GC/MS [m/z 124 (M+; tR = 7.51 min)] 
A solution of p-toluenethiol (6.1 mg, 0.05 mmol) containing TEA (3.7 mg, 4.7 
µL, 0.05 mmol) in DMF (0.20 mL) was added to a stirred solution of 156 (10 mg, 0.03 
mmol) in DMF (0.2 mL).  The reaction mixture was stirred at ambient temperature for 35 
minutes to afford α-(fluoro)vinyl sulfide 142a as judged by TLC, 1H NMR, 19F NMR and 
GC/MS. Also detected from the reaction mixture was addition product 158; GC/MS [m/z 
354 (M+; tR = 9.34 min)] proving that the thiol was added to the β-carbon, while the 
methyl group was transferred to an amino acid residue. 
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5. CONCLUSION 
 I have designed and synthesized S-adenosyl-L-homocysteine analogues with the 
C5' and sulfur atom in the adenosylhomocysteine moiety replaced by a vinyl or (α-
halo)vinyl unit to further probe the "hydrolytic" activity of the enzyme. Negishi Pd-
catalyzed cross-coupling between the protected 5'-deoxy-5'-(iodomethylene)adenosine 
and the readily available alkylzinc bromide (EtO2C(CH2)3ZnBr) afforded 5-(5'-deoxy-
2',3'-O-isopropylideneadenosin-5'-ylidene)-pentanoate as a single E-isomer. 
Deacetonization with TFA/H2O followed by saponification with NaOH/H2O provided the 
fully deprotected 10-carbon analogue of S-adenosyl-L-homocysteine. Palladium-
catalyzed selective monoalkylation between (E/Z) 5'-(bromofluoromethylene)-5'-deoxy-
adenosine with alkylzinc bromides yielded a mixture of geometrical isomers of ethyl 5-
fluoro-5-(5'-deoxy-2',3'-O-isopropylideneadenosin-5'-ylidene)pentanoate. Deprotection of 
this compound afforded a 10-carbon analogue of S-adenosyl-L-homocysteine with a 6'-
fluoro(vinyl) unit. 
The 5',6'-vinylic adenine nucleosides were tested against human T. cruzi and 
AdoHcy hydrolase. The most active inhibitors were found to be 10-carbon non-
halogenated vinylic analogues. The 6'-fluorovinylic analogues proved to have a lower 
activity then its non-fluorinated counterpart, perhaps in accordance with the fact that 5'-
deoxy-5'-(fluoromethylene)adenosine showed the lowest enzyme inactivation efficiency 
among all 5'-halomethylene derivatives. It was also found that the free carboxylic acid 
derivatives have a time-dependent inactivation of the enzyme. 
I developed the germyldesulfonylation methodology for the synthesis of novel 
pyrimidine and purine nucleoside analogues modified at the sugar moieties with vinyl 
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germane functionalities, and further tested their application towards the synthesis of vinyl 
halides. The auxillary vinyl sulfone precursors were synthesized by treating nucleoside 
5'-aldehyde derivatives with sulfonyl-stabilized Wittig reagents. The pyrimidine and 
purine nucleosides underwent desulfonylation with either trialkyl- or triarylgermanes 
giving single 1-{6-[tributyl- or triphenylgermyl]-5,6-dideoxy-2,3-O-isopropylidene-β-D-
ribohex-5(E)-enofuranosyl} uracil and the corresponding adenine counterpart. The 5'-
(tributylgermyl)methylene-5'-deoxyadenosine and uridine derivatives underwent efficient 
halodegermylation reaction upon treatment with N-bromosuccinimide (NBS) or N-
iodosuccinimide (NIS) to give the 5'-deoxy-5-halomethylene nucleosides. It was found 
that TFA effected simultaneous protiodegermylation and removal of the isopropylidene 
protecting group from the vinyl 6'-tributylgermanes (alkyl germanes) to produce 5'-
deoxy-5'-methyleneadenosine. On the other hand, the vinyl triphenylgermane (aryl 
germanes) counterparts were found to be stable under acidic conditions and towards 
treatment with NBS or NIS. 
 Germydesulfonylation was also successfully applied to the synthesis of multi-
substituted alkenes located at C2' of the nucleoside. The vinyl 2'-phenylsulfone 
underwent germyldesulfonylation with Ph3GeH to produce 2'-deoxy-3',5'-O-(1,1,3,3-
tetraisopropyl-1,3-disiloxanyl)-2'-[(triphenylgermyl)methylene]uridine as a single Z- 
isomer. Desilylation with TBAF produced 2'-deoxy-2'-[(triphenylgermyl)methylene] 
uridine. Thus, germyldesulfonylation reaction was found to effectively remove the 
sulfonyl group from either the exomethylene or isolated double bond present in the sugar 
moieties of nucleosides. 
110 
 
 
 
 I developed radical-mediated thiodesulfonylations of vinyl and (α-fluoro)vinyl 
sulfones with aryl thiols to provide access to vinyl and the virtually unknown class of (α-
fluoro)vinyl sulfides. Reaction involving the conjugated vinyl or α-(fluoro)vinyl sulfones 
with benzenethiol in the presence of 1,1'-azobis(cyclohexane-carbonitrile) as a radical 
initiator at reflux in toluene  produced the corresponding vinyl or α-(fluoro)vinyl sulfides. 
This type of radical thiodesulfonylation reaction was also successful in aqueous medium. 
In both fluorinated or unfluorinated cases, thiodesulfonylation appeared fairly general 
since sulfones with the alkyl (Me), electron-withdrawing (CF3), or electron-donating 
(MeO) substituents on the phenyl ring attached to the double bond also proceeded 
efficiently to afford either vinyl or (α-fluoro)vinyl sulfides. GC–MS and 1H NMR 
analysis showed that radical-mediated thiodesulfonylation of the vinyl sulfones occurred 
with retention of the E stereochemistry although small amounts of the Z isomers were 
also detected. In contrast, the thiodesulfonylation of α-(fluoro)vinyl sulfones produced 
mostly inseparable mixture of E/Z isomers of α-(fluoro)vinyl sulfides. The relative 
kinetics of thiodesulfonylation reaction was studied with both vinyl and (α-fluoro)vinyl 
sulfones. It was found that (α-fluoro)vinyl sulfides were approximately formed 4 times 
faster than its vinyl sulfide counterpart. 
 Thiodesulfonylation methodology was applied towards the synthesis of the 
fluorinated analogue of the known antibacterial agent, 2-(3-hydroxy-5-methoxyphenyl)-
1-phenylthioethene, which contains vinyl sulfide functionality. Thiodesulfonylation of 
the suitably constructed (α-fluoro)vinyl sulfone precursor with benzenethiol effected 
thiodesulfonylation and subsequent deprotection afforded (E/Z)-1-fluoro-2-(3-hydroxy-5-
methoxyphenyl)-1-phenylthioethene.  I also synthesized other (α-fluoro)vinyl analogues 
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of  2-(3-hydroxy-5-methoxyphenyl)-1-phenylthioethene, containing a sulfonyl or 
sulfoxide moiety. These analogues were tested against Mycobacterium smegmatis. 
Results showed that the fluorinated and non-fluorinated vinyl sulfides have a similar 
antibacterial activity. Data obtained also showed that oxidization of the sulfur atom to the 
sulfoxide or sulfone actually removes activity from the analogue; and that the styryl 
group is required to have a meta hydroxy/methoxy pattern in order to possess 
antibacterial activity. 
S-Alkylation of alkenyl or (α-fluoro)alkenyl phenyl sulfide with iodomethane and 
silver tetrafluoroborate generated quantitatively the alkenyl or (α-fluoro)alkenyl methyl 
phenyl sulfonium salts. 1H NMR and 19F NMR analysis showed that methylation of the 
sulfide occurred with retention of the E stereochemistry of the double bond. These 
sulfonium ions were found to be a good alkyl group donor and transfer a methyl group to 
common functionalities present in amino acids such as alkyl or aryl thiols, phenols and 
amino groups in the presence of a base.  
 
 
 
 
 
 
 
 
 
112 
 
 
 
REFERENCES: 
1.  (a) Suhadolnik, R.J. Nucleosides as Biological Probes; John Wiley & Sons: New 
York, 1979; (b) Suhadolnik, R.J. Nucleoside Antibiotics; John Wiley & Sons: 
New York, 1970.      
 
2.  (a) Kenakin, T. Pharmacologic Analysis of Drug-Receptor Interaction; 
Lippincott, Raven Publishers:  Philadelphia, 1997; (b) Kenakin, T. Molecular 
Pharmacology: A Short Course: Blackwell Science: Cambridge, 1997. 
 
3.  Silverman, R.B. The Organic chemistry of Drug Design and Drug Action; 
Academia Press, Inc.; San Diego, 1992. 
 
4.  Silverman, R.B. Mechanism-based Enzyme Inactivation Chemistry and 
Enzymology; CRC Press, Inc.; Boca Raton, 1988. 
 
5.  Ueland, P.M. Pharmacol. Rev. 1982, 34, 223-253. 
 
6.  (a) Yuan, C.-S.; Wnuk, S.F.; Robins, M.J.; Borchardt, R.T. In advances in 
Antiviral Drug Design, Vol. 2; de Clercq, Ed.; JA1 Press Inc.; Greenwich, 
Connecticut, 1996; pp 41-88; (b)  Yuan, C.-S.; Wnuk, S.F.; Robins, M.J.;  
Borchardt, R.T. Nucleoside Nucleotides 1995, 14, 439-447; (c) Liu, S.; Wolfe, 
M.S.; Borchardt, R.T. Antiviral Res. 1992, 19, 247-265; (d) Wolfe, M.S.; 
Borchardt, R.T. J. Med. Chem. 1991, 34, 1521-1530. 
 
7.  Biological Methylation and Drug Design; Borchardt, R.T.; Creveling, C.R.; 
Ueland, P.M., Eds.; Humana Press: Clifton, 1986.      
              
8.  Chiang, P.K. Pharmacol. Ther. 1988, 77, 115-134. 
 
9.  Capdevila, A.; Decha-Umphai, W.; Song, K.-H.; Borchardt, R.T.; Wagner, C. 
Arch. Biochem. Biophys. 1997, 345, 47-55. 
 
10.  Mizutani, Y.; Masuoka, S.; Imoto, M.; Kawada, M.; Umezawa, K. Biochem. 
Biophys. Res. Commun. 1995, 207, 69-74. 
 
11.  Porter, D.J.T.; Boyd, F.L. J. Biol. Chem. 1991, 266, 21616-21625. 
 
12.  (a) Ueland, P.M.; Refsum, H. J. Lab. Clin. Med. 1989, 114, 473-501.; (b) Chen, 
P.; Poddare, R.; Tipa, E.V.; Dibello, P.M.; Moravec, C.D.; Robinson, K.; Green, 
R.; Krugger, W.D.; Garrow, T.A.; Jacobsen, D.W. Advan. Enzyme Regul. 1999, 
39, 93-109. 
 
113 
 
 
 
13.  (a) Malinow, M.R.; Clin. Chem. 1995, 41, 173-176; (b) Refsum, H.; Ueland, 
P.M.; Nygard, O.; Vollset, S.E.; Annu. Rev. Med. 1998, 49, 31-62; (b) Langman, 
L.J.; Cole, D.E.C. Crit. Rev. Clin. Lab. Sci. 1991, 36, 365-406. 
 
14.  (a) Yuan, C.-S.; Sasa, Y.; Lazarides, E.; Borchardt, R.T.; Robins, M.J. Exp Opin. 
Ther. Patents, 1999, 9, 1197-1206; (b) Yin, D.; Yang, X.; Borchardt, R.T. In 
Biomedical Chemistry: Applying Principles to the Understanding and Treatment 
of Diseases; Paul F. Torrence, Ed.; John Wiley & Sons: New York, 2000, pp 47-
71; (c) Yuan, C.-S.; Wnuk, S.F.; Robins, M.J.; Borchardt, R.T. Nucleosides and 
Nucleotides, 1998, 14, 439-447. 
 
15.  Bethin, K.E.; Cimato, T.R.; Ettinger, M.J. J. Biol. Chem. 1995, 270, 20703-
20711. 
 
16.  Bethin, K.E.; Petrovic, N.; Ettinger, M.J. J. Biol. Chem. 1995, 270, 20698-20702. 
 
17.  (a) De Clercq, E. Biochem. Pharmacol. 1987, 36, 2567-2575. (b) De Clercq, E. 
Nucleoside and Nucleotides 1998, 17, 625-634; (c) Cools, M.; De Clercq, E. 
Biochem. Pharmacol. 1989, 38, 1961-1067. 
 
18.  Daelemans, D.; Esté, J.A.; Witvrouw, M.; Pannecouque, C.; Jonckheere, H.; 
Aquaro, S.; Perno, C.-F.; De Clercq, E.; VanDamme, A.-M. Mol. Pharm. 1997, 
52, 1157-1163. 
 
19.  Masuta, C.; Tanaka, H.; Uehara, K.; Kuwata, S.; Koiwai, A.; Noma, M. Proc. 
Natl. Acad. Sci. USA 1995, 92, 6117-6121. 
 
20. (a) Bitonti, A.J.; Baumann, J.; Varvi, T.; McCarthy, J.R.; McCan, P.P. Biochem. 
Pharmacol. 1990, 40, 601-606; (b) Henderson, D.M.; Hanson, S.; Allen, T.; 
Wilson, K.; Coulter-Karis, D.E.; Greenberg, M.L.; Hershfield, M.S.; Ullman, B. 
Mol. Biochem. Parasitol. 1992, 53, 169-184. 
 
21. Wolos, J.A.; Frondorf, K.A.; Esser, R.E. J. Immunol. 1993, 151, 526-534. 
 
22.  (a) Wolos, J.A.; Frondorf, K.A.; Babcock, G.E.; Stripp, S.A.; Bowlin, T.L.; Cell 
Immuniol. 1993, 149, 402-408; (b) Wolos, J.A.; Frondorf, K.A.; Davis, G.F.; 
Jarvi, E.T.; McCarthy, J.R.; Bowlin, T.L. J. Immuniol. 1993, 150, 3264-3273. 
 
23. (a) Palmer, J.L.; Abeles, R.H. J. Biol. Chem. 1976, 251, 5817-5819; (b) Palmer, 
J.L.; Abeles, R.H. J. Biol. Chem. 1979, 254, 1217-1226. 
 
24.  Porter, D.J.T.; Boyd, F.L. J. Biol. Chem. 1992, 267, 3205-3213. 
 
25.  Parry, R.J.; Askonas, L.J. J. Am. Chem. Soc. 1985, 107, 1417-1418. 
 
114 
 
 
 
26.  Vederas, J.C.; Floss, H.G. Acc. Chem. Res. 1980, 13, 455-463. 
 
27.  Yuan, C.-S.; Yeh, J.; Liu, S.; Borchardt, R.T. J. Biol. Chem. 1993, 268,17030-
17037. 
 
28.  Turner, M.A.; Yuan, C.-S.; Borchardt, R.T.; Hershfield, M.S.; Smit, G.D.; 
Howell, P.L. Nature Struct. Biol. Chem. 1998, 5, 369-376. 
 
29.  Hu, Y.; Komoto, J. Huang, Y.; Gomi, T.; Ogawa, H.; Takata, Y.; Fujioka, M.; 
Takusagawa, F. Biochemistry 1999, 38, 8323-8333. 
 
30. (a) McCarthy, J.R.; Jarvi, E.T.; Mattews, D.P.; Edwards, M.L.; Prakash, N.J.; 
Bowlin, T.L.; Mehdi, S.; Sunkara, P.S.; Bey, P. J. Am. Chem. Soc. 1989, 111, 
1127-1128; (b) Jarvi, E.T.; McCarthy, J.R.; Mehdi, S.; Mattews, D.P.; Edwards, 
M.L.; Prakash, N.J.; Bowlin, T.L; Sunkara, P.S.; Bey, P. J. Med. Chem. 1991, 34, 
647-656; (c) Mehdi, S.; Jarvi, E.T.; Koehl, J.R.; McCarthy, J.R.; Bey, P. J. 
Enzyme Inh. 1990, 4, 1-13; Bitonti, A.J.; Baumann, R.J.; Jarvi, E.T.; McCarthy, 
J.R.; McCann, P. P. Biochem. Pharmacol. 1990, 40, 601-606. 
 
31.  (a) Robins, M.J.; Wnuk, S.F. Tetrahderon Lett. 1988, 29, 5729-5732; (b) Robins, 
M.J.; Wnuk, S.F.; Mullah, K.B.; Dalley, N.K.; Yuan, C.-S.; Lee, Y.; Borchardt, 
R.T. J. Org. Chem. 1994, 59, 544-555. 
 
32.  (a) Wnuk, S.F.; Robins, M.J. J. Org. Chem. 1990, 55, 4757-4760; (b) Robins, 
M.J.; Wnuk, S.F. J. Org. Chem. 1993, 58, 3800-3801. 
 
33.  (a) Wolfe, M.S.; Borchardt, R.T. J. Med. Chem. 1991, 34, 1521-1530; (b) Yuan, 
C.-S.; Wnuk, S.F.; Robins, M.J.; Borchardt, R.T. In Advances in Antiviral Drug 
Design; Erik De Clercq, Ed.; JA1 Press: Greenwich, CT, 1996, Vol 2, pp 41-88. 
 
34.  Liu, S.; Wnuk, S.F.; Yuan, C.-S.; Robins, M.J.; Borchardt, R.T. J. Med. Chem. 
1993, 36, 883-887. 
 
35.  Wnuk, S.F.; Yuan, C.-S.; Borchardt, R.T.; Balzarini, J.; De Clercq, E.; Robins, 
M.J. J. Med. Chem. 1994, 37, 3579-3587. 
 
36.  Wnuk, S.F.; Robins, M.J. Can. J. Chem. 1991, 69, 334-338. 
 
37.  Tius, M.A.; Kawakami, J.K. Synlett 1993, 207-208. 
 
38.  (a) Yuan, C.-S.; Liu, S.; Borchardt, R.T. Biochemistry, 1994, 33, 3758-3765; (b) 
Yuan, C.-S.; Wnuk, S.F.; Liu, S.; Robins, M.J.; Borchardt, R.T. Biochemistry, 
1994, 33, 1919-1924. 
 
115 
 
 
 
39.  Liu, S.; Wolfe, M.S.; Yuan, C.-S.; Ali, M.S.; Borchardt, R.T. Bioorg. Med. Chem. 
Lett. 1992, 2, 1741-1744. 
 
40.  Liu, S.; Yuan, C.-S.; Borchardt, R.T. J. Med. Chem. 1996, 39, 2347-2353. 
 
41.  Robins, M.J.; Neschadimento, V.; Ro, B.-O.; Yuan, C.-S.; Borchardt, R.T.; 
Wnuk, S.F. J. Org. Chem. 1998, 63, 1205-1211. 
 
42.  Wnuk, S.F.; Mao, Y.; Yuan, C.-S.; Borchardt, R.T. Andrei, G.; Balzarini, J.; De 
Clercq, E.; Robins, M.J. J. Med. Chem. 1998, 41, 3078-3083. 
 
43. Yuan, C.-S.; Wnuk, S.F.; Robins, M.J.; Borchardt, R.T. J. Biol. Chem. 1998, 
273,18191-18197. 
 
44. (a) Loenen, W.A.M. Biochem. Soc. Trans, 2006, 34, 330-333; (b) Matsui, H., 
Kawada, N. Euro. J. Pharmacol. 2005, 509, 31-36. 
 
45. Kresge, N., Tabor, H., Simoni, R.D., Hill, R.L., J. Biol. Chem. 2005, 280, 35. 
 
46. Cheng, X., Roberts, R.J. Nucleic Acids Res. 2001, 29, 3784-3795. 
 
47. Robertson, K.D., Wolffe, A.P. Nat. Rev. Genet. 2000, 1, 11-19. 
 
48. (a) Heithoff, D.M., Sinsheimer, R.L., Low, D.A., Mahan, M.J. Science, 1999, 
284, 967-970. (b) Mashoon, N., Carroll, M., Pruss, C., Eberhard, J., Ishikawa, S., 
Estabrook, R.A., Reich, N. J. Biol. Chem. 2004, 279, 52075-52081. 
 
49. Nakayama, J., Rice, J.C.; Strahl, B.D., Allis, C.D., Grewal, S.I. Science, 2001, 
292, 110-113. 
 
50. Cheung, P., Allis, C.D., Sassone-C, P. Cell, 2000, 103, 263-271. 
 
51. (a) Robertson, K.D. Oncogene, 2001, 20, 3139-3155. (b) Szyf, M. Trends 
Pharmacol. Sci., 2001, 22, 350-354.  
 
52. Comstock, L.R., Rajski, S. R., Nucleic Acid Res. 2005, 33, 1644-1652. 
 
53. Kozbial, P.Z., Mushegian, A.R. BMC Struct. Biol. 2005, 5, 19. 
 
54. Merali, S., Clarkson, F.J. FEMS Microbiol. Lett. 2004, 237, 179-186. 
 
55. Blackburn, G.M., Gamblin, S.J., Wilson, J.R. Helv. Chem. Acta. 2003, 86, 4000-
4006. 
 
56.  Weller, R.L., Rajski, S.R. Org. Lett, 2005, 7, 2141-2144. 
116 
 
 
 
57. Webb, E.C. Enzyme Nomenclature, Academic Press, San Diego, 1992. 
 
58.   Kimzey, A.L.; McFadden, P.N. J. Protein Chem. 1994, 13, 537-546. 
 
59.   Fontecave, M., Atta, M., and Mulliez, E. Trends Biochem. Sci. 2004, 29, 243–
249. 
 
60.  Heady, J. E., and Kerr, S. J. J. Biol. Chem. 1973, 248, 69–72. 
 
61.  Heady, J. E., and Kerr, S. J. Cancer Res.1975, 35, 640–643. 
 
62.  Williams, K. T., and Schalinske, K. L. J. Nutr. 2007, 137, 311–314. 
 
63.  Luka, Z.; Mudd, H.; Wagner, C. J. Biol. Chem. 2009, 284, 22507-22511. 
 
64. Osborne, T., Weller Roska, R.L., Rajski, S.R., Thompson, P.R. J. Am. Chem. Soc. 
2008, 130, 4574-4575. 
 
65. (a) Klimasauskas, S., Kumar, S., Roberts, R.J., Cheng, X. Cell, 1994, 76, 357-
369. (b) Youngblood, B., Shieh, F.-K., Buller, F., Bullock, T., Reich, N.O. 
Biochem. 2007, 46, 8766-8775. 
 
66.  (a) Santi, D.V.; Garrett, C.E.; Barr, P.J. Cell 1983, 33, 9–10. (b)  Gabbara,  
S.;Bhagwat,A. J. Biochem. 1995, 307, 87–92. (c) Zhou, L.; Cheng,X.; Connoly, 
B.A.; Dickman,M.J.; Hurd, P.J.; Hornby, D.P. J. Mol. Biol. 2002, 321, 591–599. 
 
67.  Subach, O.M.; Khoroshaev, A.V.; Gerasimov, D.N.; Baskunov, V.B.; 
Shchyolkina, A.K.; Gromova, E.S. Eur. J. Biochem. 2004, 271, 2391–2399. 
 
68.  Welch, J.T. Tetrahedron 1987, 43, 3123-3197. 
 
69.  (a) Kirsch, P. Modern Fluoroorganic Chemistry. Synthesis, Reactivity, 
Applications;   Wiley-VCH: Weinheim, 2004, pp 8–16, 237–243. (b) Maienfisch, 
P.; Hall, R. G. Chimia, 2004, 58, 93–99. 
 
70.  Chambers, R. D. Fluorine in Organic Chemistry; Blackwell Publishing: Oxford, 
2004, 1–7. 
 
71.  Uneyama, K. Organofluorine Chemistry; Balckwell Publishing: Oxford, 2006, pp 
6–15, 81–82, 173–180, 206–215. 
 
72.  Asakura, N.; Usuki, Y.; Iio, H.; Tanaka, T. J. Fluorine Chem. 2006, 127, 800–
808. 
 
117 
 
 
 
73.  Ojima, I; McCarthy, J.R.; Welch, J.T. (Eds.), Biomedical Frontiers of Fluorine 
Chemistry, ACS Symposium Series 639, American Chemical Society, 
Washington, DC, 1996. 
 
74.  Fujii, A.; Usuki, Y.; Iio, H.; Tokoroyama, T. Synlett , 1994, 725–726; Asakura, 
N.; Usuki, Y.; Iio, H. J. Fluorine Chem. 2003, 124, 81–88. 
 
75.  Steert, K.; El-Sayed, I.; Van der Veken, P.; Krishtal, A.;Van Alsenoy, C.; 
Westrop, G.D.; Mottram, J.C.; Coombs, G.H.; Augustynsa, K.; Haemers, A. 
Bioorg. & Med. Chem. Lett. 2007,17, 6563–6566. 
 
76. (a) Lecaille, F.; Kaleta, J.; Bromme, D. Chem. Rev. 2002, 102, 4459-4488; (b) 
Caffrey, C. R.; Scory, S.; Steverding, D. C. Drug Targets, 2000, 1, 155-162. 
 
77.  Rosenthal, P. J. Int. J. Parasitol. 2004, 34, 1489-1499. 
 
78.  Meadows, D.C.; Gervay-Hague, J. Med. Res. Rev. 2006, 26, 793-814. 
 
79.  Capela, R.; Oliveira, R.; Gonçalves, L.M.; Domingos, A.; Gut, J.; Rosenthal, P.J.;  
Lopes, F.; Moreira, R. Bioorg. Med. Chem. Lett. 2009, 19, 3229–3232. 
 
80.  Sajid, M.; McKerrow, J. H. Mol. Biochem. Parasitol. 2002, 120, 1-21. 
 
81. (a) Shenai, B. R.; Sijwali, P. S.; Singh, N.; Rosenthal, P. J. J. Biol. Chem. 2000, 
275, 29000-29010. b) Dahl, E. L.; Rosenthal, P. J. Mol. Biochem. Parasitol. 2005, 
139, 205-212. 
 
82.  Sijwali, P. S.; Shenai, B. R.; Gut, J.; Singh, N.; Rosenthal, P. J. Biochem. 2001, 
360, 481-489. 
 
83.  (a) Santos, M. M. M.; Moreira, R. Mini-Rev. Med. Chem. 2007, 7, 1040-1050; (b) 
Chung, J. Y.; Bae, Y. A.; Na, B. K.; Kong, Y. Exp. Opin. Theor. Patents, 2005, 
15, 995-1007. 
 
84.  Olson, J. E.; Lee, G. K.; Semenov, A.; Rosenthal, P. J. Bioorg. Med. Chem. 1999, 
7, 633-638. 
 
85.  Singh, A.; Rosenthal, P. J. J. Biol. Chem. 2004, 279, 35236-35241. 
 
86. (a) Shenai, B. R.; Lee, B. J.; Alvarez-Hernandez, A.; Chong, P. Y.; Emal, C. D.; 
Neitz, R. J.; Roush, W. R.; Rosenthal, P. J. Antimicrob. Agents Chemother. 2003, 
47, 154-160; (b) Rosenthal, P. J.; Olson, J. E.; Lee, G. K.; Palmer, J. T.; Klaus, J. 
L.; Rasnick, D. Antimicrob. Agents Chemother. 1996, 40, 1600-1603. 
118 
 
 
 
87. (a) Sun, Z.-Y.; Botros, E.; Su, A.-D.; Wang, E.; Baturay, N.Z.; Kwon, C.-H. J. 
Med. Chem. 2000, 43, 4160–4168; (b) Kwon, C.-H.; Blanco, D.R.; Baturay, N. J. 
Med.  Chem. 1992, 35, 2137–2139. 
 
88.  Thomson, H.J.; Jiang, C.; Lu, J.; Mehta, R.G.; Piazza, G.A.; Paranka, N.S.;  
Pamakcu, R.; Ahnen, D. J. Cancer Res. 1997, 57, 267–271. 
 
89.  Skopinska-Rozewska, E.; Piazza, G.A.; Sommer, E.; Pamukcu, R.; Barcz, E.; 
Filewska, M.; Kupis, W.; Caban, R.; Rudzinski, P.; Bogdan, J.; Mlekodaj, S.; 
Sikorska, E. Int. J. Tissue React. 1998, 20, 85–89. 
 
90.  Santelli-Rouvier,C.; Barret, J.-M.; Farrell, C.M.; Sharples, D.; Hill, B.T.; Barbe, 
J. Euro. J.Med. Chem. 2004, 39, 1029–1038. 
 
91.  Farrell, N.; Kiley, D.M.; Schmidt, W.; Hacker, M.P. Inorg. Chem. 1990, 29, 397–
403. 
 
92.  Fox, B.M.; Vroman, J.A.; Fanwick, P.E.; Cushman, M.  J. Med. Chem. 2001, 44, 
3915–3924. 
 
93.  Crescenza, A.; Botta, M.; Corelli, F.; Santini, A.; Tafi, A.  J. Org. Chem. 1999, 
64, 3019-3025. 
 
94. Johannesson, P.; Lindeberg, G.; Johansson, A.; Nikiforovich, G.V.; Gogoll, A.; 
Synnergren, B.; Le Greves, M.; Nyberg, F.; Karlen, A.; Hallberg, A. J. Med. 
Chem. 2002, 45, 1767-1777. 
 
95. Parrish, J. P.; Flanders, V. L.; Floyd, R. J.; Jung, K. W. Tetrahedron Lett. 2001, 
42, 7729–7731. 
 
96.     (a) Hruby, V. J. Life Sci. 1982, 31,189-199. (b) Lambert, J. N.; Mitchell, J. P.; 
Roberts, K. D. J. Chem. Soc., Perkin Trans. 1 2001, 471-484. 
 
97. Matsoukas, J. M.; Polevaya, L.; Ancans, J.; Mavromoustakos, T.; Kolocouris, A.; 
Roumelioti, P.; Vlahakos, D. V.; Yamdagni, R.; Wu, Q.; Moore, G. J.  Bioorg. 
Med. Chem. 2000, 8, 1-10. 
 
98. Warner, D.R.; Hoffman, J.L. Biochemistry 1996, 35, 4480-4484. 
 
99. (a) Asai, K. Organic Germanium: A medicinal Godsend. Kogakusha Ltd.: Tokyo, 
1977; (b) Lukevics, E.; Ignatovitch, L.M. Appl. Organomet. Chem. 1992, 6, 113-
126. (c) Sawai, K.; Kurono, M.; Asano, K.; Mitani, T.; Ninomiya, N.; Ishiwata,  
 
 
119 
 
 
 
 Y.; Yokochi, S.; Yamada, K.; Taki, M.; et al. Eur. Pat. Appl. 1990, 11 pp. (d) 
Metal-Catalyzed Cross-Coupling Reactions; Diederich, F.; Stang, P. J., Eds.;  
Wiley-VCH: Weinhem, Germany, 1998; (e) Littke, A. F.; Fu, G. C. 
Angew.Chem., Int. Ed. Engl. 2002, 41, 4176-4211. 
 
100. (a) Stille, J. K. Angew. Chem., Int. Ed. Engl. 1986, 25, 508; (b) Menzel, K.; Fu, G. 
C. J. Am. Chem. Soc. 2003, 125, 3718-3719. 
 
101.  Denmark, S. E.; Wehrli, D. Org. Lett. 2000, 2, 565-568.  
 
102. (a) Kosugi, M.; Tanji, T.; Tanaka, Y.; Yoshida, A.; Fugami, K.; Kame-yama, M.;  
Migita, T. J. Organomet. Chem. 1996, 508, 255-257; (b) Kinoshita,  H.; 
Nakamura, T.; Kakiya, H.; Shinokubo, H.; Matsubara, S.; Oshima, K. Org. Lett. 
2001, 3, 2521-2524.  
 
103.  (a) Marciniec, B. Comprehensive Handbook on Hydrosilylation; Pergamon Press:  
Oxford, 1992; (b) Trost, B. M.; Ball, Z. T. J. Am. Chem. Soc. 2001, 123, 12726-
12727.  
 
104.  (a) Rubin, M.; Schwier, T.; Gevorgyan, V. J. Org. Chem. 2002, 67, 1936-1940; 
(b) Asao, N.; Liu, J.-X.; Sudoh, T.; Yamamoto, Y. J. Org. Chem. 1996, 61, 4568-
4571. 
 
105.  Schwier, T.; Gevorgyan, V. Org. Lett. 2005, 7, 5191-5194. 
 
106.   Ichinose, Y.; Nozaki, K.; Wakamatsu, K.; Oshima, K. Tetrahedron Lett. 1987, 28, 
3709-3712. 
 
107.  (a) Stang, P. J.; Zhdankin, V. Alkynyl halides and chalcogenides. In 
Comprehensive Organic Functional Group Transformations; Katritzky, A. R., 
Meth-Cohn, O., Rees, C. W., Editors-in-Chief; Ley, S. V., Ed.; Pergamon: 
Oxford, UK, 1995; Vol. 2, pp 1011-1038; (b) Viehe, H. G.; Mere´nyi, R.; Oth, J. 
F. M.; Valange, P. Angew. 1964, 76, 888. 
 
108.  (a) Najera, C.; Yus, M. Tetrahedron 1999, 55, 10547-10658; (b) McCarthy, J. R.; 
Matthews, D. P.; Stemerick, D. M.; Bey, P.; Lippert, B. J.; Snyder, R. D.; Sunkara 
P. S. J. Am. Chem. Soc. 1991, 113, 7439-7440; (c) McCarthy, J. R.; Huber, E. W.; 
Le, T.-B.; Laskovics, F. M.; Matthews, D. P. Tetrahedron 1996, 52, 45-58. 
 
109.  Shao, J.; Zhou, B.; Chu, B.; Yen, Y. Curr. Cancer Drug Targets 2006, 6, 409–
431. 
 
110. Wnuk, S.F.; Garcia, P.I.: Wang J. Org. Lett., 2004, 6, 2047-2049.  
 
111.  Wnuk, S.F.; Robins, M.J. Can. J. Chem. 1993, 71, 192–198. 
120 
 
 
 
112. Lukevics, E.; Ignatovich, L.; Shilina, N.; Kemme, A.; Sjakste, N.  Metal Based 
Drugs 1993, 1, 65-72. 
 
113. (a) Miyasaka, T.; Tanaka, H.; Masamori, B.; Hayakawa, H.; Walker, R.T.; 
Balzarini, J.; De Clercq, E. J. Med. Chem. 1989, 32, 2507-2509; (b) Tanaka, H.; 
Baba, M.; Hyakawa, H.; Sakamaki, T.; Miyasaka, T.; Ubasawa, M.; Takashima, 
H.; Sekiya, K.; Nitta, I.; Shigeta, S.; Walker, R.T.; Balzarini, J.; De Clercq. E.  J. 
Med. Chem. 1991, 34, 349-357; (c) Tanaka, H.; Baba, M.;Saito, S.; Miyasaka, T.; 
Takashima, H.; Sekiya, K.; Ubasawa, M.; Nitta, I.; Walker, R.T.; Nakashima, H.; 
De Clercq. E. J. Med. Chem. 1991, 34, 1508-1511. 
 
114. (a) Verdegaal, C. M. H.; Martens, F. B.; Romers, C. J. Chem. Soc., Perkin Trans. 
II, 1979, 833-834; (b) Nakai, Y.; Yamamoto, K.; Terada, K.; Uchida, T.; 
Shimuzu, N.; Nishigaki, S. Chem. Pharm. Bull. 1982, 30, 2629-2632; (c) 
Dongtao, G.; Pinzhe, L.; Cheng, S.; Fengshan, W.; Yuongshen, L. Scientia Sinica 
B 1983, 26, 1009; (d) Kemme, A.A.; Bleidelis, Y.Y.; Lidak,  M.Y.; Zhuk, R.A. 
Zhurnal Organich.  Khim. 1983, 19, 1537. 
 
115.  de Graaf, R.A.G.; Admiraal, G.; Koen, E. H.; Romers, C. Acta Crystallogr. B33 
1977, 5459-5464. 
 
116. (a) Andrei, D.; Wnuk, S. F. Org. Lett. 2006, 8, 5093-5096. (b)Wnuk, S.F.; 
Sacasa, P.R.;  Lewandowska, E.; Andrei, D.; Cai, S.; Borchardt, R.T. Bioorg. 
Med. Chem. 2008, 16, 5424–5433. 
 
117. Postigo, A.; Kopsov, S.; Ferreri, C.; Chatgilialoglu, C. Org. Lett. 2007, 9, 5159–
5162. 
 
118. (a) Lukevics, E.; Ignatovich, L. 32Ge Biological activity of organogermanium  
compounds. In Metallotherapeutic Drugs and Metal-Based Diagnostic Agents, 
Gielen, M.; Tiekink, E. R. T., Eds. 2005; pp 279–295; (b) Lukevics, E.; 
Ignatovich, L. Biological activity of organogermanium compounds. In The 
Chemistry of Organic Germanium, Tin and Lead Compounds, Rappoport, Z., Ed. 
John Wiley & Sons Ltd., Chichester, UK, 2002; pp 1653–1683. 
 
119. Wnuk, S.F.; Sacasa, P.R.; Restrepo, J. Nucleosides, Nucleotides and Nucleic 
Acids, 2009, 28, 537–549. 
 
120.  Wang, J.-F.; Yang, X.-D.; Zhang, L.-R.; Yang, Z.-J.; Zhang, L.-H.  Tetrahedron 
2004, 60, 8535–8546. 
 
121. Rapp, M.; Haubrich, T.A.; Perrault, J.; Mackey, Z.B.; McKerrow, J.H.; et al.  J.  
Med. Chem. 2006, 49, 2096–2102. 
 
 
121 
 
 
 
122. Wnuk, S.F.; Lalama, J.; Garmendia, C.A.; Robert, J.; Zhu, J.; Pei, D. S-.  Bioorg.  
Med. Chem. 2008, 16, 5090–5102. 
 
123. Kumamoto, H.; Onuma, S.; Tanaka, H.  J. Org. Chem. 2004, 69, 72–78. 
 
124. Dimopoulos, P.; Athlan, A.; Manaviazar, S.; Hale, K.J.  Org. Lett. 2005, 7, 5373–
5376.  
 
125. Patai, S.; Rappoport, Z. The Chemistry of Organic Germanium, Tin and Lead 
Compounds. John Wiley & Sons: Chichester, UK, 1995; Vol. 1 & 2002; Vol 1. 
 
126. Wang, Z.; Wnuk, S.F. J. Org. Chem. 2005, 70, 3281–3284. 
 
127. Sacasa, P.R.; Zayas, J.; Wnuk, S.F. Tetrahedron Lett.  2009, 50, 5424-5427. 
 
128. Huang, X.; Duan, D.; Zheng, W. J. Org. Chem. 2003, 68, 1958-1963. 
 
129. Kabir, M.S.; Linn, M.L.V.; Monte, A.; Cook, J.M. Org. Lett. 2008, 10, 3363-
3366. ((b) Ben, I.; Castedo, L.; Saa, J. M.; Seijas, J. A.; Suau, R.; Tojo, G.  J. 
Org. Chem.  1985, 50, 2236-2240. (c) Monte, A.; Kabir, M. S.; Cook, J. M.; Rott, 
M.; Schwan, W. R.; Defoe, L. U.S. Pat. Appl. Publ. 2007, 37 pp. (d) Laali, K. K.; 
Chun, J.-H.; Okazaki, T.; Kumar, S.; Borosky, G. L.; Swartz, C. J. Org. Chem.  
2007, 72, 8383-8393.  
 
130. Wnuk, S. F.; Dalley, N. K.; Robins, M. J. Can. J. Chem.  1991, 69, 2104-11. 
 
131. Hansske, F.; Madej, D.; Robins, M.J. Tetrahedron 1984, 40, 125–135. 
 
132. Wang, Z.; Pitteloud, J.-P.; Montes, L.; Rapp, M.; Derane, D.; Wnuk, S. F. 
Tetrahedron 2008, 64, 5322-5327. 
 
133.  Keck, G. E.; Byers, J. H.; Tafesh, A. M. J. Org. Chem. 1988, 53, 1127-1128. 
 
134.   Inbasekaran, M.; Peet, N. P.; McCarthy, J. R.; Le Tourneau, M. E. J. Chem. Soc.,   
 Chem. Commun 1985, 678-679. 
 
135. Chen, C.; Wilcoxen, K.; Zhu, Y. F.; Kim, K. I.; McCarthy, J. R. J. Org. Chem.   
 1999, 64, 3476-3482. 
 
136. Pettit, G.R.; Grealish, M.P.; Jung, M.K.; Hamel, E.; Pettit, R.K.; Chapuis, J.-C.; 
Schmidt, J.M. J. Med. Chem. 2002, 45, 2534-2542. 
 
 
 
 
122 
 
 
 
VITA 
 
PABLO R. SACASA 
 
Education 
Doctorate Candidate in Chemistry, Summer 2010, Florida International University, 
Dissertation: "Developing of germyldesulfonylation and thiodesulfonylation reactions for 
the synthesis of novel nucleoside analogues. Efficient synthesis of (α-fluoro)vinyl 
sulfides". 
Advisor: Professor Stanislaw F. Wnuk 
 
M.S. Chemistry, 2003, Florida International University, Thesis: "Synthesis of S-
adenosyl-L-homocysteine analogues with sulfur atom replaced by "vinyl unit" via cross-
coupling reactions". 
Advisor: Professor Stanislaw F. Wnuk  
                        
B.A. Chemistry, Florida International University, Miami, Fl   
    
Honors and Scholarships 
-SoFLACS Graduate Travel Award, 2007 
-RISE Graduate Fellow 
 
Publications 
1. Wnuk, S.F.; Ro, B-O.; Valdez, C. A.; Lewandowska, E.; Valdez, N. X.; Sacasa, P. 
R.; Yin, D.; Zhang, J.; Borchardt, R. T.; De Clercq, E.; Sugar-Modified 
Conjugated Diene Analogues of Adenosine and Uridine: Synthesis, Interaction 
with S-Adenosyl-L-homocysteine Hydrolase, and Antiviral and Cytostatic 
Effects. J. Med. Chem.  2002, 45(12), 2651-2658.   
2. Wnuk, S. F.; Sacasa, P. R.; Crain, L. N.; Lewandowska, E.; Zhang, J.; Borchardt, 
R. T.; Stereocontrolled Synthesis of Diene and Enyne Sugar-Modified 
Nucleosides and Their Interaction with S-Adenosyl-L-homocysteine Hydrolase. 
Nucleosides, Nucleotides & Nucleic Acids 2003, 22(5-8), 783-785.   
3. Wnuk, S. F.; Lewandowska, E.; Sacasa, P. R.; Crain, L. N.; Zhang, J.; Borchardt, 
R. T.; De Clercq, E.; Stereoselective Synthesis of Sugar-Modified Enyne 
Analogues of Adenosine and Uridine. Interaction with S-Adenosyl-L-
homocysteine Hydrolase and Antiviral and Cytotoxic Effects.  J.  Med Chem. 
2004, 47(21), 5251-5257.   
4. Wnuk, S. F.; Sacasa, P. R.; Lewandowska, E.; Andrei, D.; Cai, S.; Borchardt, R. 
T.   Synthesis of 5'-functionalized nucleosides: S-Adenosylhomocysteine analogs 
with the carbon-5' and sulfur atoms replaced by a vinyl or halovinyl unit. Bioorg.  
Med. Chem.  2008, 16, 5424-5433.  
5. Wnuk, S.F.; Sacasa, P. R.  (p-Toluenesulfonylmethylene)triphenylphosphorane. 
Encylopedia of Reagents for Organic Synthesis 2008, John Wiley & Sons, DOI: 
10.1002/047084289X.rn00884. 
 
123 
 
 
 
124 
 
6. Sacasa, P. R.; Zayas, J.; Wnuk, S. F. Radical-mediated thiodesulfonylation of the 
vinyl sulfones: access to α-fluoro)vinyl sulfides. Tetrahedron Letters 2009, 50, 
5424-5427. 
7. Wnuk, S. F.; Sacasa, P. R.; Restrepo, J.   Application of germyl-desulfonylation 
reactions to the synthesis of germanium-containing nucleoside analogs.  
Nucleosides, Nucleotides & Nucleic Acids 2009, 28, 537-549.  
 
 Communications 
1.  Wnuk, S. F.; Sacasa, P. R.; Lewandowska, E.; Stereocontrolled synthesis of sugar-
modified diene analogues of adenosine and uridine via Stille coupling. 223rd ACS 
National Meeting, Orlando, FL, United States, April 7-11, 2002. 
 
2.  Wnuk, Stanislaw F.; Sacasa, Pablo R.; Lallama, Jennifer; Lawrence, Vernon J.; 
Lewandowska, Elzbieta. Synthesis of S-adenosyl-L-homocysteine analogs with 
the sulfur atom replaced by "vinyl unit" via cross-coupling reactions.  225th ACS 
National Meeting, New Orleans, LA, United States, March 23-27, 2003. 
 
3.  Sacasa, P.R.; Andrei, D.; Dang, T. P.; Wnuk, St. F.; S-Adenosyl-L-homocysteine 
analogues with Carbon 5' and Sulfur Atoms replaced by halovinyl Unit. 233rd 
ACS National Meeting, Chicago, Il, United States, March 25-29, 2007. 
 
4. Restrepo, J. A.; Sacasa, P. R.; Pitteloud, J.-P.; Wnuk, S. F.   Application of 
germyldesulfonylation reactions in nucleoside chemistry.  235th ACS National 
Meeting, New Orleans, LA, United States, April 6-10, 2008. 
 
5. Wnuk, S. F.; Sobczak, A. J.; Malladi, V.; Sacasa, P. R.; Pitteloud, J.-Pe.   S-
Adenosyl- homocysteine vs. S-ribosylhomocysteinase (LuxS): Similarities and 
differences between two enzymes.  237th ACS National Meeting, Salt Lake City, 
UT, United States, March 22-26, 2009. 
 
6. Zayas, J.; Sacasa, P. R.; Wnuk, S. F. Radical desulfonylation reactions in aqueous 
medium using tris(trimethylsilyl)silane and thiols.  237th ACS National Meeting, 
Salt Lake City, UT, United States, March 22-26, 2009. 
 
7. Quirke, J. M. E.; Sacasa, P. Development of a rogues' gallery that illustrates 
practical errors in carrying out TLC analyses. 239th ACS National Meeting, San 
Francisco, CA, United States, March 21-25, 2010. 
 
Affiliations 
-Chemistry GSO 
-American Chemical Society 
-South Florida American Chemical Society 
-Sigma Xi 
 
